TW464511B - Pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system and preparation method therefor - Google Patents
Pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system and preparation method therefor Download PDFInfo
- Publication number
- TW464511B TW464511B TW084100440A TW84100440A TW464511B TW 464511 B TW464511 B TW 464511B TW 084100440 A TW084100440 A TW 084100440A TW 84100440 A TW84100440 A TW 84100440A TW 464511 B TW464511 B TW 464511B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- patent application
- scope
- item
- polyacrylate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 152
- 239000004820 Pressure-sensitive adhesive Substances 0.000 title claims abstract description 32
- 238000013271 transdermal drug delivery Methods 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000003814 drug Substances 0.000 claims abstract description 109
- 229940079593 drug Drugs 0.000 claims abstract description 81
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 64
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 64
- 229920000642 polymer Polymers 0.000 claims abstract description 63
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 89
- 239000000853 adhesive Substances 0.000 claims description 87
- 230000001070 adhesive effect Effects 0.000 claims description 83
- -1 polysiloxane Polymers 0.000 claims description 72
- 238000011049 filling Methods 0.000 claims description 69
- 229960005309 estradiol Drugs 0.000 claims description 48
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 46
- 229930182833 estradiol Natural products 0.000 claims description 46
- 230000002079 cooperative effect Effects 0.000 claims description 40
- 229920000058 polyacrylate Polymers 0.000 claims description 37
- 239000002253 acid Substances 0.000 claims description 36
- 229920001971 elastomer Polymers 0.000 claims description 32
- 239000005060 rubber Substances 0.000 claims description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 22
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 18
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 17
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 17
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 17
- 239000005642 Oleic acid Substances 0.000 claims description 17
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 17
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 17
- 229920001296 polysiloxane Polymers 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 13
- 239000004698 Polyethylene Substances 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 11
- 229960001652 norethindrone acetate Drugs 0.000 claims description 11
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 10
- 239000004743 Polypropylene Substances 0.000 claims description 9
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 9
- 229940011871 estrogen Drugs 0.000 claims description 9
- 239000000262 estrogen Substances 0.000 claims description 9
- 229920001155 polypropylene Polymers 0.000 claims description 9
- 239000013464 silicone adhesive Substances 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 8
- 229920002367 Polyisobutene Polymers 0.000 claims description 7
- 239000008177 pharmaceutical agent Substances 0.000 claims description 7
- 239000004584 polyacrylic acid Substances 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 229960001231 choline Drugs 0.000 claims description 6
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229940055577 oleyl alcohol Drugs 0.000 claims description 5
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 229960004126 codeine Drugs 0.000 claims description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 4
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 4
- 239000000052 vinegar Substances 0.000 claims description 4
- 235000021419 vinegar Nutrition 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000006 Nitroglycerin Substances 0.000 claims description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 239000003098 androgen Substances 0.000 claims description 3
- 239000000164 antipsychotic agent Substances 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 3
- 229960000201 isosorbide dinitrate Drugs 0.000 claims description 3
- 229920003052 natural elastomer Polymers 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 229940053934 norethindrone Drugs 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 229960003946 selegiline Drugs 0.000 claims description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 2
- 244000043261 Hevea brasiliensis Species 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229960000423 loxapine Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 229960000762 perphenazine Drugs 0.000 claims description 2
- 229960001416 pilocarpine Drugs 0.000 claims description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 6
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 3
- 229960002568 ethinylestradiol Drugs 0.000 claims 3
- 229960003604 testosterone Drugs 0.000 claims 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 2
- 108010061435 Enalapril Proteins 0.000 claims 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 2
- 241001417534 Lutjanidae Species 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 229960004538 alprazolam Drugs 0.000 claims 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 claims 2
- 229910052786 argon Inorganic materials 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 2
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 claims 2
- 229960001541 benzthiazide Drugs 0.000 claims 2
- 229960002896 clonidine Drugs 0.000 claims 2
- 229960000873 enalapril Drugs 0.000 claims 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 2
- 229940009626 etidronate Drugs 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 claims 2
- 229960001751 fluoxymesterone Drugs 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 229960003587 lisuride Drugs 0.000 claims 2
- 229960003088 loratadine Drugs 0.000 claims 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- 229960001566 methyltestosterone Drugs 0.000 claims 2
- 229960000916 niflumic acid Drugs 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229960001697 physostigmine Drugs 0.000 claims 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 229960002052 salbutamol Drugs 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims 2
- 229960003708 sumatriptan Drugs 0.000 claims 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 1
- OJHZNMVJJKMFGX-BWCYBWMMSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OJHZNMVJJKMFGX-BWCYBWMMSA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 claims 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 claims 1
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 claims 1
- WKKSOQKQSXJIFD-UHFFFAOYSA-N 1-benzylpiperidine;methyl acetate Chemical compound COC(C)=O.C=1C=CC=CC=1CN1CCCCC1 WKKSOQKQSXJIFD-UHFFFAOYSA-N 0.000 claims 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 claims 1
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 claims 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims 1
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- SZXIMJCHKWYCHX-UHFFFAOYSA-N 2-aminoethyl propanoate Chemical compound CCC(=O)OCCN SZXIMJCHKWYCHX-UHFFFAOYSA-N 0.000 claims 1
- DDTOOANXAAWWQJ-UHFFFAOYSA-N 3-oxo-2-phenylpropanoic acid Chemical compound OC(=O)C(C=O)C1=CC=CC=C1 DDTOOANXAAWWQJ-UHFFFAOYSA-N 0.000 claims 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 claims 1
- DLGKFGFBUJZANB-UHFFFAOYSA-N C(C)(=O)OC.C1(=CC=C(N)C=C1)C1=CC=C(N)C=C1 Chemical compound C(C)(=O)OC.C1(=CC=C(N)C=C1)C1=CC=C(N)C=C1 DLGKFGFBUJZANB-UHFFFAOYSA-N 0.000 claims 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 1
- LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 claims 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 claims 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 claims 1
- LRUUNMYPIBZBQH-UHFFFAOYSA-N Methazole Chemical compound O=C1N(C)C(=O)ON1C1=CC=C(Cl)C(Cl)=C1 LRUUNMYPIBZBQH-UHFFFAOYSA-N 0.000 claims 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 240000001090 Papaver somniferum Species 0.000 claims 1
- 235000008753 Papaver somniferum Nutrition 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 229910000831 Steel Inorganic materials 0.000 claims 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 1
- 229960000276 acetophenazine Drugs 0.000 claims 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 229960002749 aminolevulinic acid Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229960003515 bendroflumethiazide Drugs 0.000 claims 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 claims 1
- 229940076134 benzene Drugs 0.000 claims 1
- 229960005274 benzocaine Drugs 0.000 claims 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 claims 1
- 229960000910 bethanechol Drugs 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004037 bromperidol Drugs 0.000 claims 1
- 229960003150 bupivacaine Drugs 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960004484 carbachol Drugs 0.000 claims 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims 1
- 229960001386 carbuterol Drugs 0.000 claims 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229960004782 chlordiazepoxide Drugs 0.000 claims 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims 1
- 229960003996 chlormadinone Drugs 0.000 claims 1
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 claims 1
- 229960002155 chlorothiazide Drugs 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 chlorpromazine Drugs 0.000 claims 1
- 229960001552 chlorprothixene Drugs 0.000 claims 1
- 229960001747 cinchocaine Drugs 0.000 claims 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 1
- 229960003120 clonazepam Drugs 0.000 claims 1
- 229960004976 desogestrel Drugs 0.000 claims 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 1
- 229960003529 diazepam Drugs 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims 1
- 229960000452 diethylstilbestrol Drugs 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229950006690 dimethisterone Drugs 0.000 claims 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 1
- 229960000385 dyclonine Drugs 0.000 claims 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004913 dydrogesterone Drugs 0.000 claims 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 229960001348 estriol Drugs 0.000 claims 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims 1
- 230000001076 estrogenic effect Effects 0.000 claims 1
- 229960003399 estrone Drugs 0.000 claims 1
- 229940081345 estropipate Drugs 0.000 claims 1
- HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 claims 1
- 229960000445 ethisterone Drugs 0.000 claims 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 claims 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 claims 1
- 229940012028 ethynodiol diacetate Drugs 0.000 claims 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims 1
- 229960003976 etidocaine Drugs 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229960002690 fluphenazine Drugs 0.000 claims 1
- 229960003528 flurazepam Drugs 0.000 claims 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229960002158 halazepam Drugs 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229950003599 ipsapirone Drugs 0.000 claims 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims 1
- 229960003827 isosorbide mononitrate Drugs 0.000 claims 1
- 229960004400 levonorgestrel Drugs 0.000 claims 1
- 229960004391 lorazepam Drugs 0.000 claims 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 1
- 229960001910 lynestrenol Drugs 0.000 claims 1
- 229960002525 mecamylamine Drugs 0.000 claims 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 claims 1
- 229960001786 megestrol Drugs 0.000 claims 1
- 229960004296 megestrol acetate Drugs 0.000 claims 1
- 229960004805 melengestrol Drugs 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- 229960000300 mesoridazine Drugs 0.000 claims 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims 1
- 229960001390 mestranol Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229960004938 molindone Drugs 0.000 claims 1
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 229960001783 nicardipine Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960001858 norethynodrel Drugs 0.000 claims 1
- 229960000417 norgestimate Drugs 0.000 claims 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims 1
- 229960004535 oxazepam Drugs 0.000 claims 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229960004851 pergolide Drugs 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 229960004265 piperacetazine Drugs 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960004856 prazepam Drugs 0.000 claims 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 1
- 229960001289 prazosin Drugs 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- 229960000244 procainamide Drugs 0.000 claims 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 229960004482 quinidine sulfate Drugs 0.000 claims 1
- 229960001457 rimiterol Drugs 0.000 claims 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960002646 scopolamine Drugs 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- 229950010289 soterenol Drugs 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims 1
- 235000021286 stilbenes Nutrition 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 1
- 229960002722 terbinafine Drugs 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
- 229960002372 tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004728 thiopropazate Drugs 0.000 claims 1
- 229960002784 thioridazine Drugs 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 229960005013 tiotixene Drugs 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims 1
- 229960003386 triazolam Drugs 0.000 claims 1
- 229960002324 trifluoperazine Drugs 0.000 claims 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims 1
- 229960003904 triflupromazine Drugs 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 26
- 238000012377 drug delivery Methods 0.000 abstract description 5
- 210000004207 dermis Anatomy 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 36
- 239000004615 ingredient Substances 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 20
- 239000007789 gas Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 229910052740 iodine Inorganic materials 0.000 description 15
- 229920001709 polysilazane Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 210000002615 epidermis Anatomy 0.000 description 13
- 230000035699 permeability Effects 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000010941 cobalt Substances 0.000 description 7
- 229910017052 cobalt Inorganic materials 0.000 description 7
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 229960004618 prednisone Drugs 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 229940098465 tincture Drugs 0.000 description 6
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 5
- 238000002309 gasification Methods 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- 239000002023 wood Substances 0.000 description 5
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- QFXZANXYUCUTQH-UHFFFAOYSA-N ethynol Chemical compound OC#C QFXZANXYUCUTQH-UHFFFAOYSA-N 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 4
- 229920005591 polysilicon Polymers 0.000 description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 241000218671 Ephedra Species 0.000 description 3
- 229920002633 Kraton (polymer) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940040145 liniment Drugs 0.000 description 3
- 239000000865 liniment Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UDJZTGMLYITLIQ-UHFFFAOYSA-N 1-ethenylpyrrolidine Chemical compound C=CN1CCCC1 UDJZTGMLYITLIQ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- NAUDKYVGHCCLOT-LAQCMFAESA-N [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 NAUDKYVGHCCLOT-LAQCMFAESA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960002479 isosorbide Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- VOXZDWNPVJITMN-WKUFJEKOSA-N oestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 231100000435 percutaneous penetration Toxicity 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229920000548 poly(silane) polymer Polymers 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000005871 repellent Substances 0.000 description 2
- 230000002940 repellent Effects 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical class O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- YGBZFOQXPOGACY-NLCOOVJESA-N (-)-Ozic acid Natural products O=C(O)[C@]1(C)[C@@H]2[C@@](C)([C@H](C/C=C(\C=C)/C)C(=C)CC2)CCC1 YGBZFOQXPOGACY-NLCOOVJESA-N 0.000 description 1
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 description 1
- IGPWAITWXGQPMD-ONEGZZNKSA-N (1e)-1-fluorobuta-1,3-diene Chemical compound F\C=C\C=C IGPWAITWXGQPMD-ONEGZZNKSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical group N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- STOVYWBRBMYHPC-KAVGSWPWSA-N 2-[(E)-[(E)-(2-hydroxyphenyl)methylidenehydrazinylidene]methyl]phenol Chemical compound OC1=CC=CC=C1\C=N\N=C\C1=CC=CC=C1O STOVYWBRBMYHPC-KAVGSWPWSA-N 0.000 description 1
- NTZHUEVGKVGSPN-UHFFFAOYSA-N 2-aminoacetic acid;propanoic acid Chemical compound CCC(O)=O.NCC(O)=O NTZHUEVGKVGSPN-UHFFFAOYSA-N 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- MECVOSKQBMPUFG-UHFFFAOYSA-N 2-carboxyphenolate;morpholin-4-ium Chemical compound C1COCCN1.OC(=O)C1=CC=CC=C1O MECVOSKQBMPUFG-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical compound CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- WACQLQIAUWURGA-UHFFFAOYSA-N 3-hydroxy-2,2-bis(hydroxymethyl)propanoic acid Chemical compound OCC(CO)(CO)C(O)=O WACQLQIAUWURGA-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NVMYRXGXUBZAIU-UHFFFAOYSA-N 9-fluoren-9-ylidenefluorene Chemical group C12=CC=CC=C2C2=CC=CC=C2C1=C1C2=CC=CC=C2C2=CC=CC=C21 NVMYRXGXUBZAIU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000983381 Adenium Species 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 102100036514 Amyloid-beta A4 precursor protein-binding family A member 1 Human genes 0.000 description 1
- 101710093637 Amyloid-beta A4 precursor protein-binding family A member 1 Proteins 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 101100162203 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflG gene Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241001289384 Beloniformes Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DYXRFRWOOSCYRP-VYKNHSEDSA-N C1=CC(O)=C2C=3[C@@]45[C@@H](O2)[C@@H](O)C=C[C@H]4[C@@H](CC13)N(C)CC5.[Ag] Chemical compound C1=CC(O)=C2C=3[C@@]45[C@@H](O2)[C@@H](O)C=C[C@H]4[C@@H](CC13)N(C)CC5.[Ag] DYXRFRWOOSCYRP-VYKNHSEDSA-N 0.000 description 1
- 101100021402 Caenorhabditis elegans lis-1 gene Proteins 0.000 description 1
- 101100133721 Caenorhabditis elegans npr-1 gene Proteins 0.000 description 1
- 101100134909 Caenorhabditis elegans oig-1 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEDTXTNSFWUXGQ-UHFFFAOYSA-N Carbophenothion Chemical group CCOP(=S)(OCC)SCSC1=CC=C(Cl)C=C1 VEDTXTNSFWUXGQ-UHFFFAOYSA-N 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 102100024133 Coiled-coil domain-containing protein 50 Human genes 0.000 description 1
- 229920008712 Copo Polymers 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 229920003345 Elvax® Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 108091033322 FsrA Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101150058655 Gpam gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000910772 Homo sapiens Coiled-coil domain-containing protein 50 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- UKMCYAGVGHWTQW-UHFFFAOYSA-N I.OC(=O)CCC(O)=O Chemical compound I.OC(=O)CCC(O)=O UKMCYAGVGHWTQW-UHFFFAOYSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100011750 Mus musculus Hsp90b1 gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000995070 Nirvana Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 241001643667 Orpha Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920003079 Povidone K 17 Polymers 0.000 description 1
- 241000677647 Proba Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 229920003776 Reny® Polymers 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 244000009660 Sassafras variifolium Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 101710195641 Splenin Proteins 0.000 description 1
- 235000018087 Spondias lutea Nutrition 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102400000159 Thymopoietin Human genes 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- GTWGWCYJKHSRHO-UHFFFAOYSA-N [4-[4-[4-[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]oxyphenyl]hexan-3-yl]phenyl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound C=1C=C(OC(=O)CC=2C=CC(=CC=2)N(CCCl)CCCl)C=CC=1C(CC)C(CC)C(C=C1)=CC=C1OC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 GTWGWCYJKHSRHO-UHFFFAOYSA-N 0.000 description 1
- WXOQGOXTUJOXCA-UHFFFAOYSA-N [I].[Cu] Chemical compound [I].[Cu] WXOQGOXTUJOXCA-UHFFFAOYSA-N 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- MLKWIQODPVLVLN-SHVFRELUSA-N ac1q1oa8 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)NCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CN)C(C)C)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C1=CC=C(O)C=C1 MLKWIQODPVLVLN-SHVFRELUSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IROPMSURBDPOOZ-UHFFFAOYSA-N acetic acid 2-(aminomethyl)phenol Chemical compound CC(O)=O.NCc1ccccc1O IROPMSURBDPOOZ-UHFFFAOYSA-N 0.000 description 1
- HZSIFDFXFAXICF-UHFFFAOYSA-N acetolactone Chemical compound O=C1CO1 HZSIFDFXFAXICF-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000004840 adhesive resin Substances 0.000 description 1
- 229920006223 adhesive resin Polymers 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001826 anti-prostatic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- ZCLVNIZJEKLGFA-UHFFFAOYSA-H bis(4,5-dioxo-1,3,2-dioxalumolan-2-yl) oxalate Chemical compound [Al+3].[Al+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O ZCLVNIZJEKLGFA-UHFFFAOYSA-H 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- ZEWGRSAJWPFTRK-UHFFFAOYSA-N cobalt rhenium Chemical compound [Co].[Re] ZEWGRSAJWPFTRK-UHFFFAOYSA-N 0.000 description 1
- KPLQYGBQNPPQGA-UHFFFAOYSA-N cobalt samarium Chemical compound [Co].[Sm] KPLQYGBQNPPQGA-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- SXIGIMWLTILHMB-UHFFFAOYSA-N copper pyrrolidine Chemical compound [Cu].N1CCCC1 SXIGIMWLTILHMB-UHFFFAOYSA-N 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- HASGOCLZFTZSTN-UHFFFAOYSA-N cyclohexane;hexane Chemical compound CCCCCC.C1CCCCC1 HASGOCLZFTZSTN-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- ZSAMZEYLGUEVJW-TTYLFXKOSA-N delmadinone Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZSAMZEYLGUEVJW-TTYLFXKOSA-N 0.000 description 1
- 229950006309 delmadinone Drugs 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940074117 estraderm Drugs 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- WGORGKPZXTVEGN-UHFFFAOYSA-N ethene silver Chemical group [Ag].C=C.C=C WGORGKPZXTVEGN-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000007757 hot melt coating Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 239000002661 non steroidal estrogen Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- KPRZOPQOBJRYSW-UHFFFAOYSA-N o-hydroxybenzylamine Natural products NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- YGBZFOQXPOGACY-UHFFFAOYSA-N ozic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C(CC=C(C=C)C)C(=C)CC2 YGBZFOQXPOGACY-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- KJASTBCNGFYKSR-UHFFFAOYSA-N prop-2-enehydrazide Chemical class NNC(=O)C=C KJASTBCNGFYKSR-UHFFFAOYSA-N 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000009951 qiqi Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003726 retinal derivatives Chemical class 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000938 samarium–cobalt magnet Inorganic materials 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229960002229 sulfametoxydiazine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950001362 tebutate Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- PMTRSEDNJGMXLN-UHFFFAOYSA-N titanium zirconium Chemical compound [Ti].[Zr] PMTRSEDNJGMXLN-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 101150117196 tra-1 gene Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
- A61L15/585—Mixtures of macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B26—HAND CUTTING TOOLS; CUTTING; SEVERING
- B26F—PERFORATING; PUNCHING; CUTTING-OUT; STAMPING-OUT; SEVERING BY MEANS OTHER THAN CUTTING
- B26F1/00—Perforating; Punching; Cutting-out; Stamping-out; Apparatus therefor
- B26F1/38—Cutting-out; Stamping-out
- B26F1/384—Cutting-out; Stamping-out using rotating drums
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Description
經濟部中央梯準局員工消費合作杜印製 46 45 1 1 at B7 五、發明説明() 發叨背景 本發明一般為有_ 一穿皮給_.系統,更恃別的是有關 一穿皮給藥条統的組成物,+¾中使用一聚合物的摻台物, 以影響藥物之溶解性以及! h紐成物給予藥物之速率更明 確地説,多種聚合物(較任為彼此不T/:溶者),其包含 可容性之聚乙烯时t咯烷ffi,ii π丨對該摻合物增加藥物之巖 大有效濃度,因而〇J在維逹成治療程度怛又可維抟所欲的 結藥與黏箸特性之系統R _、}丨:,有一大量的降低。 已知使用-穿皮Μ成物 '例如一含存醫藥(岜就足藥 物或是生物活性劑)之壓力敏感黏普劑,作為鉴本上捽制 於-固定速率r給鸲的方式这;已知给藥系統涉及將一 醫藥併入一載體中,例如聚合性基質11/或-壓力敏感的 黏箸性瓿成物中’該壓力敏感黏莕剞必需有效地钴莕於皮 膚上,且令該S壤⑴載體經由吃膚而移入病入的丨to液屮_ 花單K ( mono Π t.h i C )窀皮給藥中,藥物的濃度偽隨所 使用的_物與聚合物Ιίίί廣泛池Λ變 钴普劑中之低垩物 濃度可造成在達成使該醫榘給藥至一可接受的速率,定很 困難的 '其較佧者偽為零级之動力亨 另-方面,若高藥 物濃度經常會影»該黏筲剤之黏箸待性,β傾向於促進結 晶,發生各種程度的結品偽丙大部份可洽經皮慮的藥劑並 不是完全地可溶於戍是巧貽浮於壓乃敏感黏箸劑中· &穿皮給槃系統屮,晶體(藥物或其它黏普劑或这.二 者)之存在一般是不欲的D2藥物以徹結品的形式存在 時,其無法用於由系統中稃出,丨1Ht,無法用於給藥再 本紙張尺度適用中國國家標準(CNS > A4規格(210X 297公嫠) (請先閱讀背面之注意事項再填寫本頁) 訂-- A7 * 46 45 1 1 _____B7 五、發明説明() 者 > 雖然藥物的結晶可先溶解 > 再由系统中釋出,但楚如 此的.·過稈通常在迚率受限,a傾向於降低其穿皮通透速 ml ^^^1 UK .n. , I —^^1' f—^ϋ ^^^1 n^i -It I -、一-aJ i (請先閲讀背面之注意事項再填寫本頁) 率: 藥物經山皮膚之通透速率的擴散型式教不,逋透速率 偽敗賴於κ濃度,出就是,該速率像砍賴於在壓力敏感的 黏著性組成物內藥物的ft及其飽和的程度..雖然聚丙烯酸 酯黏普劑對許多藥劑Η有高親和力,囚此傾向於溶解藥物 成較高的濃度,而非作為橡駿黏著劑,但足Μ具在-系統 中作為唯一的壓力敏惑鈷宮劑時,咅诰成在逹成Βί接受的 通透速率上與黏箸特性丄曾冇闹難 在壓力敏感站著劑以 藥物飽和而達成最人的通透性之Μ低的濃度,偽可賴由将 •對藥剳具輕徵溶解度或不具溶解度之橡膠黏著劑,慘合 至一聚乙酸®姑替則中,而達成’氾,在一多重聚合物系 統中,_物之降低溶解劑與超飽和增加的程度,造成藥物 結晶之較佳的墙境, 溶解卨濃度的活性成^ πί使用於增加,S牲成份猓由皮 膚的流動,此正作報告中常稱之超飽和条統 經濟部中央標準局員工消費合作社印製 闪此,晶®尺才及分布辱成丨‘分《要的®數,必須控 制該等參數,以逹成撮大的給荜作用 俋足此等#數通常 十分雖以控制:而,無法控制品體尺寸與分如會導致-産 物1其表ii可教小出泫産锪之製造疔法偽不适在控制下的 :更重要的是,大Μ的品體存在丨:,特別足過Μ的品體存 在下,對黏替型的穿皮吸收_足fi吉的庄該Μ力敏感糸 統之衷面上的晶體β Ε筱與皮膚接觸,S對皮廣造成不良 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4 6 4 5 1 1 Α7 Β7 五、發明説明() 刺激作用 丨谘充 (請先閲讀背面之注意事項再填寫本頁) 可溶性的pvp偽已知為穿皮製劑之結晶化反應之抑制 劑。但是,PVP ’在足夠高的濃度下,會降低或是破壞藥 劑之治療量的给葉通透速率以及壓力敏感型黏著_之黏著 性。在1992年10月12日申請之Schering AG的EPO專利公開 案W093/08793,其名稱為“含有結晶抑制劑的穿皮治療糸 統”,描述PVP在一單一聚合物黏箸劑糸統中作為結晶化 反應抑制劑。在1993年10月12日授予專利之Cygnus 5,252 , 334,其名稱為“穿皮給藥之固體基質条統”,顯 示PVP之使用於一簞一聚合物黏著条統中,而無促進劑。 申請於 1 9 9 2 年 6 月 2 2 日之 Noven Pharmaceuticals,
Inc. PCT US92/05297,其名稱為“基於給藥糸统的溶解 度參數與改變藥物飽和濃度的方法”,描述一單片穿皮给 藥壓力敏感糸統,其包含二種不同的聚合物。該橡膠,具 有低的溶解度參數•而傾向於降低在壓力敏感黏著性組成 物中之藥物溶解度·因此降低該可被溶解的藥物濃度。 經濟部中央標準扃貝工消費合作社印装 國外的專利與專利公開案未有一者曾教示,藉由在一 聚丙烯酷酯黏箸劑中,將一橡顧加入一藥物中,增加其穿 皮通透性,進而增加該条統中之藥物的飽和程度,也就是 飽和與超飽和。然*因於在飽和程度上的增加,會導致藥 物的結晶化,此等專利與專利公開案未有一者教示,不需 要犧牲增高的通透性,以降低結晶化的程度,或是教示可 藉由加入一足夠量的可溶性的PV P,以令所有的藥物,在 該多重聚合物之黏著性摻合物中溶解於超飽和濃度,但又 -6 - 本紙張尺度適用中圉國家標準(CNS > Μ规格(210X 297公釐) 經濟部中央標準局®:工消費合作社印装 4 6 45 1 五、發明説明() 保持該组合物之黏箸性,而加以補救該結晶化的問題。 太鋅聃的摘華 本案發現傜可溶性PVP在一窄範圍内,可使用於一多 重聚合物之黏箸条统,該窄範圍傜可溶解藥物至相似於該 藥物單獨為聚丙烯薛詣聚合物糸統中所溶解之量,但又對 穿皮給藥無有不良的影饗,並可使該壓力敏感黏箸性摻合 物保持所需的黏著性。 前述目的與其它目的可為本發明所達成|其傜藉由在 至少為二種聚合物之摻合物中包含一可溶性的PVP。該可 溶性的P VPfe增加在壓力敏感組成物中藥劑之載量。所使 V 用之可溶性PVP的量可足夠溶解該藥劑,但不無不欲的结 晶化作用,同時,又不同降低藥劑的通透速率或是組成物 的黏著性。為至少二種聚合物之摻合物偽述於N〇ven Pharmaceutical, Inc. PCT US92/05297' 依據本發明的一方面,一改良的壓力敏感黏著性组成 物係包含一⑴橡膠、⑵一聚丙烯酸酯、(3) —藥劑與⑷一可 溶性PVP。 在此所使甩的“超飽和” 一詞偽指該藥劑其存在量高 出其在缺少該可溶性PVP之多重聚合物黏箸糸統中的溶解 度或可分散能力。 在此所使用的w聚乙烯吡咯烷酮”或“ PVP”偽指一 為均聚物或是共聚物的聚合物,其包含N-乙烯基吡咯烷酮 作為單體單元之一。典型的PVP聚合物是均聚性之PVPs以 ______ _-7 -__ 本紙張尺度適用中國囷家樣牟(CNS) A4規格(2l〇X297公釐) 1--------4 麥-- f (錡先閱1^«背面之注^^&^項再填寫本1) ΤΓ 經濟部中央標準局員工消費合作社印製 6 4511 at B7 五'發明説明() 及乙酸乙烯酷與乙烯咯烷_的共聚物該均聚件的p y p s 偽以各種不問的名稱而為藥學:Γ業所d知,該名稱包含通 稱為聚(丨.-乙烯基-2 -吡咯烷® }以及商}f明稱為丨,0 v丨don e , F ο 1 y ν ΐ. d ο η c , Ρ ο t y ν i fj ο η u ra S I·1 ο I y ν i d 〇 η u m S' J± i(ij ^ 酸乙烯酯/乙烯基吡咯烷_傜以Copo i ,yv idon , Copolyvldoru;及Copolyvirlonum而為藥學丁業所知嗪+.泠 適的Ρ V P聚合物包含該啤Β Λ S F .M;, L u d w ί g s h a f e η ,
Gormaru之商標名為Ko 1 I i 荇.’較佳荇為Ko丨丨丨fjon msF,25,,30,(mAP"1. 在此所當對PV丨·>使W "可溶性”.一詞偽指該聚合物為 在水中可溶的,Q 般實質卜:無交鍵鏈結,並只有約低 於2,000,00δ的分子Μ —般鸾見((.(:)丨」,〖1)肿:?1:|丨..1\/1丨彳丫丨」-PYRROLIDPNH FOR Tfl[i iJ !i A K H A (; Η 0 Τ ί C Λ L iHDUSTRY, BASK AG (1992!- 雖然PVP可增加在多重聚合物之黏著系统的溶解度與 可分敗能力,但增卨該P V Ρ Μ可造成該藥物泣動的降低, 並降低該糸統的黏箸忡闪此,所選甩的可溶性藥物量匦 足夠使所存的藥劑溶解,但义.不足夠阻滞藥物出系統流出 _该_劑ft吋利用W驗加以押丨定,丨日-般Μ劑對Ρ1/Ρ的® 遼比例約為1 : ] 〇,較伴為1 : 5至5 :],而以1 : 3牵3 :】 為最佳」 恃別佳的實施例偽乜,% - 一含有--橡_與-可溶性Ρ V Ρ 的摻合物,其中該橡嘐為一聚矽氣烷· 聚矽氣垸較佳傲//卬一壓乃敏感之黏若性組成物中, 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂' Λ β A 5 1 1 a? B7 經濟部中央標準局員工消費合作社印製 五、發明説明() 其量傜在該壓力敏感組成物之约91至约97%東Μ的Μ範阐 内 > 而該聚内烯盤詣較佳存在範圖偽至:多為下 較佳為聚内烯_對橡,比例(萆.1比)fh約2 : 98丕约9G :4 ’ Η更诖為约2 : ί)8 ΐ約86 : 14,橡瞪對聚闪燏酸酯之 最佳比例為可%所諾的藥劑之最高濃度逹成约零級的動力 學,具有足夠的P H以溶解所有的藥物,m又不對危 害地影響該壓力敏惑黏箸性組成物之黏著待忏或足藥物由 該組成物之通透出的特性。 可溶性的P V P為較诖疗在於壓力敏感之黏跨性組成物 ,其量係為整體紐成物電1之约]:;;至约2 0 ¥的範園間,H. 於i:述之對藥劑如ί:述之電.比例.加人呵溶性f> V P的最 低S偽為~量,其需要增加在三重糸統中藥劑的溶解度至 在相同的二垔条統i W缺少搾腰i中的藥物溶解度..此1 可由實驗加以測定,K偽結山it:聚丙__詣加溶解所欲1 之藥_,而後加入纪驹之可溶性P V P j.'U容解該筚劑:所晚 用的臭正銳偽依賴於决糸統、並可利用富驗測定,其測定 叫Μ由加入足夠的PVP牵混合物中*以補潰ίΐΐ於加入橡膠 至該聚丙烯酸潘所造成之藥劑溶解度上的降低。 所加入之可溶件PVP的展高_偽為一 It,《 4由系統 中給*藥劑之治療最(較诖為fl台約為零級的動力學), H_不會顯若地降低守皮施用所?需萝之莱统黏_M性此量亦 可利用實驗加以测定‘抟測定偽藉由測S由条統中流出率 或穿皮通虚速宇*以岐剧j 1:該系統的鈷著持件 該墼力敏感黏著性組成物包含一較仕為约0%至約97% (請先閱讀背面之注意事項再填寫本頁) 丁 . 4¾. 本紙張尺度逍用中國國家標準(CNS ) Λ4規格(2!0X297公釐) 4 6 45 1 Ί Α7 ____Β7 五、發明説明() _ _ _ _____ —II _ _ _£ _ _ _ _ _^ ^ J t «^^^1 ^—^1 ^^^^1 1^^11 nn >m ^^^^1 ^^^^1 nfv -s' (請先閱讀背面之注意事項再填寫本頁)
重® (J1最佳為约1«歪约9,1二甫聚)的橡駿约5¾¾约 85¾:重量的丙烯酸攝,以及一較佳為约U至约20¾ ¾ Μ I更 佳為約3 ϊ 5ί約1 5 :¾ ® Μ,丨j_最诖為5 ί; A丨5 ίΐ重S ϊ之πΐ溶性 PVP 該多重聚合物之黏箸性系統包含约50¾:至90%重簞的壓 力敏感之黏箸性Μ成物:該多:聚合物之黏箸性组成物偽 與一藥劑合併’該藥劑傺為該壓力敏感之黏箸性組成物之 重最的0 - 1¾荦50¾,最佳為0 . 3%至約30% ..任擇的添加劑-例如該械劑的共溶_(牵多30¾ S Μ ) 及促進劑(至多20 %重量)可包含/〗:该整體Μ成物屮 在-特別佳實施例中,该_劑為-頻固醇,如雌激素 或肋孕劑、或二者的結合| /i:另·較佳實施例中,該藥劑 可為/8 2-腎.h腺同效劑!例如銶必妥U I buUr‘o丨+U或是 一心臓活性劑(例如硝基甘汕;:Λ其它的貫絶例中該藥 劑θ為膽鹼劑 < 例如Ρ Π OC3 Γ Ρ丨nc I •抗精神異常劑(例 如h a I 〇 - r> e r丨d 〇丨.)· 一鎮记劑/銷定劑(例如a丨p r a ?; 〇丨a ί» 經濟部中夾標準局員工消費合作社印製 )或是®醉劑或鎮痛闱冏時,近來亦認知到影響CNS的 藥劑,例如尼Λ 丁及s(H eg i丨;ne+όί穿皮給f亦在本發明的 範圍内__ 壓力敏感之黏箸性纽成物「了更進一步包含此枝藝中己 知使用於穿皮給藥組成物之浞進劑 ' 馆充劑、共溶_與賦 形劑 圖示的簡要説明 _- 10 --__ 本紙張尺度適用中國國家標準(CNS ) A4規格{ 210X297公釐) A7 4 6 451 1 B7 五、發明説明() 本發明偽可Μ由開讀卜' 述詳細說明,並配合所附圔示 加以了解 > 該圈為: 第]_為本發明之單Μ穿皮給藥裝置的概要説明. 第2圖為擴敗慑數對淨溶解度奪數之圖形C 第3圖為顯示對含有一可溶性PVP之木發明紐成物之 雌二醇的平均流動情況· 第4圖為顯示雌二醇的由本發明之PVP組成物流經人 體表皮之流動情況」 第 5 圖為顯 Α 饮諾 _ ( nr r; t h i n d「ο η ΰ i fil 1¾有雌二醇 與可溶性PVP之本發明組成物流經人體表皮之流動倩況.. 第6顧為顯示本發明之含有荠棰不同濃度之可溶性 Ρ V Ρ的組成物,平均雌二醇與炔諾®乙駿酯的流出情況: 第7圖為顯示πί溶性丨>卩卩對雌醇流經人體表皮丄的 效用 第8圖為顋示雌二_與炔諾_乙_酯由本發明含舒名 揮濃度可丨容性Ρ V Ρ之組成物:tt : 醇與炔諾®乙酸酯累積的 通透倩況· 第9画為顯示可洁性P VP濃度判雌二醇與快諾_乙駿 酯由本發明之組成物流經人體表皮的流勤情況上的效用· 第]0圖為顯不可溶性Ρ V Ρ的濃度•對由本發明之含奋 各種濃度的〇ί溶性Ρ V卩的組成物中,流經人體表皮之雌二 醇與炔諾_乙酸酯平均流勒作用丄之效甩 較伟實旃例的詳細説叨 本發明傜旮圈-壓力敏感之黏著性組成物,Κ乜含一 含有至少二種聚合物' •可溶性pvp與一藥_的搾ίν物, 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29?公釐} (請先閲讀背面之注意事項再填寫本頁) 訂“ 經濟部中央標率局員工消費合作杜印製 A7 B7 4 6 4 5 1 五、發明説明() 該含有至少二種聚合物之梅合物在此稱為—-多重聚合物黏 箸条統。在此所使用的“慘合敉”一詞傜指帶該多重聚合 物黏著糸統中的f冏聚合物間無有,或®實質上無有t學 反應或交鍵反塍ί非簡單氳铤) 在此使用“壓乃敏感黏替劑”偽指一兵黏普忡與彈性 的物質,其4黏著至人名數ff]甚宵上,!0丨畤施τ輕微的壓 力,R.可保持待久件的黏_ 一聚合物,其木身R有_ - _ 力敏感黏著劑的待性-或呈其"ί賴由與膠黏劑、可塑性劑 或是其它添加劑的撥合 > 而使其功能坷作為一壓力敏感黏 著劑者,皆/i:此所述之壞Α敏感站箬劑耆義中壓乃敏感 黏箸_ 一詞亦m含不同聚含物的涅合物以及聚合物的湿合 物i例如不同分f星之聚異.Γ _ ( P丨B :m ,所得的起合物 為--·壓力敏感黏著劑:^: . h述最後·梗倩況F *在温合物 中之低分子里的聚合物 < 被認為足“幞轱劑”,該一 Μ被 保留給僅Λ :分子_Μ上Τ :於其所加入緊S锪之添加劑 6:此所使堪的“橡_ ” 一扁像指一昆有黏苔性明彈力 的物Η,其具有堅力敏感黏箸割之特性,β含旮辛少·禅 天然或是合成的彈性體聚台物合適的捭膠包含絮砂氣烷 、聚異Γ烯及天然橡_ 在此所使用的‘‘絕劑”及其栉常物、“生物活性劑” 與“醫藥”等誠是患欲ti含最廣的範圍,具包含治療丄' 預防丄Μ /或藥理學1:或牛理h ff利的活性物茵或W;等混 合物*此等物質绐藥至话的生物體4鹿生所欲违成_ Q 一 般為利益的效用… -J 2 ~ 本紙張尺度適用中國國家標準(CNS > A4規格(2丨0X297公釐} (請先閱讀背面之注意事項再填寫本頁)
L 經濟部中央標準局員工消費合作社印製 經濟部中央標準局員工消費合作社印製 46 45 1 1 Α? Β7 五、發明説明() 更待別的是,任何nf産生藥學反應的藥劑、不論足局 部或是糸統 '不管為對/;然、對栴物或對動物具治療性、 診斷性或迸預防性苔,皆ίΐ本發明所預朋的範圆内U同[诗 *本發明範圍内亦可為生物活性劑,如農藥.疋蟲驅除劑 '防喔劑、关容劑等、要注意的s,该藥劑I]. /或生物话 性劑可單獨使用或是以二或多種该等藥劑的混合物加以使 用,ίίπ具Μ傲!4足夠ΐ浪防、治癒 '診斷或治療一疾病或 其它狀況(當其在該狀況 該藥劑偽使m “藥學有效s ” 後者一詞傜指泫藥物 的濃度傺為在組成物中,《ί造成一治療Μ的藥劑,給藥至 超過使用穿皮劑景形式所給ρ的期間,較迕其為零级動力 學。如此的给藥傺軺於許多的可變因+,包含該藥物、該 個別割m單位所使用的時間贷短、泫藥物由系統中治動的 速率以及許:多其它可罾囚子「所?溝的藥物量可苯於該藥物 流經該条統與皮廣之流動速率(常其與浞進_併用或未_ 其併用下)而利用w驗冽定出测定出所需的流動速率, 則4設計該穿皮給榘系統·以使κ η呵在治療使用期間内 所釋出速率全少為相當於η流動速率:當然、該穿皮給蕖 糸統的表® m橫亦可影響該藥物由系統中之给藥作用·
-一藥物偽存在·“超跑和” Jfi楚如「:所定義者、該超 飽和星你需要的,以增加&系統中誤可溶性藥劑的濃度' 因此該Πί溶性的p v P必湞可溶解該藥物於抟它的起飽和条 統中I nj溶性的Ρ V Ρ偽使用.· "f W :¾地溶解_劑的ϋ,該筆: 本紙張尺度適用中國國家標率(CNS) Α4規格(2ΐοχ297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂- A7 B7 46 45 1 五、發明説明() 傜大於在丨I.Uij怛缺少橡_之Μ成物中所需溶解該藥劑之量 、但逯使用之πί溶性Ρ V Ρ的最高竜應不大於雒持給予該藥 物冶療请之Μ (較挂傜為可達成寧级勁乃爭笞) β |i ri] 保持該壓力敏感之钴莕性組成物之穿皮使用的黏普待性… 舉例來詋,一類固醉,如1 7 - .θ -雌…:醇成适炔諾®乙酸酯 ,在典型的聚内烯酯壓力敏感之黏若性组成物中為坷溶的 • /丨:無加λ的PVP存ίΐ F,κ設约為2辛41雖然Schw丨ng AG在1992年〗0月】2 Η中諸之PCT專利公開衆號W0/93/ 08793已庄意到‘在缺少Ρ V Ρ存庄丫,其傾向發生結品反喏 ,且維待於室温與宰帮下傾向於加速該反憋_本案發明人 發現將一滓_加入該涅合物屮可晓低該類冏醇在聚乙婦酸 酯中的溶解度,Μ此偽與荔橡膠加入迓成也比__閃此,在 --含衔--·聚内烯_ 0¾與--橡_的系統中,必須使用足夠的 Μ P VP作為溶解劑,以補償囚橡腰加入所1S成溶解度缺少 的問題再者,僅有耑低Μ的πί溶性PVP加ΐ壓乃敏感之 黏著性組成物,i.?.m ρ Μ的增邡可造成藥_之治療-S给藥 上之可接受通透性以及所欲之黏Μ性1.的喪失 本發明偽囚發琨一藥削由壓力敏感黏箸系統中之穿皮 通透速率可被選擇性地詉節所引發出,该調節偽Μ由_整 該藥物在条統中溶解度加以逹成 在此使m的“穿皮通透 速率”是指該藥劑淹Μ皮丨f路徑的速宰;熟習此技《人 土所知者,其坷受藥劑ώ稗體釋出的速串的影響或足不受 tt ^ . 形成一多窜聚合物的_合物可造成·具有一“淨溶解 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標率局員工消費合作社印製 Α7 Β7 46 45 1 五、發明説明() 度_數”待性的黏著条統,其選擇較佳為使係該藥剤的給 藥速率為可選擇性地詉節,此偽Μ由謳整在多重聚合物特 (請先閱讀背面之注意事項再填寫本頁) 黏著系統屮之溶解度加以违成_ 溶解度參數,在此亦稱為‘‘ S厂’ ,Κ定義成所荇分Γ 間引力的總合,其偽為曹驗.h有間許多化學成份的相孖溶 解的程度:該溶解®葱數傜/f: - Vaughan,"Using Solubility P n r a m « t e r s i t) C o s m e l i c: s l·’ o r m u 丨 a L i () n ," j , .S o c .C o_sM_eC h e m . , V o 1 . 3 6, p . 3 I 9 ~ 3 3 3 ! 1 9 8 5 ) \\·} 文獻中 該多重聚合物黏萬糸統較佳為θί成為一在签溫K屬壓 力敏感之黏#性丨1又μ有其它使m於穿皮給橥技_中所欲 的黏普特性。此等持η包含對皮#具良好的黏ΐί性、對皮 膚偽為可剝離或可除大而實質h不造成外傷、隨其熟成而 保持其黏滞性等等 ·般血a,多盧聚合物黏箬系統ϋ與 有·玻璃轉移溫度n’R )约Α: -701至0 Γ間(Η偽使用一差 別榀喵里色儀加以測定) 經濟部中央標準局員工消費合作社印製 在此使用的“丙烯_聚合物”一詞,如此技術所知可 與聚內烯酸酯、聚内烯酸與两烯_聚合物互換_該丙烯醅 為基礎的您合物與砂骗為基礎的聚合物較佳為革星比分別 由约2:98至約90:10問,丨fnA2:93至36:]4較佳,選擇以丙 烯酸基礎ί在此後寛泛稱為聚丙烯擻S§ ;之聚ft物的®以 及以矽酮為基礎的聚合物(在此後寛泛稱為聚矽氣烷)的 最,以修飾在四重之多萆聚合物鈷筲臬統中的筚物飽和濃 度*以達成影響詼藥_ ώ系统經由皮膚之给藥速率 -IΓ)- 本紙張尺度適用中國國家標準(CNS ) Α4Μ ( 2丨0Χ297公嫠) 46 45 1 A7 B7 五、發明説明() 在本發明之待别改良之實施例中,该聚丙烯酸酯偽疗 在®你在壓力敏感之黏箸件組成物的約5-85¾重最之範圍 内,該聚異Γ烯偽存在a偽在整體绀成物之茧1之約 04¾重Μ範圍丨Aj。「t Η —較佳贳狍例中,_.--聚異丁烯存在 鼠偽Λ該整體纽成物之1 0-80:ΐ f .量範圍内,而該聚丙烯酸 酯的存在S傜在該整體祖成物之5 -135¾ ® _範圓内.' 在壓力敏感之黏著件組成物中,藥_之.电量濃度較佳 為約0 . 1 X至5 0 :¾,較佳為约0 . Π尘约4 0 %,巖洼為約0 . 3 S:至 約30¾ (该電景西分书偽以窀力敏感之黏著性Μ成物整體 重Μ為基礎)__本發明待別合使用於以低度使甩之藥劑 , ,例如Μ成物之1 0% ' 5 =或甚罕3:1 f哲荦劑在詨穿皮給 藥条统中為高載里或呈低載嶺1本發叨之壓力敏感的黏箸 II: Μ成物可配成,以保持K可接受的™力、_黏性及剝離 黏普特性 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 在木發明的較伎實铯例中,該聚丙烯酸酯坷為均聚物 、共聚物、三聚物或各揮丙烯酸類似物之任一者在如此 的較佳賓施例中*聚内烯酸酯較ίΓιϊ紐成為至多為該壓力 敏感之黏普性組成物之整體重遣的95% •以約3S罕ϋ〇Χ為較 佳 > 以约5%至约85%為最佳,该聚丙烯_詣的a偽砍賴於 所使用藥割的it阴型式· 在實施本發明所使用的聚闪烯酸酯uf為內烯_之-種 或多棹單體與其它叫扑识化之帶鹾肜成之聚合物,該絮内 烯_酯亦包含丙烯酸烷詣H. /或Φ莊两烯_酯H_ /成可共 聚化之二級單體或具fi宵能堪的單體锗由變化所加入毎 -1 ()- 本紙張尺度適用中國國家標準(CNS ) A4規格(2iOX297公釐) 經濟部中央標準局員工消費合作社印製 4645 U A7 B7 五、發明説明() --型式單體的簞,所洱到的聚丙烯酸酯之黏答持性可以此 技鉍所熟知者加以改—·. 一般而為·,該聚丙烯酸酯傜由Φ: 少5 0 :¾重S之一丙烯酸詣或内熥酸ίπ脂單體、0壬2 0 %之與 該丙烯酸酯可共聚化的一宵能性單體及0全4 Ο Ϊ的其t單體 所紺成 該等合適於實旃例木發明之丙烯璁黏著_之進-步洋 細説明與例子漆描述於S η L a s A <: r y j i c Λ d h 〇 s丨v e s ,,-Han.dbook _r;ess u r.e.._Se.ns ! t i y e Adhes.1 ve__ Tech n o.[.〇κ.ν .2nd e d . pp 396 -4ΠΓ) (D . S a t a s , 〇 d . ) Ban Η o s t r a n d R g i n h o 1 d , New Y ; ) r k ( I (J 8 9 5 合適的丙烯_黏¥_偽為商業丄可取得者,其包含 N a t i ο η a i S l a r c h a b (i (:h<j m 丨 c丨 C 〇 r p o r' a L. ί ο π , B r- i d ίΐ e w a 11 r , N w J 〇 r s f; y 之商標名稱為 D u r 〇 - T a k 3 0 - 1 K) 4 , 8 0 -1196,80-Π97,22S7,25]. Π 及2852之聚内烯酸酯黏著 fff 實狍本發明所使用的撺賴黏茗劑a含焊聚合物*例勿ί 然或合成的聚〔甲基厂,烯,聚丁'烯與聚異j烯·笨乙 r二烯聚合物、:乙烯-二甲基τ -二烯-笨乙烯成塊共 聚物、烴器聚合物(例如丁袪橡膠)、含旮ώ基之聚合物 i例如內藍胺乙睛-聚叫龜乙烯、聚f[乙烯、聚m亞乙烯 及聚氛丁二烯)及聚fiv氧烷及其等其它的共聚物7 合適的聚砂m烷包含w _屬力敏感黏署劑,其傜検於 二種主要成份,一聚^物或mi:體與一臌黏樹脂、该聚 矽氣烷黏箸劑之製備一般偽碚丨丨! /!:·合適的有機溶劑下, _-17-_ 本紙張尺度適用中国國家標率(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂- A7 B7 4 6 4 5 1 五、發明説明() 利用缩合反應將汰彈忭ffi (典型地為·高分子量的宠有機 矽ffi )與一拐脂交鍵ίίΙ结·以産生一上度空間的矽rn烷: 該樹脂對彈性體的比例係為-可被調整的観要闪子,以改 質該聚砂筑 ίτΐ 的持 I9 丨:._ S 〇 h i ft s k i , e ί, ίΐ 丨,,"S 丨 1 d c ο n ft Pressure Sensitive A <j h o s i v 〇 s,, ·' SI a n d b 〇 k ο f Pressure -S (; n s i t i v e A d h e s i v e T e c h η o i o g y , 2 n d (; d ., fj F>. 5 0 8 -517 ( D . S a t, a s , o (j. ) , V η π N o y I; rL a n d R c i n h ο ] d , Now
York (1 989):. 菩施木發明所4使用的壓力敏感之黏另tl: M成物進一 步詳Μ説明與實施例描迚於如T述的美國專利第4591 Π22 、4584355 > 4585836¾ 4655707^ ·· 合適的矽31¾壓力敏感黏替劑係為商茱上可取得,阡乜 ri D 〇 w (' 〇 r1 i η κ C ο r ϊ> ο r .:ί 1 i ο η , Η t· d i (; h ! P r o d u c L s , M i d -land, Michigan,之販搭的商禋名稱,¾ Βϊβ-PSA X7-3027 ·, X7-4203 * Q7-4503 X7-4603 « X7-4301 ' X7-4303 ' X7-4919、X7-2635 及 Χ7-,Ή22 之矽酮黏箸劑,X7-.4203、X-4301及X7-.彳303¾持別合適使闬於含有苜能性胺 基藥劑(例如蘇必妥I之中 在實狍本發明之較诖曹施例時,;,¾栗矽m烷較佳為構 成該壓力敏感之黏著性纽成物的整體重E之約9¾:至約117% >而以约〗2全約9 7 X較佳·述以約]4 %全約9 4 Ϊ; ,¾結佳1 一般而言,藥劑罡可使甩於本發明中_此等藥劑S含 S亥等在 MJ3 Γ. c—k.—Sjldi? x, 1 1 ). h i'; d i t i ο η H e r c h & Co. Rbhwsy ,H . J . ( 1 9 8 9:)之第t h r - 5至U f) r - 2 9貞丨:的藥劑分類與植 本紙張尺度適用中國國家標隼(CNS ) A4见格(210X297公釐) (讀先閲讀背面之注意事項再填寫本貢) 訂· 經濟部中央標準局員工消費合作杜印製 Α7 Β7 46 45 1 五、發明説明() 類: Π.ί為本發明之新額穿皮給堃条統所给藥之華劃洌f包 含俏不限於下述者: 1 · /ί -腎上腺衮問效劑,例如蘇必妥iAlbUU「M .)、 B a m b υ t ¢3 r 〇 1 ' Β ϊ t ο ί t e r ο I 1 C ;j r b u t e r 0 i 1 e n b u 1,0 r 〇} ' 甘氣喘(T h r p r e n a ί ί n e ) ' De n 0pa m ί r) f.…i) i 0xe L h 0dr ; n e、 00Pxam i iifi > ffi m M U-;F>hedr i. ne i ^ ri i: W ^ Uip i. neph-r ί n<0、乙棊麻黄鹼i R t;a f r丨ne ) 乙锅夫Φ腎]:脾素( F 匕 h y 1 - η 0 r ο p ; n e p h r i γθ ) Q)j 内喘寧(FV: η 0「0 j )、 Κ 0 r m 0 Ue ο I、六甲雙喘定(H e x 0 p r 0 n a I i n e ) ' Η) ο ί:ί a jti i η ο、 乙基異内腎丄腺素nswthar inc;、異内大甲腎丄腺素丨 I s ο p r 〇 t (:ui ο n a S ) 1 M ^ h u t qvo \ Μ -Λ t η p v 0 1, e rh π 0 1 ' rP §{, 苯丙甲胺(Mcthoxy-phonam 丨 n(:、)、麻黃笨内® ((〕xyf(.)drine )' Plrbuterol Pr en^iterol ^ IV〇(;;.n〇r〇] ^ Pro^oky-ol 、茶丨可喘事(Re _i.,r 0 i,f—r'o !).、峨喘定(R i m i I,gr·ο I )、辟 V:莊 麻黃鹼(R丨to-d「;ne)、Φ磺胺異W腎h腺素(SotGi^nol )
Ter b u 1; 0 r- ο ] /¾ X a iis 0 t ij r 0 [ 2 _ /?〜腎上腺紊阯礙劑·例如喆Γ鲶心安UcebuLo .) ' 心得舒(A I p r ρ η ο 1 (; 1 卜 /\ in,);:; u i a i. ο ΐ A f. g t ίο 1 ο 1 * 跋隨心安 ί A iw) η ο 1 c· 1 )、!)> d u η ο ! o i、B r山.3 x ο 1 ο B e v a η U) 1。1 β ; s () μ γ。I -心)ρ i r“j υ ί ν) 1 . b 丨-U: u m) 1 ο I ' Γ 映心 安(Β。f ο - i, ο 丨 ο 丨)' Β ii Ι· u r 丨 ο 丨,丁 ¥ 皆心安(β u η 丨 t r ο U) ! )、E甲苯心安(EwmnG ί o卜)、了氛祭心定Uiiaidr i r丨d 氣化 Μ、B u 10 f i I () j 0 丨 ' C a r a / ο ί 0 ! .' C n r L ◦ 0 U> I 「; ) r - v 〇 d i 1 o l ' C 0 1 i p r 0 1 0 \ ' 〇 t a οι z ο I 0 i C 1 0 r a n o 1 0 i v· D ϊ ~ _- T9 -__ 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇><297公釐) I I - -- - HI n · I III ^^^1 ^^^1 . -、一SJ | :· = (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 A7 B7 4 6^51 1 五、發明説明() 1。v a 丨。I,S μ a η。ί。丨、K s m。j ()卜! r) de η。1 〇 j (訪心安}、L a b e l a 1 ο 1 - Lovobuno ιοί ' Hop i rjdo i o 1 ^ M e L ; p r a n a i o 1 ' t () p r o 1 o )、Μ o p r o 1 o j ' N a d o x o i o !,fij!j 苯心定 Ιί- ί· e n a [ g i ) , N i μ r d i 1 o 丨、 f] x p 「 g η o 1 o i 、環戊 丁心安 f P ο n b u t ο ] o ].) ' ㈣丨 1¾ 心?iM P i n (J o 1 ο I ),龉心安(P r a c L o U) ΐ ) 、禁心定(P r' ο n e t h a i o i 、祭心安(P r o - p r a o 丨 o 1 ),屮碘 定(S o t Η ο ] ) · S u 1 f i η a i。丨,了 1 i ri ο 1 ο 丨、了 e r L a t ο - Ιοί、丨® 嗎心安(Timoiol j、甲笨心安(ToM-Pro[ol)ft X i b e η o i o i 3 ·縝痛劑,例如籁Γ醉;麻酔劑,如Λ 1 fGntan 1 1、 Α Π y j pr od i η、A 1 p h a p r()(Π r! g、iWi Π o r· i「Η n e、笨中银嗎啡 (B e n z y 1 m () r p h ί n e) ' B e d W· m i d。' 叔[1 啡(B u p r 以 、丁 喃啡(β u ί, 〇「p h ri ιί 〇 丨),C ] ο n i I, a z (: n e、可待 1¾ o d q 丨 si e i、 可待固甲基溴、可待因礎酸、可待㈤硫酸、二氣脱氣喁啡 、嗎敬痛酒心酸監M D p >: t r 〇 in 〇「a in i d e h l) e z o c i ιί i:…銷痛胺( !) i a πι p r o in ί d e )® 丨丨 ί 行因(D i h :/ d r d ()丨 η ο ) ' 二 M 可待因 嫌醇乙酸、二氳嗎啡·、Γ) i m f; η ο χ a d I . D i m ϋ f,h ο f> t μ η () 1、二甲 基 i h ί a m b u U) n e ' i) 1 o x a p h p t v i "Γ 1¾1 0h ^ "* 0® l! Μ ί !) i p i p a n () n e )、E p Ui z o c i η o,乙痛新 ΐ K t h (> h t:: p t a z ί ri t)) > 乙基屮 ft: t h i a mb u Len e、乙堪啤啡、f: t乂. n iAari (」、分太 M ( Fc n t a riy ]) ' 二氣可待銅氣基嗎_、羯基麥定(丨丨y d r o x y p e t h丨cM n d、 異美沙 _ ( ί s o in e t h a d(> n )、K c t o b e ip ί dο η 〇 1 左嗔喃(丨 e v o r p h a ri r> 1 ),L o f。n L a η M、麥定丨 M p e r i cM η θ )、M e p t a z i η ο 卜 M e L a z o c ; ιί e、M e ί h⑴j o r〖(、氣化魅、印基二德嗎啡_丨M d ο - -20 - 本紙張尺度適用中國國家標準{ CNS) Α4規格(21 ΟΧ 297公釐) (諳先閱讀背面之注意事項再填寫本頁) 訂- 經濟部中央標準局員工消費合作社印製 6 4 4 5彳彳 μ B7 五、發明説明() ρ 〇 r!) ' 嗎啡(Μ 〇 r p h ; n e ) ' [1.¾ 啡衍巾物:M .y r 〇 p h 丨 ri (:…納]-啡(1 b u p h i rK;) ' 那碎[ZI !: N a「c。i n g )、N i c o m o r p h i ri e、去 甲左嗎啡 ί N 〇 r 丨 e v o r p fi a η ο Π、去申美沙 _ f N o r m g t, h a d 〇 ri e ) 、夫甲嗎啡(thj r· m o r p ii i n )、N ο「p ϊ p a η ο n e、遇 M ( 0 μ ί u m ) 、氣口1 ( 0 x :/ c o d ο n e )、氣嗎 _ ( ϋ x y in o r μ h ο n e )、P a p a '/ o - return -蔚痛新(P e n γ o c 丨 n e .),冲邪多松 ί P h e n a rj o x ο n e ) ' Phcnaoc i n e ' Pheoper i d ϊ ne ^ '}\ -¾ 7iL ( P i ιϊι i ηod ϊ η o) ' 氰苯雙峨酷胺(P i H tr a m i de ·)、Pr o hep z i n e、 Promedol ' P r ο P g r i cH n tj、比啦胺 ί p r o p i r a ii、内氣盼(P r ο p o x ,y -phend、Sul‘en Un ; 1及機樹皮案HWl丨(Hne )及弈赃醉劑, 如對乙爾胺基酚(Ace Urn丨ηυρ ha 乙醇乙㈣酿基水碭_ 與烯S苯乙酸馬身芬 4 ·抗晒峡炎劑,例如喆Γ酿心安i A <: g b u t 〇丨〇丨.)._丙 心安(A I p r g η ο 1 ο 1 )、Α πι ί ο H w! e ' Α ιί <κΠ Μ r] g、鎮麵心安 (Λ r ο t ϊ η ο S ο 1 ) ' A ι (3 η i ¢,- i > B q ρ r ; d ; i ' Β ο ν a η t ο I ο I、B u - c u m o 1 ο 1 T 11¾ 心 ix ( B u f e l o i o 1 ) ' B u f u r β I o i 、B u η l t r o 1 o 1 、氯甲苯心安(B u P r a η o h) I )、i: a r o / ο i o )、C a r Um) 1 o ]、 t: a r v e d i ] υ 1、(:〆! i p「o j t)丨、肉桂败馬來雜酷···硫M單i D ί ]i lb /.ft m ) E p a n丨,> I - F o 1 r- (i 1 p j n ^ - G a H 〇 p· a m i I ' \ mo \ a - mine、 ΐ n d e n 〇 j o i : I s (_> s o r' b M p -二硝酸 βπ , [ s r a d i p ] η o 、 L i m a μ r· o s t、M e p i r; rk) j 〇 丨、M (-1 U) p r 〇 j o j ' M。! d d。m i d o j o i : N i c a「d i f> i nc、硝笨啦症(M i Γ (μΠ μ i no)、随笨心定 ί N i F e n a 1 ο ί ) - N 1 i v d ] p 1(\q ' N i p r a d i ] (j i ^ N i s o 1 c! ι p i η o ^ 硝蓝甘油 ' G x P r e n 〇 ! 〇 [ ' 0 x y f o d r ] ri e、i) z a g r p ί、P (:) n b u - ____~ 2 1 - _— 本紙張尺度適用中國國家標準(CNS ) A4規格(2〗0X297公釐) (請先聞讀背面之注意事項再填寫本頁)
11T 經濟部中夬梯準局員工消費合作社印製 A7 46 45 1 1 B7 五、發明説明() L ο 1 ο 1 ' P e η 1 ,ί e r y t h r i t o i VM v^i fig P ϊ η d ο I ο I > P r ο η (? I h rj ] o ! '蔡心安(P r 〇 p r· a η ο I o 1 ) S o 18 1 o j、了 e r o d i Η n e、T i m ¢) 1 o j (請先閲讀背面之注意事項再填寫本頁) ' T o 1 i - r> r ο ! o ) V o r* ;i p a m i 1 5 *抗節律不齊劑,例如A e e b u U I、A c e c a i n e、腺ΐί、 禱職靈(A」ill a 1 i ri q )、:¾两心安i A丨p r e η o i ο ί ) '乙胺碘銅p夫 (A m i o rj a r ο η ο ) 、 A m ο f) r ο χ 3 η 、 A ρ r i n d i n fi 、 A r- o t i η o i o i 、 氣絲心纪(/Heη o i g 1 1、13van U,] ο I . B「ο Ly 1 i u m 甲笨磁酸 、B υ b u ο 1 ο 1、j D 夫心岐(B u i’ e t ο 1 υ i ),].祭酿胺 ί B u n a ί’ - tine.) 、 B υ n i t; r o i o ! 、 B u p r a η ο I ο ί ., B u t \ ό r i n g it ψι, B u t 〇 bθ rui i η ΰ ' h po be rh。酸、[a r. wo [ () 1、Ca r. t“;〇 1 o 1、 C i Γ ο n 1 i n ^ ' C ] o r a η o 1 ο ί · D j s o p y r· rj rn 1 d e ' K n c 3 ί n 1 d o ^
Ksmo 1 o j. 、 F [ eca ί n i dg 、 G?j 1 a o pnm 1 i , wi 4¾ Jb λΕ 、 I ndr:〇^ - ί η ί d e、f 6 心安 ί ί n d c· r: () ί ο I )r 81. r ο ρ ί ί·ΐ m 漠、利多卡因( i, ί d o c a i rj o ) ' ί. o r j ni ; r: ο、i, o r ο e i n i d 9.、Η ο o b ^ n t i η o - Μ o - t i p r ^ η ο ] o ] ^ H e x 1 i e t i r) e " Μ o ri i c ϊ z ί n e " H a d ο κο \ ο I ' 6j'j -¥:心定 ΐ N i - f e n a ί ο I )、0 x p r o ru) i ‘ ) 1、Ρ ο n L· u U; 1 ο ί、P i n d o - I ο I - P i r m e - η ο I ' P r d c L ο ί o } 、 P r a j m a ί i n e 、 p r o c a i η π m i d e 經濟部中央標準局員工消費合作社印— 氣化氣、F r ο n r, t h a 11> 1 P 厂 o p a f e η ο η (, ' Ρ r ο ρ γ a η ο 1 ο 1 , Py -r i η ο 1 i rn 奎 Μ 定硫駿,ill 定、S ο ί. a 1 ο j、Τ a 1 ί η ο I ο i、 Τ i in ο 1 ο 1 ' Ί' ο ο a i η i d e V o r- a p m i ί · V i q u i d I 1X i b e η ^:) ί ο ί ¢3 ·抗抑蠻劑,K S含 二瑞化合物,如 li i n e d a 丨 i m C a「o x a z o n ο、C i t. a, 1 ο ρ r a ί?ϊ Λ 1) i in e t h a /. 3 π 、 ) η ϋ tj i ρ ί n v) ' F e n c ?j jji ϊ n e ' I. n - ___- 22 -___ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 46 45 1 1 A7 B7 五、發明説明() 2 d e I o x a z 1 n e M it S , N e f o p a m ^ m i f p n s i π e 1 0 x i t r ϊ p - tan' 0 x y p e r t ί π e ' 1:> π r 0 x t i m e 、 S c; r· t r a ! ] η 0 、 T h i a ~ z()s 丨 ni ' Tr· a^0d0n 0 /¾ Ze tap i ni?; _ 糾 / 胼,例如 B e ruii 0 x i n e、i p r 0 lo z i. d e、丨 p r ο η i a - z i d ^ 1 s 0 δ r b 0 x a z i d N i a 1 a m i d fr ^ ί) (H, y m (j x i η & P h n e i - zlne ^ _ 咯綜®,例如 C ο i i n i r i e ' R 0 1 i c y p r i n (?與 R 0 H p r rj in 5 四 i叢徵素,例如 M a μ r 0 t Π i n r,’M()U'aiindolo'Mi-a n s e r i n ft 0 x a p r ο ί, ϊ I i ne ::::環素,例如;A d i r i y z 0 1 n m、A ill i L r i p t y Μ n。、A m 卜 t r· ! p L y I i n 0 x i d c、Λ w. 0 x a ρ ι n f_^、- B u t r 1 p t y ] i n 0 -- Ch^mi-p r a m i n e 、 D 0 m 0 x i p 1 i .1 i n 0 ' D r· s I p r· a nu i n 0 1 D i b q. n 0 p i n ' D i iii e L ;j c r ΐ n 0、 D υ L h i e p ί n : D ο κ e p i. n 、 F I u a c i z ί n e 、 1 iR ί p r 3 mine" I m 1 p r' a m i π e \\- ^ fL P/! ! r i r? d 0 1 0 ^ l. ο ΐ e -P r a in j ne ^ Me l ί l raco.n 、 Me la pr 8 m 1 n c ^ f1)or L γ· ί r>y 丨 ί πg N 0 x i p t i 1 „! η Λ 0 p i p r s !n ο I I" i z 0 L ^ 1 i n e · P r ο p ί z c p 丨 n e、 P r i) L rk i p t y ! i n (i ' Q u \ π u p r- ?j in i n e ' T i 3 η ΐ.Λ p t i rj ΐ: Tr'inii- 經濟部中央標準局員工消費合作社印製 (請先間讀背面之注意事項再填寫本頁) P r a m i n e ί 與 其它者,例如 A d r· a f hi i 丨 ' β e rsa c t: :y z i n e ,丨)u p r· ο p ί ο η ' Β u t 'j e i i η - ί) e a η ο 丨、' D u η η ο I h c q g ] u rn a 10、D e η n 0 丨乙 肢笨甲 _ 潘 ' !) i 〇 x a d r g 丨、H t o p e r id ο n e、F o b a r h a m a S, g 、F e m 0 x () t i n e、K e n p 0 ri t n d i o ! -. I; ] u o x 01 ί n e-,V I u v o x ^ ™ mine、H e in a t 0 f> 0 r p h y i n、1! .y pr:rr. } n \ n 、 l.ovophaceto- 2 3 - 本紙張尺度適用中國國家標隼(CNS ) A4規格(2!0Χ297公釐) 4 6 4 5 1 1 Λ7 B7 五、發明説明() P e r d n e % Me(JI f o x a m i η ο ' M J n a pr } n o Μo 1 o bo m [ d e 、 0 x 3 3 a f 1 o z a n e ! ? ] h r·; r a 1 ί n e " P r o 1 ι n L a fj e 、 P y r i s u (r c i d 〇 a π ο I ' K u b i d i u m ίί · S u I p ? r ί d cj ' S η ί t o pr ί <i c 、 T () n 卜 1 o x a λ ϊ n e、ΐ h oza 1 in ο η ο T o f e n a ·。i. n T ο I ο x =i l o rs e 、
Traiiy 1 cy pr oni i n。' L-色胺酸 V ί 1 o x:θί: i n。與 Z i me j (Π ne , 7 ·抗雌激素,例如氛羥孕 P n e t ο I ^ :〔苯筑胺與 To r e jti ί「e ri e 8 ·抗性腺激素,例如炔羥雄烯異噁唑(DsnazoO、(ie -s t r I η ο η e f4 tJ ώ r o x y [> r ο ρ i ο n e . 9 ·抗高血壓劑…其包含:
羚榣乙醇胺衍牛物,例如AmosuUloi、Bufur.㈧ol、D I ί (ΐ ν a 1 ο 1 、 L 乃 b e t a 丨 ο 丨、P r ο η ^ t η 9 ι ο I 、 S g L a 1 ο i ίέ S u ! f ί η a ! ο 1 ; 芳基氣内醇胺衍ΐ物,例如醋厂醯心安(Aabu to ] ο 1 ) '心得舒(A j p r ο η o i 〇 丨)、Λ r ο L 1 η ο 1 ο i,肢 ® 心安(A L 〇 -Γί ο 1 ο I j ν B e t a χ ο I ο i ; B ί" v 8 n t ο I ο I B ! s ο ρ v o i ο I. ' P> o pindolol 、B u η ί t r ο ί (j I * Br γ"ί o 丨 o 1 ' Bu Lo f i j ο ί o i、i:ara- z ο I o 1 C a r tez ο I ο I 、 il» r v i;> d i ] ο I 、 C θ 丨? p r o 1 (—> 1 、 G e t a — m o i o 卜 F! P a ri ο I o 1 s 如心安(ί n d e ri ο I o i )、M ¢: p i ri d () t o 丨. Nl e p r a η ο I。1,H。U.丨 p r ο ί。i r o 丨 ο I ' N a d o 丨 o 丨 N i p r ti d i 1 o 1 i 0 x p r e η ο ! υ ΐ ' 環戊 j 心安(P e n b u t o ) o ! )、ild [1¾ 心 yj: (Pi n d (Μ ο I ) ^ Ρ r 〇 p r1 h η ο I o ! ^ 1' J i n 〇 ! o ] ^ T o t r .v ο I o 1 1 T ]、υ 1 ())及 ΐ () ί h> 广。丨 ; 苯甲萆硫代一吖嗦衍卞物,例如A 1 th laz;和、Ben- _-24 -_ 本紙張尺度適用中國國家標準(CNS > A4規格(2丨0><297公F) n^i .1 - .Ϊ ^^^1 ^^^1 ί —rl^i ^^^1 ϋϋ nn--aJ { (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標率局員工消費合作社印製 46 45 1 1 A7 B7 五、發明説明() d r ο Π I』m ft t h i a λ i d g ' 笨屮 _ 晴(!ΐ a n zL h i a βί d e )、苯甲甚 M % 'Mi Ilf Φ ( B ο n z y i h y d r o cr h 1 o r r; thiazide) ' B u t h i a - (請先閲讀背面之注意事項再填寫本頁) z i d c ' :ii 0¾ f C h I f; r r· I; h ) a / i d ) ' C h ] o r· l hall d ο n (} ^ i?? 五瞎噪(f;y c 1 ope n t; h i a i rj〇,琛 _ n# ( Cy i: 1 〇 t h i 以 i d())、 M 氣化物 Π)丨 a z o ; d e 〗、L· p i t h i a z Ϊ (」t>、E L h 丨 a z ί ci f;、 F ^ n q u i z ο n e ' fi ¢1 !® ^ (11yd r o c }j 1 o r o t h i ?j z i d 〇 ) ' (I y - d r ο f i u rn ο l h I a ^ i i j e ^ M e t h y c: ί r; l h \ bz\ d ί;· ^ Μ ο l i r a η o ^ M e t o 1 a z ο n g、P a r· rrf I u t i z i d ί)、I) ο I .y I: h i a z i d e、四氣 Ψ 口寒 Φ ^ T o t r a cr h 1 o r m e L h I u z I d o ) ;::: S ^ ί T r· i e h .1 rj rme- l h i a z ϊ d e ); N-羧袪烷基(胜肽/内醇胺)衍生物,冽如Alacepril 、C a p t o p r i 1 1 ( i. ί rj >_ ^ μ r- ί i ' D :} ί n p r 1 1 、 E ri a ] a pry \
Kn a 1 a p r I ! ^ t、F os i n ^.)pr1 I 1 、 !. i s I η ap r- j i ' Ho vo j t i pr i J 、P e r i n d o p r· i 1 . Q u i n a r ί ί S R a m ί p r i j ; 一· M 批晚衍牛物 * 例如 Λ m j ο (Π p i η ο、I.· e I o d i f> 丨 n e., f s r a ci i p 1 n e · Μ ϊ c a r- dip! n e ^ (¾ )¾ (Nifedipine) ^ N i i v ^ (i ί ρ i ri ' M i s o i d i p i n c.^ .¾ N \ t r ο n d i p ί n e ; 經濟部中央標準局員工消費合作社印製 胍衍生物,例如¥卿(Bdhan ;(」丨ne)、脒基四氣輿玺林 (D e b H s 〇 q u ί r丨)、1¾ 壓舰丨 G ΐϊ a η a b。η z >、鹏乙室(ti it a r丨 w I i η o) ' 1;, Μ. ιέ i ii u βά n w d r ^ I ) (Guana ^ o dine ) ψ\ 乙定(Cl ij a η o ! h i ί j i η 〇 ) U u ij η Γ a c i ί.) e ' 舰氣.潘(G u a rj oc h 1 o r )' G u a η o x a b e n / 與脈生 1 G I」9 η ο u n ); d r* a 1 ij ?: i η o = \i n ii r u \ <.1 / i n <' = H y d r rj c: u r b 3 / i η o .: H y (j r ^ - ___- 25 -_ 本紙張尺度逍用中國國家標準(CNS ) Λ4規格(210X^97公董"1 A7 4 6 45 1 1 B7 五、發明説明() a ζ ί η 〇 ' P h ο π i p r a ζ 5 ii ο、 F1 Π d r y ! κ 1 η e 與下 ο ίΐ r· a ί a η e ; 咪吨衍生物,例如氮壓定(C [ ο n i d i n e ) .,L o f 〇 x i (Η n c ·、 (請先閱讀背面之注意事項再填寫本頁) P b (} η f: ο I a ϊτι j rt e、Ί i a ίϊΐ o ni d i n Ω| T (j 1 ο η l <j i n e ; 四級銨化合物,例如噴他明ί AuineUon ium)溴化合物 氣異㈣脱 < Ch 1 〇r i sο ndaτϊΐ 丨 r)e C)ι 】or· i dο)、六烴乎跋(He ~ x a m e t h ο n i u m ) ·、P ο n t a c :y n i u m ·二(甲丛硫酸醋 > 、浪化 次戊基二甲季銳(P e n t a πι M h c; η丨u ai B r 〇 m I d <j) _,血安定( P onto l i n i u n? Ta r l h t o ) 、 Phen a ctop ί η ί u fL ίΐ? ® Φ Φ $$ (I r I m o t h i d ί u n u ni Μ o t h o s u 1 f a t e); _ _ 衍生物,例如 A I i_ 丨」z o s 丨 η、β u r丨 a z o s i’ n = D υ x a z o s ί n ^ P r a s d s ί n ^ Terazosin ti :. Ψ 0: ϋΐ ί T r· ί ni a ?; o s i n > ; 利血平衍生物,例如e L a s e r p ; n e、脱甲氣利iil〖平( D e s e r p i d i n e)、利血敍 ί. li e s c i rj ri a m i η g ) ·,利血平甜血壓 果平.ί S y r 〇 s i n g ο p i η e ί ; 磺羱胺衍生物,例如Ambus ; dr氛峨胺(C j opara丨do )、 利尿磺胺(Fu r. o s p ip 丨 d c·) ' 1 n d a p a ιη i d e U u ΐ n o t h a z o n e , T r i p a m i d e 與 X i p a ni 丨 d e :及 其它者,例如A j ϊ« a H n e、 r _ -胺基了酸、B u f e n丨〇 Q、 經濟部中央標準局員工消費合作社印製 C h J o r t h a ] Ιόο n r ' C I c ] ί ^ i n e ' C S c J o s i (j o in i n e 1 m蘆 i? ^ ( C r* y p t ο n a m i n ο T a n n a t e s ) F ο η o 1 ϋ ο p s ίη ' F!oso~ q u i π a n ^ I n d o r a in i fj K o 13 n s e r * ί ri 、 M e L b u t: ain a t c · M e 〜 c a in y丨a m〗n g、M e t h、y 1 d o p a、巾基4 -批咕基硫极基腕、 M e L ο I a ζ ο n e ^ H i n o x i d ι ί ^ H u (> I i ni i n e ^ P r g y ! ί n ^ ' P e m p i d j n o 、 i ; ί n a c i d i i ' I" i p o r o x a n , r i m a e r ο n e 、 -26 - 本紙張尺度適用中國國家榇準(CMS ) A4規格(210X297公釐) 4 6 4 5^ ' a? B7 五、發明説明() Ϋ r 〇 t (.) v e r 3 t r· ί n e s、R u b s s ι η o、 R o s; rr i m o t ο I -, R ] I m o - η ΐ d o rn S a r a I a s i n、骑费納隐、T i c r )/ n a f t> η、T r i m c - t h a p h s π C a m s .v I a I; e ^ SS K 3¾ Βίϊ * T y r o s i n ^ s e ) lil II r a p i d i 1 10 ·抗炎(非類固醇)藥·,K包含 胺基芳基駿辨衍物,例:¾] E n f ο n a m丨c Λ c丨d、K t ο ί ο -riamatF: F i u Γeη n m i c Ac I d ί sοn i x i η ' Μec i of en a m i 〇 i\ c i d ' M e f a n a m j c A c i d ^ N i f' ] u m i c ή c i d ^ T a i n i f ] u - ma f:e 、 T e r ο ί ο n a in s i e /¾ T ο ί f e n a m i c A (' i <j ; 芳基乙酸衍卞物,例如丨n、烯氯苯乙酸Blf 5.ί ( A 1 (: 1 ο ί e h a c j、(\ in f ο n a c、B u f o x a ni a c- ' ί" ί ri m t n p, i n、 C 1 ο p ] r-9 c ^ D ϊ c 1 o f ο η h c Sodium · E t o ¢.1 ο ί a c I" e f b ; n 9 c ' F e n c ] o f e n a (;、F (〕n (.,ί υ r oc ' K e n c 丨 o z i c Acid、F ^ n 1: i. a -zuc ' G ] u c a me t a c i n ' i b u f e n g c ^ 抗炭㈣ ί I η d o in o t h ^ c ,i n )' I s o f e z o i a rr ' I y o x c p a c ' L υ ")丨 a c、M ei ι a z i n i c
Acid、ϋ x a ίϊ) e t a c 丨 η ο、P r o gi u m o l« c- i n、S u 〗ϊ n d a c 、 Ί i b - r* a m i d ο 、 T o ] jh e t j n iii 7. o in o p i r· 3 c ; 經濟部中央標隼局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 芳基]駿衍 1 物,Ml 如 B u,d ; z ο η ' 3 u i. . j b u Γ e n、F e n -b u i' e η ί'ι| X e n b u c i n ; 芳甚®酸衍生樹,例如C丨丨d a n a c、K o丨,〇 r o i a c與ΐ i η o -r I di n ί 芳基乙_衍生物*例如Λ丨m i η o p r 〇 f (.: η ' B e ιί (,x丨丨p r o f。n ·' B u c ! o x i c Acid ^ ί' n r p r ο Γ e n ^ i-¥: % :S< 4j. f L· PWJ ί G 3¾ ( F o - η o p r ο f ο n ) 、 F I u η o x a p γ o f' ο n 、 F ] u r b h> r o f ο n 、異」-ΐ 丙 本紙張尺度適用中國國家橾隼(CMS ) A4規格(210X297公釐) 6 4 4 5 11 a? B7 五、發明説明() W, ί I b u ϊ> r1 ο f ο η ) ^ i h u ρ r ο χ a m,I nd ο ρ r ο f g η、綱笨两酸( (請先聞讀背面之注意事項再填寫本頁) K e t o p r'· o f ο π ) ' L ο x o p r ο Γ η ' H i r o p r* o f ο n 、 U a ρ r o x e n 、0 x a p r ο z I η > P i k e i o p r ο ΐ ο π ' P i r- ρ r o f ο, η ' P r a η o v r of e n 1 P ri o t / /: i n i c Acid ' S u p γ ο Γ e n T i a p r o J1 ο η ί c ή c i d ; Π比唑物,例如笨iH安咄唑(IHfenamizde.)與 [{P i r ϊ ^ ο 1 e ΐ _ Πΐ· B林銅,例如 A P a z () ϊκ)、 B e n / p i p o rf y i (, ri ' f; e p r a zone Λ Μ o f o b u l a z ο n e 、 Μ o r a z ο n <:、0 χ y i> h e nbuia z ο n c-、 iJ h e n y b u t a zon ο 、 P 1 p e b u z ο η o ' F1 r o \> y p h e n a z ο o e Λ li 8 m i 一 f e n a z ο η o ' S u x i b u z ο n e i>f T h i a z o 1 i η o b u l a ο n e ; 水楊酸衍7ί:物1例如靖羅( Λ c e L ai ri o s a〗o丨)、l>j斯 匹林(A S P i Γ i )、撲炎痛〔[5。410!^】^9)、1!;「01110821]8«^]『1 、乙酷基水楊酸 、丨)i Π u !Ί 丨 s 丨、K t s 丨 a t c、Fn d ο -ssl、Genii s〗(: Acid '水楊酸乙二酯.眯唑基水揚酸酯 離胺酸乙醯基水揚薛酯' Mesa丨mn i nc、嗎啡啉水揚酸 醋、1 ~ Μ 基水楊 _ 酿、ΙΠ s a 1 a j i n e、P a r s a 1 m i d e、·¥>_ ft 乙®基水掲酸ft、苯荜水楊酸酯、乙瘂水楊酷胺、水揚 胺0-乙酸、水揚®硫酸· Sal sal ate與柳氮磺胺毗啶( 經濟部中央標隼局員工消費合作社印製 S u i f y s a U丨 z i n e 丨; D塞 P秦破醢胺,例如 I)r ϋx 丨 f:a ra,] so x i c:a jn、P i r o x i ca οι 與 T e η o x i ( ; n ni i 以及 其它,冽如E-乙醢胺基癸酿、S-腺轩中硫胺酸 3-胺 .¾ - 4 _ 輕基厂趙 * Λ m i >^· t: r i η β .. ΐ ㈣ 1¾ ( B e n d a z a r )、Β ϋ η z y d a in i n e 、 B u c o J o m e - D ι f e- n p i r- a in i d e 、 \)\ Ihzo l , K m o r* f a ^ 28 一 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4 6 4 5 1 1 經濟部中央標隼局員工消費合作社印製 A7 B7五、發明説明() zone ' G u 9 1 a z u I n ^ 、 N a bum ί-10 n c; ίΠ ίϊΐ e s υ 1 i d e - Π r g 010 in 、 (J x a c p r 0 1 Λ P a r1 s n y I ΐ n e - !; 0 r 1 s 0 x ti J 、 P i f ο x ί ίϊΐ e Λ P ri o q u a z 0 n e ' 1) r 0 x s z ο I g 0:{ T η ϊ d a p 11 ·抗賛瘤劑、其包含: 2-胺基-乙醯丙酸與K化劑,其包含 ίΐ基礎酸,例如白消安ί B u s u 1 f 9 η )、1 Hi ρ「〇 s u丨f a η _ 晴消安(l> i P 〇 s u I f a η ); 氮河促,例如 B e ri0 d f* p a、C ;:u· b ¢) q u 0 n e、M a 11」r1 g d e i) a 與 U r。d e p a ; 乙撑亞胺與甲基蜜胺,例如/W t.reUmine、三乙撑基 蜜胺三乙撑基磷醯胺三乙撑基硫磷醯胺與三羥甲基蜜肢 , 気,Μ 如方」酸&芥 U: h 丨 〇 r a m b I」(:丨 Η ' C h 1 〇 r n a p h a 2 ί n e、 C h 0 1 0 p h 0 s p h ?j ΐϊΐ ΐ d R ' M " ~ 0? n Si! ( E s t r a /11 u s t ΐ n e ) [f 0 s Γ a m i d e 、 M e c h I 0 r e t b ίί ni j η β · M 0 c h ί 0 r p t h a mine ϋ x i d 0 Hydrochloride 1 M e .1 p h y i a η N o v e Jti b i 0 h 1 n P h 0 n e s t e r i η g ·、Predn i rous t i n (3,Tr,oi_os fa ffl i de與张喃晚抒 < Urac i j H u s t a r d); 亞硝基腺,例如Camstirie、HttM亞硝脲氣乙鏈腮 lM 素(G' h 】〇 厂 ο z () t 〇 c i η ) '1- F 01 0 in u s t i n e 、 L 0 jd u s ΐ. I /) e ' H i m u ~ s t: ί n e 與 R a n i /n u s i i ιί e ;以及 其它,例如[)a c a r b a z i η ο、M a η η o m ΐ」s t i η ο ' M i t o b r 0 n } t。1、 Hi L 0 i a c t ο I a n d P 1 p 0 b r 0 jii ?ί n ; 抗生素’例如A G 1 a c i n 0 m y c丨n s *放線徵素F、輕徽素(A n - -29 * (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) Λ4规格(210X297公釐) 4 6 451 A7B7 經濟部中央標隼局員工消費合作社印製 五、發明説明() t ra my c i η ) ' Μ Μ: W βί ^ Aζa sοr i η e ) !W ΐί(· Μ Μ (Β 1 ^οm.y - c i n s ) ^ C a c t i η o m y c in ' Csr ub i c i n 0¾ ^ (¾ ^ ( C β r r: i n o - ph i 1 i n ) ' tii ® S i: C [sromom,y ^ Ins) Ψ. f\:. Wi M t 〇^c I. i ηo my - c i n )、道选红黴素(D a u η o r u b丨c丨n )、 6 '~m-氣L ~去甲 ίί胺酸、阿黴幕U) o x o r u丨)i c i n .)、丨〕p ; r u b丨c丨n、絲裂徽志( M i L o m y c: i n s )、黴酸酸(.M y <、o p h e η ο 1 .ί <: A c: i <i)、謀加徽志( N ()ga 】a J^y c i η )、橄欖黴紊 ί ϋ j 丨 v ο/ώy ί:丨 n s )、匹.來黴:(厂(,-ί) .1 o m y e i η 、fM ; c a in y e ί ri、甲莬綠裂黴素 ί P 〇 r Π r 〇 my。i γι 【漂昤徵素(P u r o Hi .y c i ri ).鏈黑 1¾ 素 i S t. r e p Lor) i g r i η )、 鏈脶黴素iSUiptc^oc h〗)、結核黴素(Tuber cadhu、 iJ b e n i m g x、新製搞微素(ZJ η o s L a i. i η )與 Z o r ϋ b i c i η : 抗代謝劑,其包含: 藥酸類似物…例如1) e π ο pi. e r ί η、Μ (H」J^n r g x a k、 P t e r·。p 1: e r. i r丨與 T r i m。t, r·。x a t e ;嘌呤類似物,例如FludarA丨ru!、G-競挂嘌昤. T h j a m ί p r_丨n c與硫腮;以反 嗯旋頻似物,例如瑞跑啦(A n c i Ui b丨n c:) > A z a c丨t i -«J j· n e、6 〜氮诚赔丨淀.〔:a r j]Ki f f] r、可糖胞 ΐ? ( C\y U』r a b i n e )、 i) o x i Π u r· i d i γϊ e、E η ο ci L a b i nc?,藏賊聰虛脫 S 核 1/ ( F 1 o x - u r i cl i n e)、氣嵌喷從(F i u r ο o u r a c i 1)與 T e g a f I」r ·; 酶,例如I,天冬瘦胺酶;以及 其它,洌如乙酸韶㈤鹄内酯( Accs丨atone)、 Amsa-c r i n e 、 B e s t r ^ b u c i i 15 i s ^ n t r ^ η c : C y r b ο μ 丨 a L 丨 n 、 C i s - p S a t i n 、 D e ϊ ο i a jn i (J o 、 D t· m 〇 c o 】i 门 o 、 D i a z J q u ο η ΐ 、 E 丨一-;j〇 - (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4 6 4511 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明() f 〇 ri i t h i n e ^ E ] 1 i p !. i r> i u in A rr e n a t ο ' E t o g hj ο Ϊ d ^ E l o f> (j -s i d e、(] a 1 1 i u m N i U_ a k、羥基祕素、干搜素i、千接索-/5 ' ί ·接素"、間 Η 裘-2、L n t: i n r」η, L ο η i d a πι i η ο 1 Mi I ο g u a ζ ο η e Λ Μ 丨 t ο ;< a π ί 厂 g η e 、 ρ 丨 d a 爪 ο 丨、fU L 厂 iuy ί n e ' F e n t 〇 s L a tin λ P h n a ni a t ' \} \ r n r· u b j c ί n ^ F o d o p h y jj ί ί n i i' c A c: ϊ d ^ 2 - K t h y t h y (J r a I d e λ P r o c a r b a ^ i n p ^ p S K r ' R a 7: o -xanc ^ S i z ο Π r a n ' S \> 1 r o g e r m a n ! u m ^ 1' ;:i x o i、T e π i ρ o s i d o 、T nua z ο n i c A c ί d、、乙趙亞版來爾 f T r· ί a z i quo ιί 〇 ’、 2.2 ’ 2 ·’ -二氣二 <^ffiK、UreUian、\/inbiasLine、Vin-c r i s t ί n e V i n d e s ] η ο ΐ12 ·抗《瘤劑(激素類)-其iii含: 雄激素,例如二甲翠丨us^rorid、内酸甲®睪( Droffiostano J ono P r ο p i ο n n t o ) 、 F p i h i o s t. a η o 1 、 Η ο p i. 11 o *-s L a n ft與去氣睪丸内酿(T e s t o la c L ο n e ); 抗腎上腺素,例如胺堪笨乙败〖ίϊ ΦΜ Am丨ηog 1 uth i ni丨de J * 氣苯 氣乙院 ί M 丨 ί, o t if no.)與 T r i i ϋ s t a n g ;抗雄激素,例如F丨u i: a πι ί ci e與N ί ί u t a m i d (〕;以及 抗雌激素,例如 T a in <) x i ί 〇 n 與 j 〇 m ] iV.1 η g、 U ·抗巴金生氏病M劑,例如乂琛癸烷胺Ai^raadine、 Beriserazido、安克·ίΒ;ΡΘΓί(·^η)、Br〇-in o c r i p t i n e B u d I p i o · (: a r b i d o p a ' D e ρ r e n y ί ' D e x o t i -m i d g ^ 0 i t * t h a ,: i η o 、 D r α x I d o p a t L h <v p r o /) ii z i η g .' Ethyl-bd zhydram ί m' 左旋多巴(Le vodopa ,)、Naxagol.idfi、Pw gol id e 、 P i r*o h e p t 1 n e ' P r i d 丨 η o 丨、P r o d ί ρ ϊ n e 、 T c* r g u r i d e ^ 31 ^ (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 6 Δ 經濟部中央標準局員工消費合作社印製 Λ 5 ^ ' Α7 Β7五、發明説明() 、T i g 1。ί d ί η ⑸與 T r; h。y p h e η ΐ y 1 fi y d r 〇 ¢.: h 1。r i d e . 14 ·抗前列腺肥大藥劑,例如17-羥基-丨9-去中基-4-孕 m )¾ ( G 〇 s I: ο η ο ro η e a ϊ> r (j a to) Me p 3 r t r· i r: i ff > 0 x c ii d ο I ο n e pi P r 〇 s c a r r -1 5 ·抗精神病藥劑,其包含; Γ 醯苯類,例如 β ο n p e r i d 〇 i ·、·沒啦 丁笨 f β r g m ρ 〇 r‘ i d ο 1) 、D r o p e r i d o 丨 ' F I u a n i s ο n e、氟岐 丁苯 Ula ! ο p g r Η 〇 L!、 3 Μ ΰ 1 p e r ο n (' 、 Mope r ο n e ' P 丨 μ λ ni p e r ο n <_、 ' S η i p e r1 ο n e 、 T i m i -P o r ο ώ e T r ! f ] u ρ o r 1 ό o !; 苯_ _類*例如乙S舊乃興(Aretophenwlm)、Γ毗 啦 _ (β u t a p e r a d ri e )、卡紛那 _ ((; ?j r p h e d 以 i n。). C h j o r -P r o e t h a z i n e 、 m Of U; h ί o r p r o m a z 5 n e } 、 C 1 a s ρ ί r a ^ i η o 、 Cy a inen?az ϊ η ο 、 ϋ l Kyr^ z i n e , F I u ph eη η z ί n p 、 ;. )i\ i c ! οpz ί n e 、M e p a z i m·甲楓達峰(Μ ο s ο「Wj ϋ z ·【n e )、〗p 氣内瞻(M a -t h o x y p r o in a z ί n c ) ' He to [ cn ^ z s i c 0 x ^ f ί u n? ,ί z ϊ η β * P o r a -i n e 、 P e r i c y a z i η ο、P e r i m h h y ^ i n e ' 畜乃 Μ ί Perphenazine) .、Ρ i ροrace taz i n e 、 P ί p ot, lU ηc 、 Pr och I or per a -zinc ^ P r o /n a ^ I η o ' Sul f o r i (j a ^ i n e ' u 0¾ ^ ί T h i o f> rv op^-z a t e )、甲硫達晴(T h i o r Η i】d n e)、ϊ「ΠΊ u ο ρ o r a z ί n 與:: 氣氣 i闲讀(T r 丨 f i u r o m a z i n。); _ _類,例如泰爾登〖C h k) r p r o t h j x e n e )、氣0¾嗔( C i o p e n t h i x () 1) ' 三氟 ί® 顿(F I u p t? n U x ο [)與胺诞晦:喷( T h ί ο L b i x η ο ); 其它的二塌類,例如 B e η z <i u i n a m i d e、ί: a r p 〗p r ?i m 〗η ο、 -32 - (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) Α4规格(2丨0Χ297公釐) 經濟部中央標隼局員工消費合作社印製 五、發明説明() C j 〇 c a p r a in i n ft ' C 1 〇 m a c「a η、C I ot Si i a ί> ; η ο、C 1 〇 z b ρ ί n e、 Up I ΡΓΒΐΐΐο 1 ' Proth ι pondy I · t ;j bοn a z i η ^ξ5ί Zο lop 1 π e ^ 以及 具它,例如 A 丨 ίζ a P r ; d e、A jii i s u I p r id u、B u r a iT! a t e… i; I u s p ] r i j ο n e ' Μ ο I i n d o n<^ · P f,· η Γ ) u ri ) d o [ ^ p i m 〇 / i <j ^ > S p i r i 1 ¢) n e i?4 S u \ p \ r l <} e, 1 5 * 解接 _ _,例如 Λ Π b e γϊ d o !、/\ π b lj c f; U:i ni i ij ft,π 1 ηο-ρ r o m a 2: i n e 、 去水 H 品 ί£ ( AF>〇月 l· r o p i n。)、Be v ο n h」in Ψ 基硫 @r Λ B i e t a hi i v e r* i η o ^ B u t a v 〇 r i n e · B u t r ο p i u πι B r o m i d o ‘ N ~ 8 u l y i s c ο p o 1 a rrf m ο n i u m B r· o m l d 〇 C a r υ v o r i n t; 、 C i - in. e t r o p i u B r o iii i d e · (; i η n a m o d r i η o 、 C 1 o b o p r i ά e ' ^ -¾ ίΐ齡授化氣(C ο η Π n g Π y d r υ h r f) m丨d g )、歐毒序齡氣化氣( (.' ο n i ί η ί- Η y d r ο c h lor l d r:) ' C y c ί o nluia I o d i d o 1 ΰ \ ΐ (-m e ~ i i n e , f) i i s ο p r o /n i n (、, D i o x a p h e t .v \ B u t y r b t e , D I ο p ο n 1 u m B r 〇iii i d o ' D r o f c η ί η ο E m ο p ο n i :j πι B r o in i (i e 、 K t h a v o r i η o ' Fec 丨 e oi i ru1 、 l; f3 n a ί a in 1 d(i 、 Fο n v ^ r i rie 、 l·’ e n p i pra ne 、 F e n p 丨 v e r i n 丨 u in B r r; /π ί d e 、 F ί- η t ο n i u id P) r (> hi 丨(k, 、 K 1 b v o x a t g 、¥ l opr op \ ο π o . ® 搪酸 ί U j u <·: o r山:Acid) 、 ti u a i y c: 1, r.i in ί 、11 y d a iii i t r a z i n e 1 St y m e c r ο πιο n e ' L g ί ο p y r r o 丨(-)、Μ o b e - v e r- i n e 、 Η o x a v o ? i η o N a f i v e 广 i fi e ' 0 c i, a ?«y 1 ^ n) \ n e 0 c t y — v e rl i rf ο Λ P e n 1; a p i p r i d e · P h ο n y mac] <\ e H y d r o c h ί o r i d o ' P h 1 o r o g 丨 u c i n () Ίι 、 P i n a v e r i u m b r o in ί ί j 〇、!f i. p (j r 丨 I a t 、P ί - P υ x ο 1 a ri H y d r o cf n ! o r· i d 、 P r a m i v ^ ri i n 、 P r l ΐ ί nl uiu B r o m i d o 、proper1 ί ό i n e ^ iJ r ο p i v η o 、 Fropyroma^ i ne " (j r o ^ a p ί n e Ο «-Λ *' (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家樣隼(CNS ) A4规格(210X297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明() ^ R a c 〇 f ^ m i η ο ' Κ ο c i ν ο r ί η e S ρ s jh ο 1 y ί, ο i · S t: i 1 ο η t tj tn Iodide 1 S u 11 r1 ο ρ ο n i u m ' T i o rn ο n ] u m l o d i d ο ' Ί i (¾ u ί ^ ί u m H r o in i d o T I r o p r m ni i d e ' Ί r ο ρ i b u ); ί; η ο ' Ϊ r i c r o y ί > ΐ r i ~ f。] i um、Tr i MbuU ' U + 子甲基- :5, 3 -二苯基-内胺、 ΐr 〇P eη 2 i 1 e、T「ο3p i " ίΐί ί'h 1 οr i de Xf;nyirop i ;j [a Bγόin i de1 7 ·抗焦慮劑,其包含: 斤基 ί® 啦,j列如 B u s ρ i r g ri e - G e ρ ; r ο n e 與 ί p .¾ a p ; r n ¢); 苯並::衍生物,例如 A 1 p r a z 丨 a m,B r 〇 jm:: g p a m 1 (: a -ra a z e p a m 、 C h 1 o r d 1 a z β ρ ο x 1 d e 、 C \ oh si a ni 1 C 1 o r s z e p a t e C h o t i a ^ e p a in * C 1 o x ,¾ λ o i a in " D i u z e p a irL ' Γ- thy ί Kof 1 hzop^i t (、 、Etlzolam ' l: i u i d ^ ;: e p a in 、 ί; ! u l z o i a ra - ϊ; I a t o p r y ί ? p a ni 、Ha ] a,7:epam - Kg t azo 1 a jti Loraxepa m 飞 Loxa p i n e Ηeda -z e p a m Meta c i n ^ p a in , M (.) x 幻乙()丨;:i m 、 Η o r d 7: o p a m 0 χ a ^ e ~ para 1 0 x a z o ! a rn 、 P i n a z ο ρ ^ m 、 P r* a /: <:; p a in T o f i s o p a m ; 胺基甲酸酿,例如(:y<·:丨 a a,k、!ΐmy 1 <ϊa ma t;e _* H y d r o x > p h ο n a in a t e 、 M e p r* o bii ma t ^ ' P h e n p r o b π m :-i L e 與Ty bama Le ;以及 其它,例如 Λ 1 p i ί j (> ii' [Η,η z o c t, a iii i n e、C ?j p t,() d i a rn i nc、 C h i o r m e μ η ο η c K i. i !',) x i r! F h」o r o s ο n。' 毂胺酸、控峰—( H y d r o x y z l n ^ ) 、 Μ o i o ?· a 3 u r a H e p h e ri o x a i ο n e 、0 x « n a - m i 山)、,P h e n a g 1 y r 〇 <1 o i S u r I c !. ο α o i 8 苯並二_拮沆劑,例如K h」mazen i 1,19.支氣管擴張劑,沣包,% -34 ~ (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) 464511 經濟部中央標隼局員工消費合作社印製 A7 B7 五、發明説明() 麻黃鹼衍生物物,例如.e、^(Aibutprol)、Bainbij-t e ri ο 1 1 B i l ο 1 t e r ο I C » r b a tero i C 1 e n b u t: g r ο I、C i o r - P e n 1 i n e ' D i r; x g Ui f) d r· i r! o、麻葑驗 ί K p lu? r d i n e )、[i p 卜 n i p h r 丨 n e、f·: i> r π i η o ]、乙塔麻黃齡 i !U a f o d「丨 n e ,i、乙魅夫 甲麻黃厳 UH h y i n。r ΰ p ί n ft p h r i n g ),F () η o t g r ο 丨、六中 51 喘 定(H c* x o p r e n a 丨丨 n ¢:.)、乙 1ί 喘 g.定(【s υ e L h a r ; η ο >、異内去 Ψ h If :^h ( i sopr o t or eηo j ) Mabu tero ) Me tiiprote-r 〇 ri () 1、[卜甲基麻.¾ 齡、P i r· b I」t: e r o 丨1 P r o c a L e r o 丨、P r o t o, k y 1 ο 1 ^ R e p r*o l e / o 1 · R j m Π, o r5· ο I ' So t; o r r; no! Ί' fj r h u l a - line ΐ u i o b u t e r o1 ; 四級銨化合物1例如β a v 〇 n丨u in M e t h :/ i S u】H i k、 C 1 u t r ο p i u ni B r o in i (j e ’ 丨 μ r h L r υ p i u m B v o id i ό ^ 0 x i t r o plum B r o m i d -: * ; 黄喂隐衍生物,例如 Ace f y ί 丨 i n(_i ' A('g f :y Π i ηe P ί p-r a z i n e ' A m l) u p h y ! 1 i n e A rr, i η o p h y ! 1 丨 n 、 B a m i i' y 1 I i rj e ·
Mn ( c h ο ί i rt e ) T h ο o p ii y 1 ! ! a i ^ > ί) ο x ο f y \ line ' Dy phy \ ~ line、Erspr o f y Π 1 n (? ^ \i t a m i ph y 1 I i η ' K U〉f >y 丨丨 hi g ' C υ a i t h y I I i n e λ P r (> x ^ p h y ! 1 i n ^ - T h c b r1 o ra i n e λ 1 - T h g o - b r* o m i η ο n c o t \ c Ac i. <1 與 了 h f; () p h y Π i n c :以及 其吃,例如 ί7。n s μ i r ΐ d p ' M g (j i b y z i n e、Μ g t h o x :/ p h e ^ rj ii r,i !u e 丁 r e t ο ς u i n (> I.. 20 ·鈣調節劑,洌如帶化龌(Ga ] c ΠΉ i o 1 )、ΡΪ鈔素((:a i c 1 L o ji i n ) ^ C a 1 c j t r i ο 1 ' I o d r ο n i o A cm; ^ 1) i h y ti r o L a ^ chysler^ol ' E 1 c a t ο η ; n 、 ): t i d r1 ο n i c l\ c I d 、 1 p r- ι Γ ί ο v ο n 、 _ 9 Γ, _
J 本紙張尺度適用中國國家^準(CNS ) A4規格(210X297公釐1 (請先閲讀背面之注意事項再填寫本頁) 訂 A7 464511 _ B7 五、發明説明() P a m i d r ϋ n i e A e i d,副屮狀腺累與 Te r i p a r s t i 和 A 以、ί a t (). (請先閲讀背面之注意事項再填寫本頁) 2 ] * 強心劑,例如 A (: c个/丨 H ri e、A c e t y 1 d i g H i t. 〇 x i n s 2 -胺铯-4-Φ基ntU定· AmH now…琥珀呋酮(β㈣I’urwj i 1 H e in i's u c e i n a t e )、β u d a s d e g i ri Γ.…黄 ίΐ 来竹桃次 Η B Π: e r 〜 b g r ο s i d e ) ' C a in ρ h ο L a jt! i. d c ' 鈴蘭毒 ί. | ( G ο η ν a I i a t () χ i ιί ) ' 新來竹桃麻Κ·素(C y m a r i n .)、D e η o p a πι丨n e、脱乙酸®毛托i¥ 地異 ΙϊΓ C (. i) e s ί ίί η o s i d e )、D 丨 Uj 1 i η,E 地 M U ( 0 ΐ g i t π Π s ) 、详地黃羞 1.1" ( D i ii ‘i t o x i n 狄戈新(D i g o x i n )、多巴J· 胺(Debut a m i ώ f ).' -多巴胺 ί D ο p ί-j m i n e ) 、 D ο p o xnm\ n e Ιΐηο -x i mo n e、紅皮素(E r yt, h r o p h i e 丨 r! e.)、妒醉胺 U; (i rf a ί ί: υ πι i n e i 、洋地黃全甘(G丨Ui I丨n )、羥甚洋地黃离甘(G ί i ox丨n j、脈 基乙内黯胺(.tl ] y com i n (:) ·,.¾胺醇(Hep t a m丨η ο Π、北类 黃連欠臟(Π:/ d r i η i η (ν)、11>。p a πι i η e、L 9 d ο t ο d i s ο s Μ。-t a in i v ci m、Μ i ] r1 .i π ο η <i · Η o r j i f ο Π η ' ϋ I e a n d r i n ' 0 u a b b i γϊ ^ Oxyfedrino、卩 r ο n a 1 U) r‘ o 丨 P r g s i j hi r 丨(Ή n、R o s ihu- f o g e n i n s S c 1 M ^ r ο n ^ U 丨丨;^ r.,_) η ί n = S t r- o p f j a n t h i ri、S u 卜 m a z o 1 e ', T h e o b r o mint1 X ^ m 〇 t ^ r ο Ϊ 經濟部中央標隼局員工消費合作社印製 2 2 * 螯合题,例如 I) c Γ e m i η o、D Π i ru: a r b S o d i u m ^ 敗地_鈣二ifi、砍地酸二納依地酸納、放地酸5鈉、啬 fl£ IS ( P 〇 n i c ί 1 I a til i η ο ί ^ :1 ^ n t (? I a 1. C a 1 u m ΐ r i s o d i u irs '
Pont e c l i. ο Λ c i d λ S u c c i ^ o r ί-^4 T r* I e n t ϊ n 2 2 ·多巴胺受體间:¾劑,例如B r 〇 ni o c r丨p t丨ri (…丨)o p ¢) x a mine. ^ F e n o j (J (; p a tii Λ I ί) o p a m } η o ^ L s s u r i d e - N ij x ;j g ο ί i 6 o 01 P e r g o 1 j d f;. - 36 - 本紙浪尺度適用中國國家標準(CNS ) Ad現格(210Χ297公釐) 4 6 4 5 1 1 A7 B7 五、發明説明() 2 4 *晦誘#劑(肝系的),例如F lu m e e丨η 〇卜: 25 *雌激素,其包含 (請先閱讀背面之注意事項再填寫本頁) 非類固醇類的雌激志,例如苯雌酚iBenzcstrw Ν、 \] Γ ο Pa r*ο(}s tr'ο I , Ch 1 orυ t r i ίΐ π 丨 sf) ne D i gπes t r υ 1 、 l)ie~ I:h y 1 s t i i t)os t r o 1. > D i e ίh y 1 s t i I bes t r' ο I D i pr'〇pr ί ο na t e D i πϊ e s t r o 1 F o s f e s t r ο i H e x e s t; v <; i - Η o t h a 1 ! e η o s t r i ] & M e? Μί e s t r o 1 : A 及 類固醇類的雕激素,例如Co丨por㈣n、缀合雌激素、 馬楚 1| fi (E q U ί 1 C η ί η )、馬稀雌 _ ( K q U ; Π ΪΊ )、雌」醇 ί l·: S -t r a d i ο ])、苯 ψ 酸雌二酷 ί E s t: r a d i ο ] 3 e η γ (κι L e)、雌二醇 i 7 /ϊ - y j> i ο η a t e、雌―:醇 R s t r ί o 丨、雌闹 f: s t, r ο n e,乙快雌 .一 _ ( E t h i n y 1 E s 彳,r a d i ο 1 )、块 1隹甲 _ ί M g s L r 。1 )、 Η ο x o - s t r ο 1 .、JO UU r ί g η ¢) d i ο 】·* S 厂ι!雌一醇 ί ij 丨j i m) s t r a <[ί ο I )與 炔雌 K ( Q u 丨 n e s L r o j i ' 2 6 .醫 h 腺皮質激素 '例如 2 1 - Λ c (j t o x .y f> r e f ri e ri (> j ο n e、 Λ a i c 1 o m o t ^ s ο n e 、 ψ ψ i A 1 g f; s l ο n e ) ’ A m i c i η ο n i d c ' 倍氣美松 U丨ec 1 ome L haso r〗e )、倍地米松丨 Ba id〇 thas (>n())、 Bud f; s ri i d o ' C h ! o r ί) wm:1 η i s ο n e、「I o b g t a s o 丨:B h)ve- 經濟部中央樣準局員工消費合作社印製 t a s ο n e ' C I o c o r t o 1 ο n e il I 〇 p r e d η ο i、皮質類 fi〗酵(t i- c o s ί e r o ri g )、口7 體松(t i s o n)、C o r L'i v a z o 1、i) g f 1 a z a -cor t、 D e s ο n i d e ' D o s o x i m o t a s ο η o i.) o x ?im o t h a s ο η θ . D i -Π o r a s o rur' 二氣米松(D i Π u c o r L o 丨 ο n e ;、滞 T 二謹龍〖I) i -f i u p r o d n a t c ) . !ΐ η o y. ο I ο η o ^ K i υ a z ^ c ο 11 ' F 1 u (、丨 o r ο n ; (h)、 氟甲松 IM ii m g t h a s ο n。、!· 1 u n i s o 1 i d e、_ 輕忪(fM u ο Μ η o - -;Π - 本紙張尺度逍用中國國家標準(CNS ) A4規格(2川><297公釐) 46 45 1 1 A7 __B7_ 五、發明説明() 1 ο n e ) A c e t ο n i d e ' F hj ο o i η ο n i d e K l u o c; o r* l ; n 15 u t y I ' 11 考龍 ί F 1 iHM: o r_ l o j ο n。)、氣「p M 孕松(Π u 〇 r. ο ίϊΐ e L h o 丨 ο n g )、 (請先閱讀背面之注意事項再填寫本頁) 覦潑羅龍乙酸詣(Flup^ro lone Acetate)、氣氳潑尼松乙_ Pm ( F \ up r c d n i d ο n c A c e t. a U:)、® 潑尼松 ^(Flupreijniso-i ο n e)、F I ij r a n d r e η ο I i d e、氟中酷鹿 ί F r mo e o rk L a 1 )、H 3 卜 c i η ο n i (J (i 、 H a 1 o in e t, a s ο n e 、 li a I ο p r e d ο n e A f: e t a l. e 、 Hydro-c ◦ r U㈣t f;、氫化可體松(Π y d r ο ί: o r L i s ο n e ),ffi化可體松乙 酸醋(HydrocorU sone Acetate )、 M化可體忪碟酸酷丨H .y -d r o c o r t i s ο η ΰ P h o s p h a t ο),fi 化可松 2 1 -城拍酸納(H y -d r ο ο o r L i s ο n e 2 1 ~ S o d i u fii Succinate)、11 yd r oco r U sone Tebut a t e * Ma z I p r ^ dο n (=:- 、 Μ(ΐ d i-y s ori e , U e p v e (J n i s ο n ^ Me t h y ο 1 p r e d η i s ο 1 ο n e · Η o m t n s ο n v u r ο ΰ t e、P .·ϊ r a ^ q t h a -s ο n e、P r e d n 丨 d r b a t e、潑)·£ 松 ί Pr Ci d η ί s o 1 ο η g > ·潑咕松 龍in-二乙胺乙_酯、潑尼松磷酸納·潑尼松M琥珀酸納、 潑尼松龍:n-m-磺笨φ _納、潑尼忪龍2]-硬酯酸乙一醇酸 、Predn i st; 1 ο ne Teb u ta t,〇、潑尼松能2卜三甲搖乙酸、潑 尼松、P r g d n i v a 卜 P「?> d n .y 1 i (i e m P r e d n y 1 i d (} η o 21 - \) i -
本紙張尺度適用中國國家標準(CNS ) A4規格(2I0X297公釐) 46 45 11 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明() iproniazid · I s 〇 c y b ο x η > i d ' U o c ! o b e in i d ^ 0 t ο πι ο x I n 、 a r g y ί in e 、 P h e n e ] z i π c ' P h e η i) x v p r o f> a /: i rj e Λ P i v 3 1 ;y i 一 he n z h y dr a z 11\ e Pr οά i p i n e 7ϋ ί υ x b t (,η e與 Ί·r;] n y h:8 y p ro -mine2G ·肌肉β馳劑(#骼)、例如Une、亞松安; A 1 r- u r ο η i u m 、 A t r r) c u r 1 u m Β e s .y 1 a t; ο - B a c I o i' ^ n、 B () r! z ου t 己 爪 i n B e π z u i rw) η i u /A C h 1 r i d e - C - C a J e h a s s ϊ n c:、 Car i s ο p r o d i ' (' h l o r m e ^ 3 η ο n (? ' C h i o r p h c n cs l r\ (" a r' b ti -mate ·、C h I o r proo L. h a ^ i η o (; h 丨 ο z o x y z ϋ n e Curare 、 (; y -c I a r ba itia t o、i' y π ! 〇 b e n / a p r ; π o、i)a n t: r o i e n e Λ IV) c;j me tho/n· uin lirojn i de、氣甲笨基苯并二 _ 學(D i azopajB,) * E p e r ί s ο n f; 、 F a / a cH n i u in B r o m i d o l·’ 丨 u in d r a ib i d 、 (} ;i i - i a m i n e Trie t h i. 〇 d ι H < - H x a c ;ϊ r· b e h o ) ί η ο β r nt i d g , Η o -x a f 1 u o r ο n i u iri B r ο io i d o 、 l·] r o e i.丨 m ΐ (i e 、 !, a u o x i u m M e !, h y i S u 1 f a I;e Lep t odat y 丨】n e、i ne ' Hep hη os i n Mo -P h e η υ x a ion e、M e t a x a i ο n 、Methocarbamol、H e t. ο c u r* I n e Iodide 、 N i πι o l ^ z ^ p <i iB Π p h e n ^ d r i η o ’ a n c u r ο n wi in Brom 1 d e ' h o rt p r o b a in a t, 〇 ij h (? π y r :¾ m i d o 丨、P 丨 p r.丨 u m Brora i Λ Prom ο x ο I ^ n c ίΐ )b tin ί fl u i r) i η o S u ί f a le J ' S tyrama U、溴化琥钔韹 K 膽驗(Succ i n«y 】cho Π nebr om i de )·、氣化琥泊_裱膽鹼Su(”.:ln:y ](卟〇]丨no (:h lor He、碘化琥 拍酸越膽齡 S u c c i n y 丨h ο Η η 〇 .[ 〇 d i n e ' S u x o L h ο n i u m S r o -jn i d e ' T e i r a z e p h jji Λ Ϊ h I o o 1 c h \ c o s 1 d ' Γ; z a η m i ί ri(; ' To i Por- i son e、Tubocu r^r i n^Ch ί or i do、 Vecuronium___ - 3 9 - 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨OX297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂_ E Λα 45 1 1 A7 __B7_ 五、發明説明() B r 〇 m ! d ο Ζ ο x ο 1 a ιτι i η ^ . 3 0 ·尼占―]措抗劑' 例如氣苯 ΙΦ (/\ ni i p h e n a 2 ο 1 e )y -c I y z o c i η o ί. o v a ί I o r p h a η ' K a d i d o · l m f ο η f; ^ N a 1 o r p h i ne ^ Nalorphine f) ί n o 匕 i n a t ο 、 N a ! ο x n e N β ί t r· x ο η e . 31 ·黃S詷,例如烯丙基雌酵UHykstreriG】 g f,s t ο η e、氫地孕 乙酸晶(C h 丨 ο r. υ d i η ο η e Λ r: 〇 t π L e ) ' Delmadinone A c e t a t o D e jneg o s l ο n e 、 I) e s o g e s t r ίΛ ] , i) i -me ϊ:h ί s t er οne 、 ϋy dr*oges t e ors e 、 i; t h i s t orοne 、 K i h :/ η o -d i o 1 、 l; 1 u r o g e s t ο n e A ο ο 1 a i, e , G s t o d ο n i: ^ G g s t ο η o r ο n e Cat>r 〇a、Ha 1 or)rog(.,s Ler·ono、1 7-辟基-1G -甲 if 甚-;體 EP、1 7 α -徑搖黄體 _、] 7 σ Hi y d r () x .y g e s t: θ r ο n t) C a [>「ο π t, ο 、L y n e s t r ο η ο 1 . Μ ο d r ο g ο s I ο η ο 、 φ JP- 3|tj ( Η ο d roxy ρ r ο g ^ -s t e r one) ^ Μ e ^ ο r, t r ο 1 Λ ο <; I a I ο ^ Μ ο Ιο η g e s t r o i ti·^ ^ίϊ Wi ( N o rf e t h \ η d r ο n e ) 、 N o r. e t h y ruuj「Ή、N o r g a s U) r. υ n e、Norge s L i m a t ^ ' N o r g e s i, r ^ I 、 N o r g e s t r i e n f j π ο * N o r v 丨 η ί s t c:-rone 、 Pent ages t r 〇 n e 、 ;S: Μ 、 P r o ic ^ « o s l ο η o ' 0 u i a g e -s 1: r ο n e 與 T r g η β ¢:1 M ο η o 與 H:等酷類 3 2,血膂擴張劑〗冠狀血管丨,例如AmotriphenG、地巴 晚(βeη d& ζ ο 1),號泊映 ( B。η ΓU r 〇d i 1 He m ΐ s u cc ϊ ria U?)、 Qenz I oo ο n e ^ C h I o y c i 7: i n e C h r- ¢) m ο n a r ' C 1 o b ο n f u r' ο I 、 C J ο η ί t r a 1; e 、 1) i i a z e p - \) i p y r \ d m ο i e ' D r o p r e η ϊ i a m ί η o 、 E f I o x e t e K r' y t h r* i ^ o 1 ^ f·. r y l h r I t .v i T e 1, r a rii t; r a t e hi t ^ Γ e η ο n 9 ' l; ο n d i 1 ί η o · 1;) o r o d i 1、G a n g 1 () n e、己雌跑二( η '二乙版乙 _ ) 、 lioxohend i ne ^ ! ί r ώmin Tosy ). a t ^ -40 - 本紙張尺度適用中國國家標準(CNS ) Μ規格(210Χ297公釐) (請先閱讀背面之注意事項再填寫本頁)
IT 經濟部中央標準局員工消費合作杜印製 6 d 45 1 1 A7 B7 五、發明説明() K h e I I i η ' Li (J οί I s λ i π e ' }i-j Wi 1i 3¾ ' H a rj n 11 o i ΐί x a n i - (請先閲讀背面之注意事項再填寫本頁) t r 4e )、Mha n e、N ΐ co r a ri d i !、硝基 f.卜油(N i t r(jκ i y -c o r ί n ) ^ F! e η i: a (ϊ i' y t h r i t o J T p t rani t rale ^ P ο n t r' ΐ n i r, r- ί P o r h ci x i J In e ' P ί m 1' .y ] 1 i η ΐ:· 、 P r ο n y i a m i n ?? 、 !: r o p a l y ! N ί t r a t e ' P y r i ( j。i\y ] ] ί η ί.; 了 r a p i d Μ、T r i (’ r () m y ί ' T Γί- ^ίΐ e t a z i d i r! g 、 T r o 1 n i t r n t. ο P h o s p h a t o ^ n ci V i .ς h a d i n e 0ί 血當擴張削()ΐ] ί#]血宵)1例如煙驗酸錦、βamethan -B ο n c y c J a n e ' B g t a h 1 s {; ί n (; ' Sf £S i!Hi, ( B r d y k ί η ; n ) ^ B r o - v i n e a m i n r P> u f ο n i o d e、β ij f [ g in e H i S'But9Siiir!ine、i:e- L ί o d i J * C i c i ο n i c υ 1 e、l ί n i- p a ,·: ΐ d e ' di n a r 丨 y ί ri p、C y -
c I a n dg 1 a I:e、二異丙胺二 m 乙驗、R ί cdo i s i n、Fυx i d ί I 、F i ii n a r· i s i n H g r o ti i c 3 t. ί f ο n f> r o d i 丨、煙酸肌 0f 醋 ί I γϊ o s i t ο 1 H i a c i n ;j t e ) ^ i s o :< s u p r ί n c: K a i i ϊ (J i n ^ K^liik- r· e i η ι Η ο i ^ y 1 y t o; ^ H rj Γ r- ο π y 1 ' N i a m e t a t e ' H i c e r g o i i η o 、N i c J u r a η o y e、煙醇 ί Ni c o L ; n y 1 /\ ί。o h ο i 卜 N y i ; (j r. i ' P g π L i f ^ I 1 i n e? ' FJ e rt t <t x i f y 1 i 1 n < ' P I r ί b e d i i ^ Fji] ?ij f P r o 匕 a g 1 a n d ΐ η E ) s S u h) (r t i d i 3 a ri d X a n t h i π a 丨 S h) c i n a ί e 經濟部中央標準局員工消費合作社印製 該_劑_其温合物可在習知技術以不同的形式存在* 此偽砍賴於該形成產生的展伴給藥W性=囚此,在_劑的 情況f、該藥顯I可為游離的鹼或酸形式,或其鹽或酯的形 式,或足為任何藥學ί: 接受的衍生物,或作為分T複合 物的成份- -Ί1 - ___ 本紙張尺度適用中國國家標隼(CNS ) Α4規格(210Χ297公釐) 46 45 1 1 A7 B7 五、發明説明() 加入組成物中的藥_铤偽依该特殊%I劑、所欲的治療 效用以及提供治療之裝置的治療期問f t i m e s ρ a η )而變化 對大多的藥劑,該藥割的經過皮暾的通透為給橥的速率 决定步驟·因此基本h必須1擇該藥劑的Μ與釋出(句速 率,以提供·穿皮給藥,该给Μ的特徵偽在-長時間F為 零級的時間隞傺' 在系統中最低的藥削是以在提供治療 之裝置中的治療期問,該藥劑在流經皮膚之Μ為樓礎' -般而萏,在.条統中中該藥物Μ的變化係由約0. U至约50¾ 重量,最佳,卽木發明所容許的較低藥劑劑置=餘iif约 0.3至約 30¾ 當然,穿皮藥剤給藥組系統之組成物亦可含有已知可 加速該藥劑經由皮膚給藥之試_ :此等試剤在此稱為皮膚 穿透促進劑.加速劑、佐劑及吸收增進劑,此等Μ劑在此 集合稱為“促進劑” 此一頸的試劑包含該些具W不闾作 用_構者,該機構包含該等具有增進藥劑在該多增聚合拘 中的溶液性與擴散性之功能者,以及該增進經由皮膚的吸 收 > 例如可Μ由改變該角質層的保溼的能力、軟化皮膚、 改進皮膚的通透性、作為守透補助劑或足毛®濾泡打開劑 ,或里改變包含有邊界層的皮膚狀態:此等試劑中的·# 是具有多於-種的作用機構*但基本h,其皆可促進藥劑 的給藥·…浞進劑可包含在一藥劑給藥条統中Μ至约20% 重量。g -促進劑彼fci含於其屮,刖該促進劑較佳偽以約 0¾至约10%重量之S存在_.該促進劑的--座例/^為多羥醇 ,例如可促進藥劑溶解度之二内撐基二漭 '内二醇及氓乙 _ 4 2 ^ 本紙張尺度適用中國國家標隼(CMS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)
、tT 經濟部中央標準局員工消費合作杜印製 經濟部中央標準局員工消贽合作社印製 4 6 4 5 11 A7 B7 五、發明説明() 二醇;油脂,例如橄欖油'魚肝油姑_綿羊脂;聚乙二 醇醚以及脂肪_,例如鲸蠟Μ與汕趙酗;脂肪酸詣,例如 可促進藥割擴散的肉S寇Κ酸異闪酯;脂肪酸_,例如油 酿醇;尿S及尿素衍生物,冽如可影饗角質層保涅的诚責 素;極性溶劑,例如―中基芡基锆氣化物(phoSP〇x丨de )、 '甲基鲸擷基亞颯、二甲基月杜基酸胺.〖--.基咄咯烷詷 、異山梨醇 '」甲基乙超_得(a c g U η丨rie )、二ψ基亞H '癸基甲基亞题及一甲基屮S胺,此等物質影響角質齡的 通透忭;水揚酸,其可軟化角質層;胺基酸,其為穿透促 進劑;姑酸:甲詣,K為毛_滹泡祗開劑:及較高分子紙 的脂質衷跖活件_,例如.Π桂Μ硫酸鹽,其坷改變皮膚表 面的狀態與給f藥劑’其它的試劑包含汕龉 < 亞油酸、抗 壞血酸.泛黯醇.Γ基化羥1申苯、生裔謝.乙薛生苛療 .亞油酸生窗gg,油酸丙詣、棕櫚酸異丙詣.油超胺' ICI Amer ;cas, inr所販 s 之商標名稱為 Bri j :50、93與 97 之聚氧乙烯(4;月桂歷.聚氣乙烯(2)油駿醇酗以及聚氣乙 烯Π0)油g醚,以及iC i /iJiieHras, ]r,c所販垮之商標名 稱為20之聚山贺酸酯。 在本發明的·些宵施例中,叼塑性劑或p黏劑足p|加 入該組成中,以改進該擊力敏感之黏葚性紐成物的黏著待 性。一 fl腰黏劑待別地合適憋用於該等藥劑無法塑造該聚合 物之賁施例中_. ._合適的腺1黏剣包含⑴脂族的焊;(2)混合的 脂族或芳族烴;⑶芳族烀;⑷被取代的芳族烴;⑸氳化酯 ;⑹氫化萜烯;及⑺氫化的木樹胎或木忪岙__所使用的_ 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨〇 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂. 46 45 1 1 A7 B7 五、發明説明() (請先閱讀背面之注意事項再填寫本頁) 黏劑較佳為與該聚ί>物之撈合物可相容在較佳宵施例中 ,該膠黏劑為砂酮流體:(例如由D 〇 w C 〇 r I n g〔: 〇 r ρ 〇 r a t i ο η ,Μ i‘ d I a n <j,M〖所得到的3 ί; 0 M g d .i c a丨l; i u i d )或定礦物油。 矽流體係η;使用於包含聚矽氣烷作為主要成份之摻合物 中_备另外的實施例中,其屮例如一合成橡Ϊ®為Κ主成要 成份者,礦物油刖是_-·較让的_黏劑丙烯酸可與油_酯 、油駿油醇及其它脂肪酸衍ΐ Μ _膠黏化 --些藥劑,例如liit笤擴張劏硝基甘油> ιΐ Μ合物中為 可塑劑的功能,蓋因其可在包含該条統的聚合物屮 > 溶解 至某一程度對於在絮合物中f容易溶解的垩劑分子,可 加入該藥劑與聚合物之共同溶劑共同溶劑,例如W踌潘 、維生素A醛衍生物.生# _、二內抟基乙二醇、喆精-丙二醇、飽和或f跑和脂肪齙、礦物油 '砂銅流體、醇類 • Γ基苯甲基酚以及其等頻似物皆可使用於實施本發明 中,此偽依該藥劑在該多遥聚合物之黏筲条統中之溶解度 而定_: 對於橡膠與緊丙烯鹊詣實施例之較佳與最佳的紺成物 摘錄如下: 經濟部中央標隼局員工消費合作杜印製 -44 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 46 45 A7 B7 五、發明説明() 表1, 重量西分比 成份 較佳範圈 最任範圍 橡腰 97-9 94-1 4 聚内烯酸潘 2 - 9 Γ; 5-8Γ) ?π 1*20 5-15 共同溶劑 0-3 0 0-20 促進劑 0-2 0 0-15 藥劑 0.1- 5 0 0.3-3 0 (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印製 本發明的組成物進一本被提供有各襌在已知在穿皮給 藥使用的增稠劑、塡光劑及其添加劑_當該組成物傾向於 吸收水分時(:例如,當卵磷酯使用作為共同溶劑),抟別 S可利用親水性的物踅一一型可成地地被應用的箝水性 物質為内丄。被#現加人ί:_ί上吋改進穿皮吸收紺成物的黏 苕性,怛不普降低其給举速率.合適的白土包含高粜土 -例如 b a ο 1 i n i L e、螺陶丨.:、c k U e 及 n a e r U <〕;聚脱上, 例如蒙脫土 ' t i: ' (i« r‘ d e i. ! i f, e .¾ m ο ii t: r ο n i t e ; ] 1 .i t, e s / 白雲毋,例如Π ; ; Le及海缔石、综泥. P0丨ygorsh i Les ,例如 a p p t p u 1 g .i .多水 iH 兔土、m d A b ο Π o y s 〗丨,g _、水 鋁石英及砂酸鋁黏f: 在本發明的-装S方面,壓力敏感之黏著性組成物可 本紙張尺度適用中國國家標準(CNS) A4規格(2丨0X297公釐) 經濟部中央標率局員工消費合作社印製 46 45 1 1 A7 B7 五、發明説明() 使用作為任一穿皮給Μ系Μ中的黏箸部仂(例如·儲存裝 s),或其可包含一黏其的m η裝詈.當然,本發明的原 理砍然可應用ΐ非並壓力敏感ft包含一藥剤儲疗摩的穿給 給Μ紐成物中__ 參兒第1圖 > 其顯示-本较明之黏箸性單)1裝置1 0的 圖π説明該穿皮給藥系統包含-畀有·界定之幾何形狀 的舉體ΐ體υ,Κ在该單Η主S]]的一側具有保護性釋出 襯墊1 2 >〖衍S _-侧台背瘤1 3 _去除該保盏性的釋出襯嵆> 而可暴露出壓力敏感之多承聚含物的黏箸性組成物,該纽 成物《1作為一藥劑的載體以及作為將该糸統應用至病人的 本發明的一裝置或_-個體荦位剤《可以任何熟習此技 «人上已知的方式加以産生:迮该皮_ Μ成物形成浚*具 可以任何熟習此技莛人士已知的方式與背層接觸。該等技 術包含砑光塗佈·.熱熔融塗你、溶液塗佈等、當然,背ϋ 物質偽為熟習此技藝入丄所知,旦包含Κ列可塑性膜,聚 乙烯、乙鹋乙烯酯拐脂、聚酯、聚内烯.ΒΜΕΧ、乙烯/ 乙駿乙烯酯共聚物、聚乙烯氯、聚胺甲酸酯及.其等頟似物 •金屬薄膜·不織織物 '布及f:述物質的共擠壓物或簿層 、以及商業丄pJ取得的溥層:_該苛層物質--般具有在2 -1 〇〇〇撤米範圍内的厚度,Μ该皮組成物-般是置於背層 上II其厚度你在〗2 - 250擻米杈的範阐内._ 合適的釋出襯姑亦為此技術所熟知的,Η包含丨彳e丨a se I n t:。r'n a L i oria i de 3 i g n a I,ed B i β - R e !。y s(、襯塾及 Sϊ 1 -o f f -4 6 ' 本紙浪尺度適用中國國家標準(CNS ) A4说格(2丨〇〆297公ϋ (請先閲讀背面之注意事項再填寫本頁) 灯 46 45 1 A7 B7 經濟部中央標隼局員工消費合作社印製 五、發明説明() 76 10墊襯等商業上的鹿物 對其中聚砂氣垸為多$聚合物 黏箸糸統為其-部份較咔實施例而吉,该釋出襯玆必須 闽矽酮站箸劑柑容:.合適之商業卜.的襯墊為3M ’ s } 022Sc:〇 t ch Pa k 本發明之穿皮給藥系統的结溝可依所需及所欲而為各 種形狀與尺寸 '舉例來況,一苹-劑€單位具有汗〗至200 cm2範_内的表面面積:較茳的尺寸為5孓CQ(i2 _ 在本發明之一方法力面,為將具右不Ι5Π容解爹數之多 锺聚合物與可溶性的PV0P摻合(但石會化學反喔或是交鏈 鍵結)*以造成· Θ控制加入藥剤之流經與流入表皮之壓 力敏感的黏替性紐成物:該聚含物之摻合物會造成該聚合 物的系統中該藥劑之跑和濃度被調整,因此nj使该穿皮 給藥速率可選擇性地調整_當然,“梅合” 一詞包含選擇 合適的聚合成份S其比例,以逹成所欲的功效 在本發明的-較ίί實施例屮…一穿皮給藥糸統可藉由 將一可溶性PVP 聚丙烯酸詣 '聚氣烷、Μ劑.共同溶 劑及膠黏劑(冇有需的詁)在合適的吋揮發溶中混合、 而後再澆禱該混合物並Μ由Μ發而去除該溶劑,以形成-薄膜: 合適的揮發性溶劑包含但不限於斿類,例如.異内醇、 與乙醇;芳香類•例如」甲苯與中苯;脂族類,例如己烷 環己烷及庚烷;烷盤酯類1例如乙鎞乙醅、乙酸丁詣· 製劑的--般例π方法偽如下所述: 1 · & - ·容器Φ1合併合適V:的可溶性Ρ V p、溶劑、促 _- 47 -_ 本紙張尺度適用中國國家標準(CNS ) Α4规格(2!OX297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂 46 45 1 A7 B7 經濟部中央棹準局員工消費合作社印製 五、發明説明() 進劑與有機溶劑U列如甲苯;,並將K等芫ΐ混合1 2 ·而後將藥劑加入该混合物中,拍進行Μ拌t至这 藥劑均勺温合於其中: 3 ·而浚將合適€的聚砂氣垸及聚内烯_酯加入該藥 劑混合物中,並將其完全地混合: 4 ·再將該配方轉全·塗佈操作系統中,在該塗佈操 作糸統上,該配方係以在·控制之持定厚度塗佈&保_性 釋出襯Μ上 ifn後該塗佈産物經過一烤箱,以驅除所有的 揮發性加工溶劑- 5 ·該在襯毡丄的乾燥産物而後連接至背層,並捲成 捲軸以儲存。 6 ·由該捲軸物質中悮切出合適的尺寸與形狀“系統 ” r 步驟的次序 '成份的Μ及Μ拌或混合的.筻與時間可能 是重要的步騸,此芩依使用於该配方中的持定聚合物、藥 劑及促進劏而變化_启些因素m為熟晋此技41 /、十可調整 的,且在心中皆知此等步驟Η的偽為提供·均1J的産物| 般相佶許多的方法*包含改變步驟的次序,皆叼進行並 d得到所欲的结果除了各棟形狀外,該劑贵單位産物可 為各種尺寸:一般認為衣面面模偽在】-200平方公分的範 圍内,且存在地較诖尺寸為:5 .) 0、1 5、20 > 3 0與60妒 方公分。 該丨1[)較佳為只有約2,000至],100,000的分子量,且 較佳者為 2,000 至 1,000,000’ 以 5,000^ 1 00,000更佳,而 (請先閱讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國國家榇準(CNS ) A4規格(210X297公釐) A7 464511 B7 五、發明説明() 以7,000至54,000尤佳… 較佳筲施例包含一 4溶性的p v p以及_-壓力敏感黏箸 牲橡_與一聚丙烯_ _ 而宵持別佳的攙合物,其包含一 聚内烯酸_ _、聚矽氣烷與一 nj·溶性Γ y P的檫合物 依據本發明,己發琨注黏箸型穿皮給藥糸統中,"Π容 件PVP在溶解藥爾上是卨度有效的更特別的适,D丨溶性 P vρ已被證賁π]使用於使炔諾·乙酸酯(NR)系統與NFτΑ /雌二_系統保持在實質上不具合結品的狀態、依據,該 等持別可匯用可溶性P1/P之其它藥劑包含Μ必妥ia jt)ute-r ο 1 .) ' 雌二醇、h a i。- pr· i (J () i、y I ρ r a τ: o la m 前述較佳實旋冽中' 所需的可溶件P V P的a與頻型偽 依在黏著劑中存β的藥劑鼠舆類型以及該黏箬劑的類型不 同而有+同:例如將搀膠黏筲劑加人-%|劑與---聚内唏_ 醅黏#劑的混合物中,則曾造成該Μ劑的溶解度降低,ii 而後會闪過度飽和rfii造成藥劑,结晶化._侣是將可溶性的 P v p加入該混合物中可明頭地增加該荖剐的溶解度。晚a 之,橡膠黏替劑的々在t降is該混合物屮被,容解之#1劑 的載量,向可溶性的Ρ V Ρ之疗/ί: 4铺償此方面的不良作用 囚此…在一穿皮绐藥糸統中可溶姓Ρ V Ρ之較佳的濃度該 有足夠的吋溶件,而W浦酱丙π橡_黏著劑加.入所 造成的藥劑溶解度的降低 W溶性ΡΒΡ的最佳濃度ί-分容 易利用常用實_加以剧定 ·般而,¾,該PVP的存在炫π 約1¾至约20:ΐ重S,較佳為约3¾至·而以约[^至约 _____-49 二____ 本紙張尺度適用中國國家標準(CNS ) A#見格(2丨0Χ297公釐) (請先閱讀背面之注意事項再填寫本頁) 、?τ 經濟部中央標準局員工消費合作社印製 4 6 4 5 經濟部中夬標準局員工消費合作社印製 A7 B7 五、發明説明() 15 % Μ ί-t ' 例如,當藥剤為块諾銅乙酸酯(ΝΕΤΑ)時,可溶性|>ί/Ρ 之1 0¾重最的較佳濃垵i、',則可發現其可抑制Ν Η ΤΑ結品的 形成 > 但又不會對該N [T/U!丨多蚩聚合物黏著条統ί聚丙烯 酸酯/聚矽氣烷)冶出负·ί·:良的影響'當该藥劑為雌二醇 時,该S /;不僅可培加雌二醇的流動,同時可增加雌二薛 經由皮膚流入的整體童當該荜劑為铺必妥時,·較任的 濃度則發現為約5 X重輦_ 大里之句溶性P y卩W造成藥劑流動h的降低__例如, 當PVP存在Μ超過20%重μ時,ΝΕΤΛ的流動開始降庇 砍據本發叨所使州之溶性PVP可與本發明携合物之 -種或多種其它聚合物件的物質·起溶解 可溶性PVP的類型與_對宂成產物之黏箸持性只有顯 普的影響,_ /〖:有高剪力特性的黏转劑屮*較佳偽乜含_-低 分子量的可溶性Ρ ΙίΡ *而對低剪乃的黏箸劑·較诖刖為卨 分子1之4溶性Ρ V Ρ _ 下列的實施例中偽以詋叨圈力敏感之站笞性组成物及 穿皮給藥糸統,及戌方法,此皆在木發明的範W内=造# 實施例並非想要限制本發明之範圍 "Duro-Tak 80^111)4, 8 0 - 1 1 9G , 3 0 - 1 0 5 4 > 8 0 - 1 07 4 ^ 30-3 058 ' 8 024 3 4 δ0 - I 070 30 -6172 ' S7 -2287, 87-2 5 1 (3 及 8 7 - 2 3 5 2 ” 為 N a t. i o ji a 1 t a r ί: h a b d ί.〕h c ra i c a ! C o r.-pora L i on , Br i dge wa tor , New J er sey 之商擦名稱,其係 在有機溶液中的丙烯盤黏苕劑(聚内烯潑酿): 本紙張尺度適用中國國家標準(CNS ) A4現格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 46 45 1 1 A7 B7 五、發明説明() "BiO-PSA X7-3027 X7-4919 ' X7-2G85 X7-3122 ' X7-4603、X7 -4301、X7 -.1.303及 Q7 -.4503 - 07-450]及〇7-4 5 0 2 ” 為 D 〇 w 〇 r i n g C 〇 r ρ 〇 r a I, i ο η,M g d i e ?) ! P r 〇 d u t* U;, Mi d-land, Michigan,之販呰在冇機溶液中之矽_黏著劑 (聚矽氣烷!的商控名稱 BIO-PSA X7-4203是持別合適 使用於如F列實施例中之有宵能性胺基藥劑;例如蘇必 妥與毛果芸香鹼)之中: G e 1 v a - Μ υ I 1. i p o 1 ,y m e r Sol u t, i ο n ( G M S ) 7 3 7 , 7 8 8 , 1 1 5 1 , ] 7 [) 3 , i 4 3 0 及 2 ’18 0 ” ^Mosantocc?nipan;y,St-Lcuiii, Missouri的商樘名稱,其傷ίϊ旮機溶液中的丙烯 酸黏箸劑」 V i s ί; ϋ n e X L Η - L .S * L (;,f ,¾ E x x ο n C h o ni i t: a i !' o m p a n .y , Houston, Texas,約商搮名稱…it為-具有--窩羅利(. Π ory)分_f Μ在426 00至4G 100之聚異丁檔基聚合物。 前述的聚合性黏箸物盗可以溶掖的方式加以提供或足 製備,其中該画形物之® Μ丙分率佟如Κ所示: (請先Μ讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作杜印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) £l € 45 A7 B7 五、發明説明() BIO-PSA X7-2685 BIO-PSA X7-3027 BIO-PSA X7-3122 BIO-PSA X7 4301 BIO-PSA X7-4303 BIO-PSA Q7-4501 BIO-PSA Q7-4502 BIO-PSA Q7-4503 BIO-PSA X7-4603 BIO-PSA X7-4919 Duro-Tak 80-1194 Dur〇-Tak 80-1196 Duro^Tak 80-1197 Duro^Tak 87-2852 Elvax 40-W GMS 737 GMS 788 GMS 1151 GMS 1430 GMS 1753 Kraton D 1101 Kraton D 1107 Kraton G 1657 Vistanex LM-LS-LC ^ J o oo ^005000000055540210100000 ,,,j 556666666544431344441111 (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印繁 3 6 0 Medical K 丨 u 丨 d"為 ί) ί) w Coring C () r p o r a 15 o ri 之聚二T基砖酮流體:在本發明的一些實飽例中,加入 3 6 0 M e d i c a Ϊ F〗u i d作為膠黏劑,μ改沒終産物之黏莕特 性… « ΆΜ Λ
•一雌二醇聚合物之混合物的製備如下:在-合適的:U 器中合併〗· 〇份的雌二® ' 6 . 〇伪的二内撑某乙二醇,3 . 0 扮的油酸、35,0份的Φ笨、5 . 0份的聚乙烯吡咯烷® ί ΚοΠΗοη 30)及Ι23.03份聚闪烯酸酯黏箸劑(GMS 737), 充份混合直至該混合物均勺.而後將66 . G7份的聚砂sa烷 -52 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4 6 451 1 A7 B7 五、發明説明() 黏箸劑(Bm-PS/'i 07-4503)加入其中,再將混合物充分温 合。所得的成份物在“乾燥”的基礎下,It就足,在去除 揮發忡溶劑歩驟後,K中成份所具冇嬙度如K所示: 成份 重量β分比 聚矽氣烷黏替剤 4 0.0 (BIO-PSA 07-4S0:i! 聚丙烯酸酯黏箸劑 4 0.0 (GMS 737) 油酸 8, 0 二丙撑基乙二醇 6,0 聚乙烯咄咯烷酮 5.0 (Κ 〇 1 } i d ο η .Ί 0 ) 雌二醇 — ................... 10 0.0 在下列筲施例屮、傺以合適景的起始物質,利闬實施 例1之方汰,所逄生之员冇K列成份濃度的組成物 (讀先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央橾準局員工消費合作杜印製 -5 3 - 本紙張尺度適用中國國家標準(CNS )八妨見格(2丨0X297公釐) 46 45 1 1 Α7 Β7 ίϋ 乇丨 五、發明説明() 實施例2 實施例3 成份 重量百分比 聚矽氣烷黏著劑 (BIO-PSA Q7-4503) 39,0 48.0 聚丙烯酸酯黏箸劑 (GMS 737) 40.0 30.0 油Μ 8.0 6.0 二丙撑基乙二醇 6.0 4.0 聚乙烯吡咯烷酮 (Koi i idon 30) 5.0 10.0 雌二醇 2.0 2.0 100.0 100.0 I---------裝-- .i r清·*?β*^ε6<?ΐ意事Ϊ 填寫本頁) 訂 經濟部中央標車局員工消費合作杜印製 實施例2與3之条统對雌二醇在活體外之經由人體表 皮的通透情況傺顯示於第3圖。此圖説明本發明組成之給 藥情況傜顔箸地大於商業上可得到的雌二醇産物
Estradernir 0 簧施例4 一雌二醇/炔諾酮-聚合物之混合物的製備如下:在 一合適的容器中合併〇 · 份的雌二醇、3.0份的炔諾酮乙 酸酯、4.0份的二丙撑基乙二醇、6.0份的油酸、1 0 · 0份的 甲苯.、10 · 0份的聚乙嫌吡咯烷酮.(K 〇 1 Π d ο η 3 0)、1. 〇份的 -5 4 - 本纸張尺度適用辛國國家標準((^)44洗格(210父297公釐) 46 45 1 1 A7 B7五、發明説明() 丁甚化痒基Η香及()2.0¾聚丙铽鹄SS黏著劑(GMS 737i ,充份混台£至該混合物均匀|丨fr丨後将93 . 0 ^的聚氣烷 黏馨劑< B [U-PSA Q7-4503 )加入K中,再将E合物充分混 合所得的成份物/1: “乾燥” ff)基礎Τ,ϋ;就萣,在去除 揮發性溶劑步驟後·其中成仂所R·有濃度如下所β : ,_t'i 1,'· 萆a百分比 聚矽氣烷黏箸劑 5 5.95 (BIO^PSA Q7~45〇m 聚丨习烯酸黏砮劑 2 0.0 0 L / * 1 I ί-Τ <Λ 1—> . * U Μ 厶 i ) 油酸 ().0 0 't -LJ' ~ r .·—λΓ.Λ —m芏进6…醉 4.0 0 聚乙烯毗咯烷阑 1 0.00 ••.If 1 1 » 1 Γ1 /, ·. \ho ι ϊ i αο η ^υ ) • Γ - tj- /! if./ί fci- r- ·#· ΐΤ. 」暴1[扦发;回& 1 . 0 0 炔諾_ 3.00 雌二醇 0.05 10 0.0 在F列筲施例中,偽以u適彔的起始物質,利用筲施 例4之方法,所库生之R有Τ列成份濃度的組成物. (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標隼局員工消費合作社印裝 _ 5 5 ~ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 46 45 1 1 A7 B7 五、發明説明(
•5 t·) 1 i I iv; i 一 L___________i_ 經濟部令央標準局員工消費合作社印製 — *.·.?» τ i m m id rm, 聚矽氣浣! j ί D 1 ϋ ^ ί1 ύ r 1 07-4503/ ' 1 55.9 1 | j i 1 55.8 i ! 1 ! [ 55.G | I 1 1 i i r厂~ i vi.;. 1 | 1 __ . i I 1 ] ! ! ] 55.4 ί i I ------11 _ ^ ,. |i '0 || || || 1 ί 聚丙烯酸衞 黏箸劑 I iGMS 737) .一~! ,':1Λ Λ : ί ! 20.0 ' 20.0 .ΟΛ Λ L.'-l . V/ T 20,0 i 1 ! 20.0 ί ....ii Si || 油酸 6*0 6,0 R.O 6.0 6,0 0.0 6.0 二i巧擇基 乙一 P7 4,0 4.0 4.0 4.0 4.0 4.0 4.0 聚乙烯_ 咯烷齦] f.Ko] 1 idon 30) 10.0 10.0 10.0 )0.0 10.0 10.0 10.0 丁基化羥 基尚香 1.0 1 *0 1.0 1.0 1.0 KO !.0 炔諾_ 3.0 3.0 ILO 3.0 3.0 :[0 3.0 雌二醇 0,. 0.2 0.4 0.5 0.G 0.« 1.0 100.0 1 100.0 100.0 ! 100.0 100.0 : 100.0 100.0 i 56 (請先閱讀背面之注意事項再填寫本頁} 本紙張尺度適用中國國家榇準(CNS ) A4規格(210X297公釐) 4 6 4 5 11 at B7 五、發明説明()
實狍例4 on 1 ( 0 . 05%至1 . 0¾的雌二醇量)之系統對 雌二_在活體外經山人_表皮通透情況煤顯π於第4障ί 此圓顯π Μ由本發明改寶Κ中雌二辩的濃度之組成可逹成 十分廣範圔的雌二®的流動情況:_ m块諾_乙酸酯的流勁 則不為雌二醇之濃度所影鬻,而保持芘约為0 . 8Hg/h「的P1 定速率F (請先閱讀背面之注意事項再填寫本頁) 甲苯、0 . 0份的聚乙铺卩让略;Ιΐ綱丨K()丨丨i don 30 )、1.0份的 丁基化拜基ϋ香及Μ, 52份架闪域酸酷黏萬劑(GMS 737) ,充仿温合直至詨混合物均勺: ifii後將93. 0份的聚砂® 烷黏箬劑(1^10-『)$6 07-4503.)加入^中*再將混5物充分 混含··•所得的成份物在“乾燥”的S礎下,tt就是*汴 去除揮發性溶劑步鄧投·其中成伤所貝有濃度如F所y : 1T. 經濟部中央標準局員工消費合作杜印製 實施例1 2 一雌二醇/炔诺網-聚: &物之显 合物的製備如卜: ύ: 一 合適的容器中合併0.21 %的雌二 醇、3.0份的炔諾簾1乙 酸酯 、4.0份的二丙挖基乙 —二 ^ 、 6 . 0伤的油酸、β 0 . 0份的 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 5 4 6 4
7 7 A B 發明説明() 成份 童景百分比 聚矽氣烷黏箸劑 f; Γ). 8 (BIO-PSA Q7-4503) 聚丙烯酸詣黏箸劑 2 0.0 (GMS 737) 油酸 β· 0 二丙撑基乙二醇 4 . 0 聚乙烯吡咯烷_ 0.0 f Κ ο 1 I i d ο η 3 0 ) 丁基化羥基茴番 ].0 炔諾_ 3.0 雌二醇 _______0.* 2 -. 100.0 莅F列實施冽中,盗以ί>適量的起始物質•利用實施 例12之方法,所産生之Η有F列成份濃度的組成物… (請先聞讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印製 58 - 本紙張又度適用中國國家標率(CNS ) A4規格(210X297公釐) 45 1 1 A7 B7 五、發明説明() 實施阏1 3 實施例]<1 成 ~Tr k=l 丄:/ +., E [ 识南.ί:丨刀—比 聚砂氣'm誇劑 / η τ r> c λ η ^ λ r λ. 〇 ·, 1. Γ; 1 U ' Γ ^ rt - m" 0 0 , ύ {-< /\ Γ> U \; . 0 WJ 品匕 Trf- ii-i- V^if K'j >.itr m riei m fa Aij / γ 丨 i c* n ^ \ \ li H O l J ! } 20.0 Λ Λ i: ϋ . υ i 油酸 0 . 0 G , G 二丙撑基乙」醇 4.0 4 . 0 聚乙烯吡咯烷圈 (R ο 1 ί i d ο η 3 0 ) 2 , 5 5.0 了基化羥基敁香 1.0 1 . 0 坎諶_ 3.0 3.0 雌二爵 0.2 0.2 100.0 10 0.0 C請先閱讀背面之注意事項再填寫本頁)
1T 經濟部中央標隼局員工消費合作社印製 -59 - 本紙張尺度適用中國國家標率(CNS ) A4规格(210X297公釐) 五、發明説明() Α7 Β7 實施例1 5 成份 量芑分比 聚矽氣烷站箸劑 "i <^ι (BIO-PSA Χ7-460:η 聚丙烯酸酯黏箸劑 5.0 iGMS 737) 二丙撑基乙二醇 4,0 油酸 ί3. 0 聚乙烯吡咯烷銅 ]0 , 0 (Κ 〇 1 1 ϊ d ο η 30 .) 炔諸綱 3.0 邶.二醇 __________0,7___________ 100.0 (請先閲讀背面之注意事項再填寫本頁) 第6圖顯不對f间a的聚乙烯吡咯烷ίΐ (〇至10¾)之条 統基本_h Η仓柑同的镇劑(雌醇與炔諾_乙酸酯)之流 動情況,但足聚乙烯吡咯烷〖1被發現相冏的条統中對藥 劑的闻结晶具有功效 U:就足,當聚乙烯吡咯_的濃度增 加時,該形成結晶的發牛诘況會被降低;参見表丨!ί 訂 丧n ·聚乙烯咄咯烷銅對結品形成的效m 纽成 聚乙烯咄咯烷_ % 在敷Μ中之结品Η 經濟部中央標準局員工消費合作社印製 寶施例1 2 0.0 60 土 4 贳施例1 :〗 2. 5 5 G ± 3 筲胞例14 5.0 20 土 4 實施例6 10.0 0 :::其為在1 4 .〗cm£敷片中》ί兒之結品數Η ; 每Ε3個敷Η的平均悄及搜准差。 -0 0 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 46 45 1 1 A7 B7 五、發明説明() 實施例1 6 一異山梨醇(i sosor b i )二硝酸詣-聚合物之混合物 的製備如下:在一合適的容器中合併20.0份的異山梨龄Γ. 硝酸酯、4 · 0份的.一内搾基乙二醇、4 . 0份的油酸、β 0 . 0份 的甲苯、丨0. 0份的聚乙Μ _咯烷刚(Κο丨lidon 30 )-及G7. 0份聚丙烯酸酯黏箸劑(Duro-Tak 80-119β),充份混合斑 空該混合物均勻:汪此實拖例中,該異山梨醇二硝酸酯偽 以在甲笨中的溶液加入Κ中· !iu後將53 . 0份的聚矽氣烷黏 箸劑(B丨0-PSA Q7-4503)加人R中,再將混合物充分E合 …所得的成份物在“乾燥”的芘礎卜,比就足,在去除揮 發性溶劑步驟後,其屮成汾所ft有濃度如F所f : (請先閱讀背面之注意事項再填寫本f) -1Τ 經濟部中央標準局員工消費合作社印製 成份 道Μ百分比 聚砂氧烷姑普劑 32 . 0 (BI0-PSA Χ7-4603» 聚内烯酸酯黏箸劑 30.0 (Duro-Tak 80-1138;) 聚乙烯咄咯烷_ 10.0 (Kollidon 30) 二内撑基乙二醉 4 . 0 汕馥 4.0 異山梨_硝酸旃 „ 2 0,..0 10 0. 0 本紙張尺度適用中國國家揉準(CNS〉A4規格(210X297公釐) 6 4 45 11 A7 B7 五、發明説明() 實施例1 7 -炔諸_乙酸弼-聚合物之温合物的Μ備如K :在- 合適的客器中合併3 · 0份的炔諾_乙駿酯-4 . 0伤的二内撑 银乙二醉+、「>. 0份的油酹、GO . 0份的甲苯,1 0 . 0份的聚乙 烯U比咯烷_ ( κ » 1 Π ( j ο η V /\ β 4 )、1 . 0份的r迖化稗某间S 及β4.52份聚+内烯酸酯黏转劑ί (〗MS 737),充份混合白'牵该 混合物均tj。而後將;)5 . 00份的聚砂1¾垸鈷若劑ίβ 10-PSA Χ7 -4 Π(Π )加入其中,洱將混合物充分混合 所得的成份物 在“乾燥”的箪礎下,就楚,仵去除揮發W溶劑步驟後 ,其中成伢所具有濃度如1:所示雖然f列的菖_例含有 2.0辛3.0S的块諾緋丨乙酸溫,較作偽為在1辛]2%¾最範_ 内._ (請先間讀背面之注意事項再填寫本頁)
經濟部中央標準局負工消費合作社印I 成枴 φ »占分a 聚的氣烷黏转劑 5 7.0 (,ΒΙΟ-PSA Q7 -4503 ) 聚丙烯酸酯黏著劑 20 . 0 fGHS 737) 二丙樘某乙—..醉 4.0 汕酷 6.0 聚乙烯吡咯烷_ i 0 . 0 (Ko H i don 3 0) 炔諾® 3 . 0 100.0 在下列實施例中,ί%以合適暈的起始物質,利闬智施 例1 7之方法,所產4之具有F列成份濃度的組成物 -62 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 5 4 6 4 B7 五、發明説明() 經濟部中央標準局貝工消費合作社印製 實施例: 18 20 21 22 23 24 25 成 份 重量百分比 聚矽氧烷黏箸劑 (BIO-PSA X7-4603) 54.7 26.2 12.0 0.0 0.0 0.0 0.0 聚矽氧烷黏著剤 (BIO-PSA Q7-4502) 0.0 0.0 0.0 5.0 0.0 0.0 0.0 聚矽氧烷黏著劑 (BIO-PSA X7-4301) 0.0 0.0 0.0 0.0 52.0 0.0 0.0 聚矽氧烷黏箸劑 (BIO-PSA Q7-4501) 0.0 0.0 0.0 0.0 0.0 65.0 65.0 聚丙烯酯酯黏箸劑 (GMS 737) 23,3 0.0 0.0 0.0 0.0 0.0 0.0 聚丙烯酯輯黏箸劑 (Duro-Tak 80-1196) 0.0 45.3 0.0 0.0 20.0 0.0 0.0 聚丙烯酯酯鈷箸劑 (Duro-Tak 87-2852) 0,0 0.0 0.0 70.0 0.0 15.0 15.0 聚丙烯醋_黏著劑 (Gelva 788) 0.00 0.00 60.0 0.0 0.0 0.0 0.0 油酸 5.8 2.0 2.0 5.0 8.0 0.0 0.0 榉樺酸 0.0 0.0 0.0 5.0 0.0 0.0 0.0 二乙基乙二醇 3.9 4.0 6.0 0.0 5.0 0.0 0.0 聚氧乙撐基(4>月桂醚 (Brij 30) 0.0 6.0 5.0 0.0 0.0 0.0 0.0 聚乙烯Stt咯烷P (Kollidon 30) 9.6 9.5 0.Q 0.0 10.0 0.0 0.0 聚乙烯毗咯烷醑 (Kollidon 17PF) 0.0 0.0 5.0 5.0 0.0 0.0 0.0 聚乙烯吡咯烷p (Kollidon 90) 0.0 0.0 0.Q 0.0 0.0 5.0 5.0 藥粼(炔諾酮乙酸醋) 2.7 0.0 0.0 0.0 0.0 0.0 0.0 阿普當諾雷 (Aprazolaai) 0.0 7.0 0.0 0.0 0.0 0.0 0.0 蘇必妥 0.0 0.0 10.0 0.0 0.0 0.0 0.0 δ-胺基乙醢内酸 0.0 0.0 0.0 10.0 0.0 0.0 0.0 努太尼 0.0 0.0 0.0 0.0 5.0 0.0 0.0 尼古丁 0.0 0.0 0.0 0.0 0.0 15.0 0.0 穗雷吉林(selegiline) 0.0 0.0 0.0 0.0 0.0 0.0 15.0 所聖 100.0 100.0 100.0 100.0 100.0 100.0 100.0 正事 章務 (請先閱讀背面之注意事項再填寫本頁) - G:5 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 45 1 1 A7 _B7 五、發明説明() 實施例2ϋ 成份 車鼠否分比 聚矽氣垸黏箸劑 57 . 0 (ΒΙΟ-ί^Λ 07-4 503) 聚丙烯酸酯鈷箸劑 20,0 CGMS 73?) 聚乙烯吡咯烷if] i 0 . 0 (Koilidon 90) Μ苯內酸 3.0 100.0 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4645 1 1 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明() 實施例27 一雌二醇聚合物之混合物的製備如K : —合適的容 器中合併2.0份的雌二醇,4.0份的二內撑基乙二醇、4,0 份的油酸、3. 0份的卵if酯與5.0份的聚乙烯吡咯烷涮( Kol ndon 17PF),充丨分混合点至该显合物均勻.在此實施 例中,雌二醇偽(以在屮苯中的溶液與67 . 0份的聚異丁烯 混合)加入MffJ後將12彳.0伤的矽氣烷黏转劑(ΒΙϋ-PSA X7 -4301 )加入其中,再將温合物充分Μ合。所得的成份物 在“乾燥”的基礎下,t就足,在夫除揮發性溶_步驟後 ,其屮成份所具有濃度如K所+: 成份 m量yr分比 聚矽氣烷黏著劑 6 2 , 0 (BIO-PSA X7-4301) 聚丙烯酸酯黏著劑 2 0.0 (H s t a n e s X L Μ - L S _C i 二丙掙基乙二醇 4. 0 油酸 5.0 聚乙烯吡咯烷® Γ). 0 (KolSidor, 17PF.) 卵磷酯 3,0 雌二醇 ..,2J) _____ 100.0 在下列實施例中,你以合適谨的起始物質,利用賁施 例2 ?之方法,所産生之具荇F列成份濃度的紐成物· -Π5 - 本紙張尺度適用中國國家揉準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 4 6 4 5 11 a7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明() 實胞例28 成份 :® Μ π分比 聚丙烯酸酯黏莕劑 5 5,0 (GMS 737) 聚異Γ烯 20.0 (V i s 1: a n e s X 1, Η -1, S - L C f 二闪撐s乙二醇 5 . (J 油酸 8 . 0 聚乙烯_咯烷· i 0 _ 0 ί Κο 1 ί i do η 30,) 氣哌r苯 ..2.0 100.0 實施例29 成0} 桌鼠分比 聚内烯酸酯黏著劑 (;9 . 0 (Duro-Tak 80-Π 96) 聚乙烯吡咯烷i® 10.0 (Κ 〇 1 I i d ο η 0 5 :二醇 5 . 0 油酸 8. 0 乙酸生窗詣 3.0 (乙酸維生素K 1¾ ) [3,0. __ 10 0 . 0 (請先閱讀背面之注意事項再填寫本頁) 丧施例30 -雌二醇聚合物之妝合物的閩備如F :在_ -二適的容 器中合併i . 6份的雌' ί齡' 6 . 0份的:―:内檔基乙二醇.8.0 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 4645 1 1 A7 __B7_五、發明説明() 份的油激U份的聚乙烯吡咯烷銅(K G i丨丨do η 30 ) * 50伤 的聚内烯酸酯黏著_ ( G M S 1 4 3 0 ),] 7 . 0份的聚矽氣烷Λ黏 箸劑(B lil-PSA Χ7-4β〇3)及聚矽氣烷Β黏箸劑ίίΠΓΜΙΑ Q7M5 03 )充份混合ώ至该混含物均勻所得的成份物《“ 乾燥”的基礎下,it就足,在去除揮發件溶劑步驟後 > 其 中成份所具有濃度如K所;『:: (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 實铯例3 1 成份 重量吞分比 聚矽氣烷Α黏箸劑 Γ). 0 (BIO-PSA Q7-4503,; 聚矽氣烷B黏著劑 rt -ί {、 (1 ί . ί> (BIO-PSA X7-4603J 聚丙㈣酸酯黏箸劑 5.0 (GMS 737? Wlf醯胺 6.0 二丙搾甚乙二醇 2 , 0 聚乙烯吡咯垸簾1 5.0 (K 〇 1 1 i d ο η 3 0 ) 聚氣乙檔基(2 )油酸 2,0 (P>rtj 03) 炔諾_ 3.0 雌二醇 0 . 4 100.0
>1T -67 - 冢紙張尺度適用中國國家標準(CNS ) A4規雇(2l〇X297公釐) 46 45 1 1 五、發明説明() 經濟部中央榇準局員工消費合作社印製 實施例32 成份 虚Μ β分[:匕 聚矽氣垸Λ黏著劑 5 , 0 (Βίϋ-PSA Q7-4503) 聚黏箸劑 71 . β iBBIO-PSA X7-4603.) 聚丙烯酸酯黏替_ 5 , 0 (GMS 737) 油醯胺 6,0 二丙if基乙二醇 4,0 聚8乙烯咄咯烷麵 5,0 (Kol1 idon 30) 炔諾酮 3.0 雌二醇 _0.J 100.0 實施例33 成份 虚S 7ΐ分tL 聚fi矽氣烷黏箸劑 71.2 (BIO-PSA X7-4603) 聚内烯酸酯黏箬劑 5*0 (GMS 737) 汕醇 ϋ * ο 聚氣乙撑基(2 )油酸 4,0 (Bri.i 93) 聚乙烯吡咯烷銅 10.0 (Kol 1 id ο η Ι/' A () 4 } 炔諾酮 ;5. 0 雌二醇 0. Λ 1 00.0 .. + __ In - - n^— m- 1^1 i^i - / ^ m - -I 、JSJ I ; (請先閱讀背面之注意事項再填寫本頁) -68 -本紙張尺度適用中國國家標率(CNS ) A4规格(210X297公釐) ngyiv A7 B7 五、發明説明() 雖然本發明已描述了 κ待殊的贳狍例與其應m >然熟 0r 範Π'Ι 案亦 木, 出此 超因 不 -h Hhu /ί 汐 ’ 拖 容嘗 内的 :小它 教tt、 的成 案形 本 K-於神 基 精 BI之 人本 SH 技背 比不 習或 -TJ ψ 本 解 於 肋 有 傷 僅 明 式 _ 之 , 供 圍 提範 所絮 明本 #制 本限 解欲 (請先閲讀背面之注意事項再填寫本頁) 經濟部4-央標準局—工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4规格(210Χ297公釐) Α7 Β7
4 6 4 5 五、發明説明() 圖式簡要說明 第1圖為本發明之單片穿皮給藥裝置的概要說明。 第2圖顏示以表觀硝基甘油擴散傺數作為本案多重聚 合物黏著条統之溶解度参數的一函數。 第3圔顯示雌二醇從本發明(實施例2與3 )以及 Estraderm’M等配方在活體外通經人體表皮之平均流動。 每一者為5次細胞重覆實驗之平均。 第4画顯示從具有濃度為05%至1. 0%之雌二醇的 本發明糸統(實施例4至11)在活體外通經人體表皮之平 均流動。每一者為5次細胞重覆實驗之平均。 第5圖顯示炔諾酮乙酸S旨由具有濃度為0.05%至 1.0%之雌二醇與3 %之ΝΕΤΑ的本發明条統(實施例4至 11)在活體外通經人體表皮之平均流動。每一者為5次細 胞重覆實驗之平均。 第6圖顏示在帶有不同的聚乙烯吡咯烷酮濃度(0-10¾) 之本發明糸統中,雌二醇與炔諾酮乙酸酯之平均流動。 每一者為5次細胞重覆實驗之平均, 第7圖顯示聚乙烯吡咯烷酮(PVP >對於雌二醇在洁體 外流經人體表皮上之作用。其中以實施例6 (10¾ PVP)和 實施例12 (0¾ PVP)作比較。 第8圔顯示源自於一含有各種濃度的可溶性PVP之本 案組成物[Noven lots 931026-1 <10 kol> 與 931026-4 U 5 ko 1)]的雌二醇與炔諾ϋ乙酸酷之累積通透率,F 1 ϋχ -70 - 本紙痕尺度逍用中國國家標準ί CNS ) Α4規格(公t ) (讀先閲讀背面之注意事項再填寫本頁) ^ 經濟部中央標準局員工消費合作社印裝
五、發明説明() 349。 第9圖頭示可溶性PVP Uollidon 30)之濃度對於雌 二醇活體外(E2)與炔諾酮乙酸酯(ΝΕΤΑ)在活體外從本發明 組成物[砂酮/丙烯酸衍生物系統(20%丙烯酸衍生物)] 通經人體表皮之流動的影響。每一者為5次細胞重覆實驗 之平均。 第10圖頴示在使用含有各種濃度之可溶性PVP (具有 6%月桂醇的K0LLID0H 30)的本案組成锪下,可溶性PVP之 濃度對於雌二醇與炔諾酮乙酸酯的平均流量之影饗。使用 940202-G (10¾ 737, 10¾ K0LLID0N 30)以及 940202-Η (10Π37,15¾ K0UID0N 30)作比較。 ---^-------J A------IX '(請先閲讀背面之注$項再填寫本頁) 經濟部中央榉準局貝工消費合作社印製 本紙張尺度適财國财標準(CNS ) A4規格(21()><297公$ )
Claims (1)
- 4 6 451 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 六、申請專利範圍 第084100440號專利申請案申請專利範圍修正本 修正日期:90年2月 1· 一種適供用於一穿皮藥物輸送系統之壓力敏感型黏著 組成物’其包含一由下列所構成之摻合物: (a) —種橡膠黏著劑,其係選自於聚矽氧烷、聚異丁烯 與天然橡膠所組成之群中,且其中該橡膠黏著劑之 存在量係占該組成物之總重量的5wt%至97wt%之數 量, (b) —種聚丙烯酸酯,其存在量係占該組成物之lwt%至 85wt%之數量,其中該聚丙烯酸酯對該橡膠黏著劑之 比例為自2:98至96:4, (c) 一藥學上有效量之一種藥劑或者二或多種藥物之一 混合物’其中該藥劑之存在量係占該組成物之總量 的〇_1%至50%,以及 (d) —種可溶性聚乙烯吡咯烷酮,其中該可溶性聚乙烯 0比略院醐之存在量係占該組成物之總量的1。/〇至 20% . 其中該藥劑對該可溶性聚乙烯吡咯烷鲷之比例為自 ι:ιο至io:i,且 其令該可溶性聚乙烯吡咯烷酮之量係為足以溶解所有 的該藥劑,而該藥劑之存在量超過其在一含有一橡膠黏 著劑及一聚丙烯酸酯但無可溶性聚乙烯吡咯烷酮的組 成物内之溶解度。 2.如申請專利範圍第i項之組成物,其包含有,以該組成 本紙張尺度逋用中國國家橾率(CNS ) A4洗格(210 X 297公着) —--------▲ -------ir------·*! (請先閱讀背面之注意事項再填寫本I) •13· 6 45 1 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 、申請專利範圍 物之總重量為準,5%至94%之聚矽氧烷作為該橡膠黏著 劑、1 %至8 5 %的聚丙稀酸醋、1至15 %的聚乙稀u比略院 酮、0%至20%的共溶劑、〇至15%的促進劑以及〇3%至 30%的藥劑。 3. 如申請專利範圍第〗項之組成物,其中該聚乙烯吡咯烧 酮具有一為7000至54000之分子量。 4. 如申請專利範圍第1、2或3項之組成物,其中該藥劑係 選自下列群中:類固醇類、冷2_腎上腺素同效劑與阻礙 劑、心臟活性藥劑、膽鹼同效劑、鎮定劑、痲醉劑 '止 痛劑、抗贅瘤劑、中樞神經系統作用的藥劑血管擴張 劑、治療帕金森氏症用藥、抗精神病用藥以及非類固轉 性抗發炎藥。 5. 如申請專利範圍第4項之組成物,其包含至少二種藥 劑。 6. 如申請專利範圍第4項之組成物,其中該藥劑係選自於 由下列所構成之群中:共軛化雌激素(conjugated estrogenic hormones)、酯化雌激素(esterified estrogens)、愛斯球皮佩特(estropipate)、17 召-雌二醇(17 冷-estradiol) ' 馬稀雌嗣(equilin)、块难甲醚 (mestranol)、雌酮(estrone)、雌三醇(estriol)、乙快雌二 醇(ethinyl estradiol)、己稀雌紛(diethylstilbestrol)、黃 體 酮 (progesterone) ' 19- 去曱 黃體酮 (19-norprogesterone) ' 快兹酮(norethindrone)、快 1¾ 綱 乙酸酯(norethindrone acetate)、梅雷賈斯球 (請先閲讀背面之注意事項再填寫本頁) 訂' 本紙浪尺度逍用中國國家標隼(CNS ) A4洗格(210x297公釐) -14 - 6 45 1 A8 B8 C8 D8 經濟部智慧財產局員工消費合作钍印製 々、申請專利範圍 (melengestrol)、氯地孕酮(chlormadinone)、經脫水孕剩 (ethisterone) ' 曱孕嗣乙酸酯(medroxyprogestrone acetate)、經基黃體 8¾ 癸酸醋(hydroxyprogestrone caproate)、雙醋炔諾 _ (ethynodioi diacetate)、異诀諾銅 (norethynodrel) 、 17 α -經基黃體_ (17 -hydroxyprogesterone)、脫氫逆孕綱(dydrogesterone)、 炔甲睪酮(dimethisterone)、 乙快雌烯三醇 (ethynylestrenol)、18-甲块諾酮(norgestrel)、單美教斯 酮(demegerone)、博美教斯啊(promegestrone)、甲地孕 鋼乙酸酯(megestrol acetate)、間普羅特雷諾 (metaproternol)、特普他林(terbutaline)、蘇必妥 (albuterol)、卡爾布特羅(carbuterol)、經底甲苯二盼 (rimiterol) '芬蕊醇(fenoterol)、經曱項胺心定 (soterenol)、确基甘油(nitroglycerin)、異山梨醇二硝酸 δ旨(isosorbide dinitrate)、異山梨醇單硝酸輯(isosorbide mononitrate)、奎尼定硫酸酯(quinidine sulfate)、普卡因 酿胺(procainamide)、节狄 塞 β桊(bendroflumethiazide)、 千氟甲 °塞°秦(benzthiazide)、氣 σ塞嗓(chlorothiazide)、石肖 笨0比峻(nifedipine)、尼卡得皮(nicardipine)、戊脈胺 (verapamil)、硫氮革酮(diltiazem)、噻嗎心安(timolol)、 萘心安(propanolol)、克普頭普利爾(captopril)、氣壓定 (clonidine)、0底嗤嗜(prazosin)、膽驗(choline)、乙酿膽 絵'(acetylcholine)、乙醜甲膽驗(methachoine)、卡巴可 (carbachol)、胺基曱醯曱基膽鹼(bethanechol)、毛果芸 (請先閣讀背面之注項再填寫本頁) 訂·- 本紙張尺度逋用中國國家榡隼(CNS > A4規格(210X297公釐) -15- 5 4 6 4 8 8 8 8 ABCD 經濟部智慧財產局員工消費合作社印製 六、申讀專利範圍 \j香鹼(pilocarpine)、毒蕈鹼(muscarine)、阿雷克林 (arecoline)、阿普雷諾雷(alpraz〇lain)、甲胺二氮箪 (chlordiazepoxide)、克羅雷林婆佩特(clorazeptate)、海 羅林佩(halazepam)、去曱羥安定(0Xazepam) '環丙安定 (prazepam)、克羅納林佩(cl〇nazepain)、氟瑞林佩 (flurazepam)、泰爾阿羅佩(triazolam)、婁羅林佩 (lorazepam)、氣甲苯基苯并二氮酮革(diazepam)、硫普 ^^(thiopropazate)、氣丙〇秦(chlorpromazine)、三氟普 羅馬嗪(triflupromazine)、美索瑞達嗉(mesoridazine)、 派啶乙醯嗓(piperacetazine)、甲硫達嗓(thioridazine)、 乙醯奮乃興(acetophenazine)、氟非那嗓(fluphenazine)、 奮乃興(perphenazine)、三說普雷新(trifluoperazine)、氣 普雷塞克新(chlorprothixene)、氨讽嘆嘲(thiothixene)、 鹵0底丁笨(haloperidol)、臭 〇底丁苯(bromperidol)、羅克 沙皮(loxapine)、摩林酮(molindone)、利多卡因 (lidocaine)、丁卡因(tetracaine)、達克羅事(dyclonine)、 狄布卡因(dibucaine)、普魯卡因(procaine)、卡波卡因 (mepivacaine)、求平維卡因(bupivacaine)、依它同卡因 (etidocaine) ' 丙胺卡因(prilocaine)、笨佐卡因 (benzocaine)、芬太尼(fentanyl)、叔丁 》非 (buprenorphine)、可待因(codeine)、尼古丁(nicotine)、 罌粟驗(papverine)、丁啡哈(butorphanol)、氩化嗎。非酮 (hydromorphone)、氧基嗎啡明(oxymorphone)、美力〇 明 (mecamylamine)、雙氣滅痛(diclofenac)、苯氧基氩化阿 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本萸) 訂一 -16- 5 4 6 4 8 8 8 8 ABCD 經濟部智葸財產局員工消費合作社印製 六、申請專利範圍 托酸(fenoprofen)、氟聯苯丙酸(flurbiprofen)、異丁苯丙 酸(ibuprofen)、酮笨丙酸(ketoprofen)、甲氧萘丙酸 (naproxen)、17比氧 11 塞口秦(piroxicam)、5 -胺基-乙醯丙酸(<5 -amino-levulinic acid)、戴普寧(deprenyl)、穗雷吉林 (selegiline)、巴比隆(buspirone)、氟雪丁(fluoxetine)、 蘇大林(sertaline) ' 普雪丁(peroxetine)、利索瑞 (lisuride)、溴克普丁(bromocriptine)、利索瑞(lisuride)、 普高利(pergolide)、月亏炔諾酯(norgestimate)、雙醋炔諾 ¥1 (ethynodiol diacetate)、德索傑瑞(desogestrel)、依 普皮隆(ipsapirone)、依那拉普(enalapril)、依那拉雷 (enalaprilet)、氮氣滅酸(niflumic acid)、東茛菪驗 (scopolamine)、蘇馬頓(sumatriptan)、加拉巴爾豆驗 (physostigmine)、瑞伐敏(rivastigmine)、睪固嗣 (testosterone)、甲基睪固酮(methyl testosterone)、氣經 甲基睪丸素(fluoxymesterone)、苯11 瓜咬醋酸甲酉旨 (methylphenidate)、莫它平(mirtazapine)、洛它丁 (loratadine) '辛伐平(simvastatin)、普伐平 (pravastatin)、謝伐平(cerivastatin) ' 甲疏 σ米峻 (methimazole)、亞倫都寧(alendranate)、阿提都寧 (etidronate)、羅必吟(ropininrole)以及普明必若 (pramipexole)。 7. 如申請專利範圍第3項之組成物,其包含5至10%的聚乙 烯0比嘻烧i5!。 8. 如申請專利範圍第5項之組成物,其包含一個由一促孕 (請先閔讀背面之注意事項再填寫表頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇><297公釐) -17- 46 45 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 六、申請專利範圍 劑與一雌激素所構成之混合物。 9. 如申請專利範圍第5項之組成物,其中該組成物包含一 個由一雄性類固醇與一雌激素所構成之混合物。. 10. 如申請專利範圍第9項之組成物’其中該雄性類固醇為 睪固酮或曱基睪固綱,且該雌激素係選自於由乙炔雌 二醇、炔雌甲醚舆17/3-雌二醇所構成之群中。 11·如申請專利範圍第5項之組成物,其中該等藥劑包含一 或多種炔諾酮及炔諾酮乙酸酯。 12. 如申請專利範圍第8項之組成物,其包含70%的聚矽氧 烷、5%的聚丙烯酸酯、1〇%的聚乙烯吡咯烷酮、3%的 炔諾酮乙酸酯以及0.7%的雌二醇。 13. 如申請專利範圍第6項之組成物,其包含60%的聚矽氧 烷、20%至55%的聚丙烯酸酯、10%的聚乙烯吡咯烷酮 以及4%的炔諾酮乙酸酯》 14. 如申請專利範圍第6項之組成物,其包含25%的聚矽氧 烷、45%的聚丙烯酸酯' 10%的聚乙烯吡咯烷酮、7% 的阿普雷諾雷(alprazolam)以及10%的促進劑。 15. 如申請專利範圍第6項之組成物,其包含的聚矽氧 烷、60%的聚丙烯酸酯、5%的聚乙烯吡咯烷酮以及1 〇% 的蘇必妥(albuterol)。 16. 如申請專利範圍第6項之組成物,其包含5°/。的聚5夕氧 烷、70%的聚丙烯酸酯、5%的聚乙烯扯咯烷綱以及1 〇% 的胺基乙酿丙酸。 17. 如申請專利範圍第6項之組成物’其包含50%的聚石夕氧 ----------^表--^-----訂------米 (請先閲讀背面之注意事項再填寫本X} 本紙張尺度速用中國國家榡率(CNS)A4规格(210x297公董) -18- 45 1 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 κ、申請專利範圍 烷、20%的聚丙烯酸酯、:ί 0%的聚乙烯吡咯烷酮以及5% 的芬太尼β 18. 如申請專利範圍第6項之組成物,其包含65%的聚矽氧 烷、1 5%的聚丙烯酸酯、5%的聚乙烯吡咯烷鲷以及15% 的尼古丁* 19. 如申請專利範園第6項之組成物,其包含65%的聚矽氧 烷、15%的聚丙烯酸酯、1 5%的聚乙烯吡咯烷酮以及15% 的穗雷吉林(selegiline)。 20. 如申請專利範圍第6項之組成物,其包含5%的聚矽氧 烷、60%的聚丙烯酸酯、5%的聚乙烯吡咯烷酮以及30% 的酮苯丙酸。 21 如申請專利範圍第1項之組成物,其包含60%的聚矽氧 烷、20%的聚丙烯酸酯、5%的聚乙烯吡嘻烷酮以及2% 的17yS -雌二醇。 22. 如申請專利範圍第1項之組成物,其中該聚乙烯吡咯烷 酮具有一約-7〇°C至0°C的玻蹲轉化溫度。 23. 如申請專利範圍第1項之組成物,其更包含一或多種選 自於由促進劑、填充劑、增塑劑、增黏劑與共溶劑所 構成群組中的添加劑。 24. 如申請專利範圍第1項之組成物’其包含依組成物之總 乾重計為約5%至90%之矽膠黏著劑作為橡膠成份、約 f 1%至20%的聚乙烯吡咯烷酮、約1%至25%之二丙二醇、 約0.5%至10%之油酸以及約1%至1〇%的阿普雷諾雷 (alprazolam) 〇 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -19 - 4 6 4 A8 B8 C8 D8 經濟部智慧財產局員工消費合作社印製 六、申請專利範圍 25. 如申請專利範圍第1項之組成物,其包含依組成物之總 乾重計為約25%至75%之矽膠黏著劑作為橡膠成份、約 5%至50%之聚丙烯酸酯、約1 %至20%的聚乙烯吡咯烷 _、約5%至8%之二丙二醇、約2%至6%之油醇以及約1% 至20%的克羅納林佩(clonazepam)。 26. 如申請專利範圍第1項之組成物,其包含依組成物之總 乾重計為約5%至90%之矽膠黏著劑作為橡膠成份、約 5%至85%之聚丙烯酸酯、約1%至20%的聚乙烯吡咯烷 酮以及約1%至10%的氯壓定(clonidine)。 27. 如申請專利範圍第1項之組成物,其包含依組成物之總 乾重計為約40%至85%之矽膠黏著劑作為橡膠成份、約 2.5%至20%之聚丙烯酸酯、約5.0%至15%的聚乙烯吡 咯烷酮、約2%至10%之二丙二醇、約2%至10%之油醇 以及约0.5%至5.0%的氟氫可體松。 28. 如申請專利範圍第1項之組成物,其包含依組成物之總 乾重計為約5%至75%之聚丙烯酸酯、約5%至75%之矽 膠黏著劑作為橡膠成份、約2%至25%的聚乙烯呲咯烷 酮、約2%至25%之油醇以及約5%至20%的酮苯丙酸 (ketoprofen) 〇 29·如申請專利範圍第1項之組成物,其包含依組成物之總 乾重計為約5%至65%之矽膠黏著劑作為橡膠成份、約 5%至70%之聚丙烯酸酯、約1%至1 5%的聚乙烯吡咯烷 酮以及約5%至30%的苯哌啶醋酸甲酯。 30.如申請專利範圍第1項之組成物,其包含依組成物之總 n m 11..... - H — 1 — - I - - I. n m I —J— - -1 -- i ^^1 f— an -- - „ ' ^ f (請先閔讀背面之注意事項再填寫本頁) 本紙張又度逋用中國國家揉準(CNS ) A4規格(210X297公釐) -20 - 46 45 1 1 8 οο 8 8 ABCD 經濟部智慧財產局員工消費合作社印裝 六、申請專利範圍 乾重計為約5%至70%之矽膠黏著劑作為橡膠成份、約 5%至70%之聚丙烯酸酯、約2%至20%的聚乙烯吡咯烷 酮以及約5%至30%的笨哌啶醋酸甲酯。 31.如申請專利範圍第1項之组成物,其包含依組成物之總 乾重計為約5%至75%之矽膠黏著劑作為橡膠成份、約 10%至50%之聚丙烯酸酯、約5%至20%的聚乙烯吡咯烷 網以及約0.5%至20%的特平那芬(terbinafine)。 32·如申請專利範圍第1項之组成物,其包含依組成物之總 乾重計為約40%至70%之矽膠黏著劑作為橡膠成份、約 5%至30%之聚丙烯酸酯、约2%至15%的聚乙烯吡咯烷 酮、约0%至10%之二丙二醇、約0%至10%之油醇以及 約1 %至10%的雌二醇。 33. —種穿皮藥物輸送系統*其包含一由固定幾何形狀所 構成的薄片,該薄片包含有一如申請專利範圍第1至32 項中任一項之組成物。 34. 如申請專利範圍第33項之穿皮藥物輪送系統,其係呈 單一劑量單元之形式。 35. 如申請專利範圍第33項之穿皮藥物輸送系統,其包含 一被疊覆於該組成物之一表面上的背層材料,該背層 材料係實質上無法使藥物通透,以及一被疊覆於該组 成物相對於該背層之另一表面上的釋出襯墊。 36. 一種製備一用於穿皮藥物輪送系統之壓力敏感型黏著 组成物的方法,其包含摻合: (a)—種橡膠黏著劑,其量依該組成物之總重量計為5% 本紙張认逋用中關家標i ( CNS )八4胁(2丨0X297公釐) ---------Λ--^----- I訂, (請先閔讀背面之注意事項再填寫本頁) -21 - 46^5 1 1 A8 B8 C8 D8 經濟部智慧財A局員工消費合作社印製 π、申請專利範圍 至 97% ; (b) —種聚丙烯酸酯,其量依該組成物之總重量計為5% 至85% ’其十該聚丙烯酸酯對該橡膠之比例為自2:98 至96:4, (c) 一治療上有效量之穿皮藥物輸送用藥劑,抑或一由 二或更多種穿皮藥物輸送用藥劑所構成之混合物, 其中該藥劑之存在係占該組成物之總量的〇 .丨〇/〇至 50%,以及 (d) —種可溶性聚乙烯吡咯烷酮,其中該可溶性聚乙烯 咐嘻烧綱之存在量係占該組成物之總量的1 %至 20% . 其中該(等)藥劑對該可溶性聚乙烯吡咯烷之比例為自 1:10至 10:1,且 其中該可溶性聚乙烯咕咯烷酮之量係為足以溶解所有 的该藥劑’而該藥劑之存在量超過其在一含有一橡膠及 一聚丙烯酸酯但無可溶性聚乙烯吡咯烷酮的組成物内 之溶解度。 37.如申請專利範圍第1至3項中任一項之組成物,其中該藥 劑係擇自下列群組:依那拉普(enalapril)、依那拉雷 (enalaprilet)、氟雪丁(fluoxetine)、氮氟滅酸(niflumic acid) 、《比氧噻嗉(piroxicarn)及蘇大林(sertanne)。 38_如申請專利範圍第1至3項中任一項之組成物,其中該藥 劑係擇自下列群組:東茛菪驗(SC〇p〇lamine)、蘇馬賴 (sumatriptan)、加拉巴 _ 豆驗(physostigmine) ' 睪固納 本紙張尺度適用中國國家標準< CNS ) A4規格(210 X 297公釐) ,言. (請先聞讀背面之注意事項再填寫本頁) -22 - 4 5 4 8 8 8 8 ABCD 六、申請專利範圍 (testosterone)、甲基睪固酮(methyl testosterone)、I 經 甲基睪丸素(fluoxymesterone)、笨0底喊酷酸甲酯 (methylphenidate)、洛它丁(loratadine)、辛伐平 (simvastatin)、普伐平(pravastatin)、甲锍咪唑 (methimazole)以及阿提都寧(etidronate)。 (請先閲讀背面之注意事項再填寫本頁) 訂 t- 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標率(CNS > A4况格(210X297公釐) -23 ^
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/178,558 US5656286A (en) | 1988-03-04 | 1994-01-07 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Publications (1)
Publication Number | Publication Date |
---|---|
TW464511B true TW464511B (en) | 2001-11-21 |
Family
ID=22653013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW084100440A TW464511B (en) | 1994-01-07 | 1995-01-19 | Pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system and preparation method therefor |
Country Status (22)
Country | Link |
---|---|
US (3) | US5656286A (zh) |
EP (2) | EP0737066B1 (zh) |
JP (1) | JP4339398B2 (zh) |
KR (1) | KR100363052B1 (zh) |
CN (1) | CN1121854C (zh) |
AT (1) | ATE235898T1 (zh) |
BR (1) | BR9506470B8 (zh) |
CA (1) | CA2180530C (zh) |
DE (1) | DE69530177T2 (zh) |
DK (1) | DK0737066T3 (zh) |
ES (1) | ES2196055T3 (zh) |
FI (1) | FI121527B (zh) |
HU (1) | HU227814B1 (zh) |
IL (1) | IL112269A (zh) |
MX (1) | MX9602656A (zh) |
NO (1) | NO319377B1 (zh) |
NZ (1) | NZ278769A (zh) |
PT (1) | PT737066E (zh) |
SG (1) | SG49331A1 (zh) |
TW (1) | TW464511B (zh) |
WO (1) | WO1995018603A1 (zh) |
ZA (1) | ZA95108B (zh) |
Families Citing this family (498)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
US6492349B1 (en) * | 1993-03-31 | 2002-12-10 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
AU7396294A (en) * | 1993-06-25 | 1995-01-24 | Alza Corporation | Incorporating poly-n-vinyl amide in a transdermal system |
DE4442999A1 (de) | 1994-12-02 | 1996-06-05 | Hexal Pharma Gmbh | Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten |
DE4443888A1 (de) * | 1994-12-09 | 1996-06-13 | Bayer Ag | Dermal applizierbare Formulierungen von Parasitiziden |
US6024974A (en) * | 1995-01-06 | 2000-02-15 | Noven Pharmaceuticals, Inc. | Composition and methods for transdermal delivery of acid labile drugs |
IL116539A (en) * | 1995-01-06 | 2002-02-10 | Noven Pharma | Preparations given through the skin of unstable anti-acid drugs |
DE19503338C2 (de) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Arzneiform zur Abgabe von Kollagenase an Wunden und Verfahren zu ihrer Herstellung und ihre Verwendung |
DE19512181C2 (de) * | 1995-03-31 | 2003-11-06 | Hexal Pharma Gmbh | Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer |
AUPN262595A0 (en) * | 1995-04-24 | 1995-05-18 | Novapharm Research (Australia) Pty Limited | Biocidal surface films |
US6730294B1 (en) | 1995-04-24 | 2004-05-04 | Novapharm Research (Australia) Pty Limited | Method of forming a water soluble biocidal film on a solid surface |
US6316022B1 (en) | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
NZ309980A (en) * | 1995-06-07 | 2001-06-29 | Noven Pharma | Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature |
CN1188189C (zh) * | 1995-06-07 | 2005-02-09 | 奥瑟-麦内尔制药公司 | 基质层含有17-脱乙酰基诺孕酯的经皮贴片及基质的用途 |
US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
FR2739031B1 (fr) * | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique |
US5702720A (en) * | 1995-12-22 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of flurbiprofen |
JP4154621B2 (ja) * | 1996-02-07 | 2008-09-24 | リードケミカル株式会社 | トラニラスト含有外用製剤及びその製造方法 |
US5725876A (en) * | 1996-05-17 | 1998-03-10 | Noven Pharmaceuticals Inc., | Compositions and methods for using low-swell clays in nicotine containing dermal compositions |
US6623752B1 (en) * | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
DE19635883A1 (de) * | 1996-09-04 | 1998-03-05 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination |
US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US6572880B2 (en) | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
WO1999011208A1 (en) * | 1997-08-28 | 1999-03-11 | Williams C Donald | Method and composition for transdermal administration of pharmacologic agents |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6399658B1 (en) * | 1996-12-24 | 2002-06-04 | Sumitomo Pharmaceuticals Co., Ltd. | Composition containing ascorbic acid |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DK48997A (da) * | 1997-04-30 | 1999-01-05 | Coloplast As | Klæbemiddel samt anvendelse af dette middel |
IT1292129B1 (it) * | 1997-06-11 | 1999-01-25 | Sunnimex Ltd | Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella |
JP2002505676A (ja) | 1997-06-23 | 2002-02-19 | クイーンズ ユニバーシティー アット キングストン | 微量投与療法 |
US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
US6488940B2 (en) | 1997-08-21 | 2002-12-03 | Johnson & Johnson Consumer Companies, Inc. | Use of 17-α-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy |
CA2301016A1 (en) * | 1997-08-21 | 1999-02-25 | Johnson & Johnson Consumer Companies, Inc. | Use of 17-.alpha.-estradiol for the treatment of aged or sundamaged ski n and/or skin atrophy |
CA2301706C (en) * | 1997-08-21 | 2005-10-04 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of alzheimer's disease |
DE19738643C2 (de) * | 1997-09-04 | 2001-10-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung |
US6767902B2 (en) * | 1997-09-17 | 2004-07-27 | The Population Council, Inc. | Androgen as a male contraceptive and non-contraceptive androgen replacement |
GB9720470D0 (en) | 1997-09-25 | 1997-11-26 | Ethical Pharmaceuticals South | Inhibition of crystallization in transdermal devices |
JP2001517493A (ja) | 1997-09-26 | 2001-10-09 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 生体接着剤組成物及び活性薬剤の局所投与方法 |
US20040018241A1 (en) * | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
JP3460538B2 (ja) * | 1997-10-08 | 2003-10-27 | 救急薬品工業株式会社 | 速溶性フィルム製剤 |
AU1800099A (en) * | 1997-11-25 | 1999-06-15 | Theratech, Inc. | Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties |
JP3930984B2 (ja) * | 1997-12-12 | 2007-06-13 | 日東電工株式会社 | 経皮吸収型製剤 |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US20020102291A1 (en) * | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US6146656A (en) * | 1998-01-22 | 2000-11-14 | Nitto Denko Corporation | Percutaneous absorption preparation |
WO1999044603A1 (en) * | 1998-03-06 | 1999-09-10 | Sponsel William E | Composition and method for treating macular disorders |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19814257A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
AU760408B2 (en) | 1998-04-27 | 2003-05-15 | Surmodics, Inc. | Bioactive agent release coating |
US20050196431A1 (en) * | 1998-04-30 | 2005-09-08 | Upvan Narang | Adhesive applicator tip with a polymerization initiator, polymerization rate modifier, and/or bioactive material |
US6455064B1 (en) | 1998-04-30 | 2002-09-24 | Closure Medical Corporation | Method of applying an adhesive composition over a bioactive polymerization initiator or accelerator |
US6197347B1 (en) | 1998-06-29 | 2001-03-06 | Andrx Pharmaceuticals, Inc. | Oral dosage for the controlled release of analgesic |
IT1299566B1 (it) * | 1998-07-17 | 2000-03-16 | Ifi Istituto Farmacoterapico I | Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina |
US6699497B1 (en) * | 1998-07-24 | 2004-03-02 | Alza Corporation | Formulations for the transdermal administration of fenoldopam |
ATE269063T1 (de) * | 1998-07-24 | 2004-07-15 | Alza Corp | Formulierungen zur transdermalen verabreichung von fenoldopam |
JP3943724B2 (ja) * | 1998-07-31 | 2007-07-11 | 東光薬品工業株式会社 | フェンタニル含有経皮投与マトリックス型貼付剤 |
US20040170675A1 (en) * | 1998-08-03 | 2004-09-02 | Easterling W. Jerry | Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method |
US7097849B2 (en) * | 1998-08-19 | 2006-08-29 | Jagotec Ag | Injectable aqueous dispersions of propofol |
DE69933775T2 (de) * | 1998-08-20 | 2007-10-04 | 3M Innovative Properties Co., St. Paul | Sprühverband und wirkstoffabgabesystem |
US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
ATE273698T1 (de) * | 1998-10-02 | 2004-09-15 | 3M Innovative Properties Co | Systeme zur arzneistoffabgabe an schleimhäute |
US6475514B1 (en) | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
WO2000033812A2 (en) * | 1998-12-07 | 2000-06-15 | Elan Corporation, Plc | Transdermal patch for delivering volatile liquid drugs |
US20030170195A1 (en) * | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
CA2331264C (en) * | 1999-01-14 | 2008-09-23 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
US6337086B1 (en) | 1999-02-06 | 2002-01-08 | Dow Corning Corporation | Pressure sensitive adhesive compositions for transdermal drug delivery devices |
DE19906152B4 (de) | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
US6455055B1 (en) | 1999-02-12 | 2002-09-24 | The Procter & Gamble Company | Cosmetic compositions |
US6309657B2 (en) | 1999-02-12 | 2001-10-30 | The Procter & Gamble Company | Cosmetic compositions |
US6224888B1 (en) | 1999-02-12 | 2001-05-01 | The Procter & Gamble Company | Cosmetic compositions |
CA2299950C (en) * | 1999-03-03 | 2010-09-21 | Nitto Denko Corporation | Oral adhesive sheet and oral adhesive preparation |
US7063859B1 (en) | 1999-04-28 | 2006-06-20 | Noven Pharmaceuticals, Inc. | Barrier film lined backing layer composition and method for topical administration of active agents |
AU5325000A (en) | 1999-06-05 | 2000-12-28 | David Houze | Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use |
DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
EP1191927B1 (de) * | 1999-07-02 | 2003-03-12 | LTS Lohmann Therapie-Systeme AG | Mikroreservoirsystem auf basis von polysiloxanen und ambiphilen lösemitteln |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6780880B1 (en) * | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US7052714B1 (en) * | 1999-10-13 | 2006-05-30 | Senju Pharmaceutical Co., Ltd | Ophthalmic adhesive preparations for percutaneous adsorption |
EP1231877A4 (en) * | 1999-11-04 | 2009-03-18 | Xel Herbaceuticals | TRANSDERMALE ADMINISTRATION OF HUPERZIN |
WO2001035883A1 (en) * | 1999-11-19 | 2001-05-25 | Xel Herbaceuticals | Transdermal delivery system for alkaloids of aconitum species |
US20050042271A1 (en) * | 1999-11-19 | 2005-02-24 | Xel Herbaceuticals, Inc . | Transdermal delivery system for alkaloids of aconitum species |
US6896898B1 (en) | 1999-11-19 | 2005-05-24 | Xel Herbaceuticals, Inc. | Transdermal delivery system for alkaloids of aconitum species |
US6974588B1 (en) * | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
US20020004065A1 (en) | 2000-01-20 | 2002-01-10 | David Kanios | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
US6905016B2 (en) * | 2000-03-14 | 2005-06-14 | Noven Pharmaceuticals, Inc. | Packaging system for transdermal drug delivery systems |
US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
DE10012908B4 (de) * | 2000-03-16 | 2005-03-17 | Lts Lohmann Therapie-Systeme Ag | Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung |
FR2806625B1 (fr) * | 2000-03-23 | 2002-08-30 | Pf Medicament | Dispositif matriciel pour l'administration transdermique de rilmenidine et son procede de preparation |
JP2003528914A (ja) * | 2000-04-03 | 2003-09-30 | エフ.ホフマン−ラ ロシュ アーゲー | カルベジロールの濃縮溶液 |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
KR100452972B1 (ko) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
DE10025971B4 (de) * | 2000-05-25 | 2004-09-02 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung |
US6579544B1 (en) | 2000-05-31 | 2003-06-17 | Nutriex, L.L.C. | Method for supplementing the diet |
USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
AU2001280100A1 (en) * | 2000-08-22 | 2002-03-04 | Nof Corporation | Lubricating agent and insertion aid solution for contact lens |
US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
KR100940245B1 (ko) * | 2000-09-19 | 2010-02-04 | 내쇼날 스타치 앤드 케미칼 인베스트멘트 홀딩 코포레이션 | 경피 약물 전달 시스템에 유용한 비반응성 접착제 |
US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
WO2002032431A1 (fr) * | 2000-10-16 | 2002-04-25 | Hisamitsu Pharmaceutical Co., Inc. | Compositions pour preparations externes |
JP2004511510A (ja) * | 2000-10-16 | 2004-04-15 | ネオファーム、インコーポレイティッド | ミトキサントロンのリポソーム製剤 |
WO2002054996A2 (en) * | 2000-10-23 | 2002-07-18 | Euro Celtique Sa | Terazosin transdermal device and methods |
GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
WO2002038139A1 (fr) * | 2000-11-07 | 2002-05-16 | Hisamitsu Pharmaceutical Co., Inc. | Preparation pharmaceutique du type a absorption percutanee |
KR20020037616A (ko) * | 2000-11-15 | 2002-05-22 | 서경배 | 케토롤락의 경피흡수제제 |
AU2002235155A1 (en) * | 2000-12-05 | 2002-06-18 | Noven Pharmaceuticals, Inc. | Crystallization inhibition of drugs in transdermal drug delivery systems |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
EP1216699A1 (de) * | 2000-12-21 | 2002-06-26 | Schering Aktiengesellschaft | Transdermalsystem enthaltend ein hochpotentes Gestagen |
US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
WO2002064093A2 (en) * | 2001-02-15 | 2002-08-22 | King Pharmaceuticals, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
BR0207955A (pt) | 2001-03-07 | 2004-02-25 | Hisamitsu Pharmaceutical Co | Agente de emplastro |
PT1381352E (pt) * | 2001-03-16 | 2007-07-27 | Alza Corp | Adesivo transdérmico para administração de fenantil |
DE20221397U1 (de) | 2001-03-16 | 2005-10-20 | Alza Corp., Mountain View | Transdermal-Pflaster zum Verabreichen von Fentanyl |
US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
US6509007B2 (en) * | 2001-03-19 | 2003-01-21 | The Procter & Gamble Company | Oral care kits and compositions |
US6514484B2 (en) * | 2001-03-19 | 2003-02-04 | The Procter & Gamble Company | Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier |
US6491896B1 (en) * | 2001-03-19 | 2002-12-10 | The Proctor & Gamble Company | Polybutene containing denture cleanser compositions |
US6500406B1 (en) * | 2001-03-19 | 2002-12-31 | The Procter & Gamble Company | Denture care compositions and kits |
DE10118282A1 (de) * | 2001-04-12 | 2002-12-05 | Lohmann Therapie Syst Lts | Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke |
RU2276998C2 (ru) | 2001-05-01 | 2006-05-27 | Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук | Гидрогелевые композиции |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
EP2277556B1 (en) | 2001-05-01 | 2016-04-20 | A. V. Topchiev Institute of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
WO2002089849A1 (en) * | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
EP1344522A1 (en) * | 2001-05-08 | 2003-09-17 | Schwarz Pharma Ag | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
JP4865958B2 (ja) * | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
NZ530227A (en) * | 2001-06-18 | 2006-09-29 | Noven Pharma | Enhanced drug delivery in transdermal systems |
US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
DE10141651B4 (de) * | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
DE10137082A1 (de) * | 2001-07-28 | 2003-02-13 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol |
DE10137162A1 (de) * | 2001-07-30 | 2003-02-20 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol |
US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
US6805878B2 (en) * | 2001-09-13 | 2004-10-19 | Noven Pharmaceuticals, Inc. | Transdermal administration of ACE inhibitors |
WO2003022270A1 (en) * | 2001-09-13 | 2003-03-20 | Noven Pharmaceuticals, Inc. | Transdermal administration of an enalapril ester |
US20030082225A1 (en) * | 2001-10-19 | 2003-05-01 | Mason Paul Arthur | Sterile, breathable patch for treating wound pain |
US20030181524A1 (en) * | 2001-10-29 | 2003-09-25 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
DE10157745A1 (de) * | 2001-11-24 | 2003-06-26 | Hf Arzneimittelforsch Gmbh | Transdermales therapeutisches System zur Verabreichung von 17alpha-Estradiol |
EP1451471A2 (en) * | 2001-12-04 | 2004-09-01 | KAG Holding A/S | Screw pump for transporting emulsions susceptible to mechanical handling |
CN100594027C (zh) * | 2001-12-05 | 2010-03-17 | 张喜田 | 番木鳖碱、马钱子碱和一叶秋碱及其盐的透皮剂 |
US20030147972A1 (en) * | 2002-02-05 | 2003-08-07 | Christopher W. Denver | Method and composition for diminishing loss of color in flavors and fragrances |
US20030219471A1 (en) * | 2002-03-11 | 2003-11-27 | Caubel Patrick Michel | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
CA2478194A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Continuous sulfatase inhibiting progestogen hormone replacement therapy |
WO2003077927A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Sulfatase inhibiting progestogen-only contraceptive regimens |
DE10212864B4 (de) * | 2002-03-22 | 2005-12-22 | Beiersdorf Ag | Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung |
JP4478757B2 (ja) * | 2002-04-19 | 2010-06-09 | 日東電工株式会社 | ビソプロロール含有貼付剤 |
WO2003090729A1 (en) * | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
AR033748A1 (es) * | 2002-05-15 | 2004-01-07 | Thalas Group Inc | Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo |
US7217853B2 (en) | 2002-05-24 | 2007-05-15 | Corium International, Inc. | Composition for cushions, wound dressings and other skin-contacting products |
US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US7097850B2 (en) * | 2002-06-18 | 2006-08-29 | Surmodics, Inc. | Bioactive agent release coating and controlled humidity method |
KR20100055542A (ko) | 2002-06-25 | 2010-05-26 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
AU2003281172A1 (en) * | 2002-07-10 | 2004-02-02 | Warner-Lambert Company Llc | Gastrointestinal Compositions |
US20040010035A1 (en) * | 2002-07-15 | 2004-01-15 | Ciociola Arthur A. | Gastrointestinal compositions |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US6958142B2 (en) * | 2002-08-02 | 2005-10-25 | Balance Pharmaceuticals, Inc. | Nasal spray formulation and method |
JP4792193B2 (ja) * | 2002-08-28 | 2011-10-12 | 久光製薬株式会社 | 貼付剤 |
AU2003268376A1 (en) * | 2002-08-30 | 2004-11-26 | Watson Pharmaceuticals, Inc. | Transdermal delivery systems and methods |
US20040086551A1 (en) * | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
ES2239196T3 (es) * | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
WO2004064841A1 (en) * | 2003-01-23 | 2004-08-05 | Shire Holdings Ag | Formulation and methods for the treatment of thrombocythemia |
US20040147534A1 (en) * | 2003-01-23 | 2004-07-29 | Foote Mary Ann | Topical composition and method for treating occlusive wounds |
GB0302662D0 (en) * | 2003-02-05 | 2003-03-12 | Strakan Ltd | Transdermal granisetron |
DE10305137A1 (de) * | 2003-02-07 | 2004-08-26 | Novosis Ag | Transdermale therapeutische Abgabesysteme mit einem Butenolid |
US9498454B2 (en) * | 2003-02-24 | 2016-11-22 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
JO2505B1 (en) | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
US20040208917A1 (en) * | 2003-04-16 | 2004-10-21 | Wilfried Fischer | Transdermal systems for the release of clonidine |
CN1829542A (zh) * | 2003-06-19 | 2006-09-06 | 科洛普拉斯特公司 | 创伤护理装置 |
US7816546B2 (en) * | 2003-06-30 | 2010-10-19 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime |
US20120058993A1 (en) * | 2003-07-23 | 2012-03-08 | Douglas Pharmaceuticals Ltd. | Stable Suspension Formulation |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
US20050036957A1 (en) * | 2003-08-15 | 2005-02-17 | Michael Prencipe | Tooth whitening dental tray and method of use |
US8815215B2 (en) | 2003-08-15 | 2014-08-26 | Colgate-Palmolive Company | Hydrophobic tooth whitening system and methods of use |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
EP1682102A2 (en) | 2003-09-10 | 2006-07-26 | Noven Pharmaceuticals, Inc. | Multi-layer transdermal drug delivery device |
US20070009582A1 (en) * | 2003-10-07 | 2007-01-11 | Madsen Niels J | Composition useful as an adhesive and use of such a composition |
WO2005033198A1 (en) * | 2003-10-07 | 2005-04-14 | Coloplast A/S | A composition useful as an adhesive and use of such a composition |
PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
US7387788B1 (en) | 2003-10-10 | 2008-06-17 | Antares Pharma Ipl Ag | Pharmaceutical compositions of nicotine and methods of use thereof |
RU2356580C2 (ru) * | 2003-10-28 | 2009-05-27 | Новен Фармасьютикалз, Инк | Композиции и способы, обеспечивающие контролируемую потерю лекарственных средств и доставку в системах трансдермальной доставки лекарственных средств |
AU2004286852A1 (en) | 2003-10-30 | 2005-05-19 | Alza Corporation | Transdermal analgesic systems having reduced abuse potential |
US7410978B2 (en) * | 2003-11-04 | 2008-08-12 | Supernus Pharmaceuticals, Inc. | Once daily dosage forms of trospium |
JP4771956B2 (ja) | 2003-11-04 | 2011-09-14 | スパーナス ファーマシューティカルズ インコーポレイテッド | バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物 |
US20060210625A1 (en) * | 2003-11-04 | 2006-09-21 | Shire Laboratories, Inc. | Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms |
EP1706128B1 (en) * | 2003-12-08 | 2010-07-21 | CPEX Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for insulin treatment |
JPWO2005072675A1 (ja) * | 2004-01-30 | 2007-09-13 | 久光製薬株式会社 | 貼付剤入り包装袋及び薬物移行抑制方法 |
US8658201B2 (en) | 2004-01-30 | 2014-02-25 | Corium International, Inc. | Rapidly dissolving film for delivery of an active agent |
US20080125485A1 (en) | 2004-02-17 | 2008-05-29 | Action Medicines | Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis |
ES2238924B1 (es) | 2004-02-17 | 2006-12-01 | Investread Europa, S.L. | Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes. |
US20070149618A1 (en) | 2004-02-17 | 2007-06-28 | Action Medicines, S.L. | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis |
US9205062B2 (en) | 2004-03-09 | 2015-12-08 | Mylan Pharmaceuticals, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
US20050202073A1 (en) * | 2004-03-09 | 2005-09-15 | Mylan Technologies, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
CA2563069A1 (en) | 2004-04-06 | 2005-10-27 | Surmodics, Inc. | Coating compositions for bioactive agents |
US20080138390A1 (en) * | 2004-04-07 | 2008-06-12 | Tsung-Min Hsu | Transdermal Delivery System For Use With Basic Permeation Enhancers |
JP4961207B2 (ja) * | 2004-04-21 | 2012-06-27 | 久光製薬株式会社 | 粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤 |
MEP25008A (en) * | 2004-04-29 | 2010-10-10 | Caldwell Galer Inc | Topical methadone compositions and methods for using the same |
EP1611882B1 (en) * | 2004-06-01 | 2010-04-07 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
JPWO2005117886A1 (ja) * | 2004-06-01 | 2008-04-03 | 久光製薬株式会社 | 貼付剤 |
US20060024246A1 (en) * | 2004-07-29 | 2006-02-02 | Prithwiraj Maitra | Oral care compositions with film forming polymers |
US20060030574A1 (en) * | 2004-08-04 | 2006-02-09 | Shire Holdings Ag | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
US7700608B2 (en) * | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
AU2005271259B2 (en) | 2004-08-05 | 2012-01-19 | A.V. Topchiev Institute Of Petrochemical Synthesis | Adhesive composition |
WO2006036899A2 (en) * | 2004-09-27 | 2006-04-06 | Corium International, Inc. | Transdermal systems for the delivery of estrogens and progestins |
WO2006044206A2 (en) * | 2004-10-08 | 2006-04-27 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device including an occlusive backing |
WO2006041907A2 (en) | 2004-10-08 | 2006-04-20 | Noven Pharmaceuticals, Inc. | Transdermal delivery of estradiol |
US8246976B2 (en) * | 2004-10-08 | 2012-08-21 | Noven Pharmaceuticals, Inc. | Transdermal delivery of drugs based on crystal size |
US20060078602A1 (en) | 2004-10-08 | 2006-04-13 | Noven Pharmaceuticals, Inc. | Device for transdermal administration of drugs including acrylic polymers |
CN101044169A (zh) * | 2004-10-19 | 2007-09-26 | 3M创新有限公司 | 生产压敏粘合剂的方法 |
PL1814531T3 (pl) | 2004-10-21 | 2010-11-30 | Durect Corp | Transdermalne systemy dostarczania |
US8252319B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
KR100810947B1 (ko) * | 2005-01-28 | 2008-03-10 | 롬 앤드 하아스 컴패니 | 에멀젼 폴리머로부터 제조된 의료용 필름 및 제품 |
US20090012181A1 (en) | 2005-01-31 | 2009-01-08 | Satoshi Amano | Patch |
JP4704764B2 (ja) * | 2005-02-03 | 2011-06-22 | 日東電工株式会社 | 爪貼付用粘着組成物および爪用貼付剤 |
WO2006082728A1 (ja) * | 2005-02-04 | 2006-08-10 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収貼付剤 |
FR2881653A1 (fr) * | 2005-02-04 | 2006-08-11 | Frederic Khodja | Dispositif permettant l'administration en continu d'une dose physiologique controlee d'au moins un mineral ou une vitamine |
ES2349544T3 (es) | 2005-02-18 | 2011-01-04 | Universitätsklinikum Freiburg | Control de la expresión génica dependiente de receptores de andrógenos inhibiendo la actividad de amina oxidasa de la demetilasa lisina-específica (lsd1). |
TW200640526A (en) * | 2005-02-24 | 2006-12-01 | Alza Corp | Transdermal electrotransport drug delivery systems with reduced abuse potential |
JP4873871B2 (ja) * | 2005-02-28 | 2012-02-08 | 久光製薬株式会社 | 粘着剤及び貼付剤 |
US7914810B2 (en) * | 2005-05-06 | 2011-03-29 | Synthes Usa, Llc | Methods for the in situ treatment of bone cancer |
WO2006122345A1 (en) * | 2005-05-16 | 2006-11-23 | Novapharm Research (Australia) Pty Ltd | Method and composition for use in preparation of a patient for surgery |
US20060263421A1 (en) * | 2005-05-18 | 2006-11-23 | Abeille Pharmaceuticals Inc | Transdermal Method and Patch for Nausea |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
WO2006130510A2 (en) | 2005-05-27 | 2006-12-07 | Taro Pharmaceuticals U.S.A., Inc. | Stable liquid desoximethasone compositions with reduced oxidized impurity |
JP2008543768A (ja) * | 2005-06-10 | 2008-12-04 | スリーエム イノベイティブ プロパティズ カンパニー | 接着性積層体区画を取り扱うための方法 |
US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
JP2008543528A (ja) * | 2005-06-27 | 2008-12-04 | スリーエム イノベイティブ プロパティズ カンパニー | マイクロニードルカートリッジアセンブリ及び適用方法 |
JP5058531B2 (ja) | 2005-09-09 | 2012-10-24 | 日東電工株式会社 | ビソプロロール含有貼付製剤 |
US20070104771A1 (en) * | 2005-09-23 | 2007-05-10 | Jay Audett | Transdermal galantamine delivery system |
EP2308480B1 (en) | 2005-09-23 | 2014-08-13 | ALZA Corporation | High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications |
WO2007035940A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal norelgestromin delivery system |
US20090130188A9 (en) * | 2005-09-29 | 2009-05-21 | National Starch And Chemical Investment Holding Company | Acrylic pressure sensitive adhesives |
BRPI0617294B8 (pt) | 2005-10-12 | 2021-05-25 | Besins Healthcare Lu Sarl | composição farmacêutica em gel hidroalcóolico e uso de testosterona |
US20070087055A1 (en) * | 2005-10-14 | 2007-04-19 | David Jan | Directly compressible extended release alprazolam formulation |
WO2007065303A1 (fr) * | 2005-12-09 | 2007-06-14 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Timbre transdermique a base de dinitrate d'isosorbide et de bisoprolol |
JP4945228B2 (ja) | 2005-12-13 | 2012-06-06 | 日東電工株式会社 | ビソプロロール含有貼付製剤 |
WO2007070649A2 (en) * | 2005-12-14 | 2007-06-21 | 3M Innovative Properties Company | Antimicrobial coating system |
WO2007070650A2 (en) * | 2005-12-14 | 2007-06-21 | 3M Innovative Properties Company | Antimicrobial adhesive films |
US20070138439A1 (en) * | 2005-12-21 | 2007-06-21 | 3M Innovative Properties Company | Denaturant for ethanol |
SE530184C2 (sv) * | 2005-12-23 | 2008-03-18 | Kjell Stenberg | Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater |
FR2895679B1 (fr) * | 2005-12-29 | 2012-06-08 | Pf Medicament | Stabilisation de testosterone au sein de dispositifs transdermiques |
EP1986618A2 (en) * | 2006-02-13 | 2008-11-05 | Aveva Drug Delivery Systems, Inc. | Adhesive preparation comprising sufentanil and methods of using the same |
JP5037831B2 (ja) * | 2006-02-15 | 2012-10-03 | 久光製薬株式会社 | 凝集力向上及び徐放化の外用貼付剤 |
CN101431988A (zh) * | 2006-02-27 | 2009-05-13 | 诺芬药品公司 | 包含东莨菪碱的透皮治疗系统 |
WO2007099966A1 (ja) * | 2006-02-28 | 2007-09-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収型製剤 |
DE102006019293A1 (de) * | 2006-04-21 | 2007-10-25 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Pflaster, enthaltend ein Fentanyl Analogum |
CA2646667C (en) | 2006-04-21 | 2014-03-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
US8778323B2 (en) * | 2006-05-03 | 2014-07-15 | L'oréal | Cosmetic compositions containing block copolymers, tackifiers and modified silicones |
US8673282B2 (en) * | 2006-05-03 | 2014-03-18 | L'oreal | Cosmetic compositions containing block copolymers, tackifiers and a selective solvent for soft blocks |
US8758739B2 (en) * | 2006-05-03 | 2014-06-24 | L'oreal | Cosmetic compositions containing block copolymers, tackifiers and gelling agents |
US8557230B2 (en) * | 2006-05-03 | 2013-10-15 | L'oreal | Cosmetic compositions containing block copolymers, tackifiers and shine enhancing agents |
US8673284B2 (en) * | 2006-05-03 | 2014-03-18 | L'oreal | Cosmetic compositions containing block copolymers, tackifiers and a selective solvent for hard blocks |
US8673283B2 (en) * | 2006-05-03 | 2014-03-18 | L'oreal | Cosmetic compositions containing block copolymers, tackifiers and a solvent mixture |
US8569416B2 (en) | 2006-06-06 | 2013-10-29 | Dow Corning Corporation | Single phase silicone acrylate formulation |
US8614278B2 (en) | 2006-06-06 | 2013-12-24 | Dow Corning Corporation | Silicone acrylate hybrid composition and method of making same |
KR101432698B1 (ko) * | 2006-06-06 | 2014-08-22 | 다우 코닝 코포레이션 | 실리콘 아크릴레이트 하이브리드 조성물 |
US20070287727A1 (en) * | 2006-06-08 | 2007-12-13 | Jacob Hiller | Anti-Nicotine Treatment |
WO2008001204A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal compositions of pramipexole having enhanced permeation properties |
TW200815045A (en) * | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
EP2037999B1 (en) | 2006-07-07 | 2016-12-28 | Proteus Digital Health, Inc. | Smart parenteral administration system |
EP2041214A4 (en) | 2006-07-10 | 2009-07-08 | Medipacs Inc | SUPERELASTIC EPOXY HYDROGEL |
CA2657592C (en) * | 2006-07-14 | 2014-10-21 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch containing fentanyl or a pharmaceutically acceptable salt thereof |
US7731604B2 (en) * | 2006-10-31 | 2010-06-08 | Taylor Made Golf Company, Inc. | Golf club iron head |
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
US7910597B2 (en) * | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
US8603444B2 (en) * | 2007-01-12 | 2013-12-10 | L'oréal | Cosmetic compositions containing a block copolymer, a tackifier and a high viscosity ester |
US8658141B2 (en) * | 2007-01-12 | 2014-02-25 | L'oreal | Cosmetic composition containing a block copolymer, a tackifier, a silsesquioxane wax and/or resin |
US8703178B2 (en) | 2007-03-08 | 2014-04-22 | Nitto Denko Corporation | Percutaneous administration device of bisoprolol |
WO2008116004A2 (en) | 2007-03-19 | 2008-09-25 | Vita Sciences, Llc | Transdermal patch and method for delivery of vitamin b12 |
DE102007020799A1 (de) | 2007-05-03 | 2008-11-06 | Novosis Ag | Transdermales therapeutisches System mit Remifentanil |
WO2008157323A1 (en) * | 2007-06-13 | 2008-12-24 | 3M Innovative Properties Company | Antimicrobial film-forming composition, antimicrobial film, and method of verifying the presence of an antimicrobial film |
CN101147739B (zh) | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂 |
AU2008289109B2 (en) * | 2007-08-17 | 2012-02-02 | Centrexion Therapeutics Corporation | High concentration local anesthetic formulations |
CN101902996B (zh) | 2007-10-15 | 2014-11-26 | 阿尔扎公司 | 芬太尼的一天更换一次透皮施用 |
US9125979B2 (en) | 2007-10-25 | 2015-09-08 | Proteus Digital Health, Inc. | Fluid transfer port information system |
US8419638B2 (en) | 2007-11-19 | 2013-04-16 | Proteus Digital Health, Inc. | Body-associated fluid transport structure evaluation devices |
CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
EP2227635A2 (en) | 2007-12-03 | 2010-09-15 | Medipacs, Inc. | Fluid metering device |
DE102008013701A1 (de) * | 2008-03-11 | 2009-09-17 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System mit stabilisierter Membran |
JP5552255B2 (ja) | 2008-04-16 | 2014-07-16 | 日東電工株式会社 | 薬物経皮投与デバイス |
EP2111857A1 (de) * | 2008-04-25 | 2009-10-28 | Acino AG | Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon |
EP2299989B1 (en) | 2008-05-30 | 2019-01-02 | Mylan Inc. | Stabilized transdermal drug delivery system |
JP5368168B2 (ja) * | 2008-06-16 | 2013-12-18 | 日東電工株式会社 | 貼付剤及び貼付製剤 |
US20090318520A1 (en) * | 2008-06-20 | 2009-12-24 | Afecta Pharmaceuticals Drive | Use of isoindoles for the treatment of neurobehavioral disorders |
US8231906B2 (en) | 2008-07-10 | 2012-07-31 | Noven Pharmaceuticals, Inc. | Transdermal estrogen device and delivery |
US8338477B2 (en) | 2008-07-11 | 2012-12-25 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
JP2011529526A (ja) * | 2008-07-28 | 2011-12-08 | ダウ コーニング コーポレーション | 複合物品 |
US8119694B2 (en) | 2008-08-15 | 2012-02-21 | Arcion Therapeutics, Inc. | High concentration local anesthetic formulations |
EP2328561B1 (en) * | 2008-08-19 | 2015-11-25 | Adcock Ingram Intellectual Property (Pty) Limited | Rate Modulated Delivery of Drugs from a Three-Layer Tablet Comprising Tramadol, Diclofenac, Paracetamol |
JP5704801B2 (ja) * | 2008-08-21 | 2015-04-22 | ニプロパッチ株式会社 | 粘着性組成物及び経皮吸収型製剤 |
US20090317451A1 (en) * | 2008-08-26 | 2009-12-24 | Hauser Ray L | Pressure-sensitive adhesive for skin surface and/or transdermal substance delivery |
NZ591834A (en) | 2008-10-02 | 2011-12-22 | Mylan Inc | Method of making a multilayer adhesive laminate |
EP2387394B1 (en) | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
JP5664991B2 (ja) * | 2009-03-27 | 2015-02-04 | トーアエイヨー株式会社 | 経皮吸収製剤 |
WO2010124187A2 (en) | 2009-04-24 | 2010-10-28 | Henkel Corporation | Silicone acrylic hybrid polymer-based adhesives |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
JP5281973B2 (ja) * | 2009-07-06 | 2013-09-04 | 日東電工株式会社 | ビソプロロール含有貼付剤 |
CN101618030B (zh) * | 2009-08-10 | 2010-12-29 | 辽宁亿灵科创生物医药科技有限公司 | 一种雷公藤内酯醇透皮贴剂及其制备方法 |
US20110037455A1 (en) * | 2009-08-17 | 2011-02-17 | Oren Navot | System for measuring electrical power |
US20090318568A1 (en) * | 2009-08-26 | 2009-12-24 | Hauser Ray L | Adherent coating for tissue surface and/or trans-tissue surface substance delivery |
US9238102B2 (en) | 2009-09-10 | 2016-01-19 | Medipacs, Inc. | Low profile actuator and improved method of caregiver controlled administration of therapeutics |
US8221994B2 (en) | 2009-09-30 | 2012-07-17 | Cilag Gmbh International | Adhesive composition for use in an immunosensor |
WO2011062851A1 (en) | 2009-11-19 | 2011-05-26 | 3M Innovative Properties Company | Pressure sensitive adhesive comprising blend of synthetic rubber and functionalized synthetic rubber bonded to an acylic polymer |
US8551781B2 (en) | 2009-11-19 | 2013-10-08 | The Regents Of The University Of California | Vault complexes for facilitating biomolecule delivery |
EP2501769B1 (en) | 2009-11-19 | 2015-01-21 | 3M Innovative Properties Company | Pressure sensitive adhesive comprising functionalized polyisobutylene hydrogen bonded to acylic polymer |
EP2506838A1 (en) * | 2009-12-01 | 2012-10-10 | Noven Pharmaceuticals, INC. | Transdermal testosterone device and delivery |
AU2010334805B2 (en) | 2009-12-22 | 2015-01-22 | Lts Lohmann Therapie-Systeme Ag | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
US20110172645A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Wearable drug delivery device including integrated pumping and activation elements |
US20110172609A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
US20110172637A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Drug delivery device including tissue support structure |
US20110172639A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Device and method for delivery of microneedle to desired depth within the skin |
US9500186B2 (en) | 2010-02-01 | 2016-11-22 | Medipacs, Inc. | High surface area polymer actuator with gas mitigating components |
EP2531096A4 (en) | 2010-02-01 | 2013-09-11 | Proteus Digital Health Inc | DATA COLLECTION SYSTEM FOR TWO WRIST |
US9014779B2 (en) | 2010-02-01 | 2015-04-21 | Proteus Digital Health, Inc. | Data gathering system |
DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
DE102010026883A1 (de) | 2010-03-11 | 2011-12-15 | Amw Gmbh | Transdermales System mit Aromatasehemmer |
WO2011130455A1 (en) | 2010-04-13 | 2011-10-20 | Najib Babul | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use |
DE102011100619A1 (de) | 2010-05-05 | 2012-01-05 | Amw Gmbh | Transdermales therapeutisches System (TTS) mit einem Gehalt an einem Opiod-Analgetikum |
WO2011152860A1 (en) * | 2010-06-01 | 2011-12-08 | Phibro Animal Health Corporation | Use of pre-d1ssolved pristinamycin-type and polyether lonophore type antimicrobial agents in the production of ethanol |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
DE102010026903A1 (de) | 2010-07-12 | 2012-01-12 | Amw Gmbh | Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff |
EP2601245A1 (en) | 2010-08-05 | 2013-06-12 | Biofilm IP, LLC | Cyclosiloxane-substituted polysiloxane compounds, compositions containing the compounds and methods of use thereof |
WO2012061556A1 (en) | 2010-11-03 | 2012-05-10 | Flugen, Inc. | Wearable drug delivery device having spring drive and sliding actuation mechanism |
WO2012092165A1 (en) | 2010-12-29 | 2012-07-05 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery system comprising levonorgestrel acetate |
US20120219516A1 (en) | 2011-02-25 | 2012-08-30 | L'oreal S.A. | Cosmetic compositions having long lasting shine |
KR20120107153A (ko) * | 2011-03-15 | 2012-10-02 | 아이큐어 주식회사 | 펜타닐 경피 패치제 |
EP2685962A1 (en) | 2011-03-17 | 2014-01-22 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
US11786455B2 (en) | 2011-05-10 | 2023-10-17 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
WO2012153396A1 (ja) * | 2011-05-10 | 2012-11-15 | 伊藤忠ケミカルフロンティア株式会社 | 非水性貼付剤 |
US9925264B2 (en) | 2011-05-10 | 2018-03-27 | Itochu Chemical Frontier Corporation | Non-aqueous patch |
US9918945B2 (en) * | 2011-05-31 | 2018-03-20 | Hisamitsu Pharmaceutical Co., Inc. | Ropinirole-containing patch and package thereof |
ITMI20111355A1 (it) * | 2011-07-20 | 2013-01-21 | Epifarma Srl | Cerotto transdermico contenente diclofenac e tiocolchicoside |
BR112014006719B1 (pt) | 2011-09-27 | 2021-09-14 | Itochu Chemical Frontier Corporation | Adesivo não aquoso compreendendo lidocaína |
EP2584016A1 (en) | 2011-10-21 | 2013-04-24 | Dow Corning Corporation | Single phase silicone acrylate formulation |
IN2014DN03247A (zh) | 2011-11-04 | 2015-05-22 | Agile Therapeutics Inc | |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP2013139554A (ja) | 2011-11-29 | 2013-07-18 | Dow Corning Corp | シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法 |
US9849270B2 (en) | 2011-12-16 | 2017-12-26 | 3M Innovative Properties Company | Foldable adhesive composite dressing |
EP2793869B1 (en) | 2011-12-21 | 2015-09-23 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
JP6576039B2 (ja) | 2011-12-21 | 2019-09-18 | スリーエム イノベイティブ プロパティズ カンパニー | オーバーレイライナを有する粘着パッチ組立体、並びにそれを作製するためのシステム及び方法 |
DE102011090178A1 (de) | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation |
WO2013138524A1 (en) | 2012-03-14 | 2013-09-19 | Medipacs, Inc. | Smart polymer materials with excess reactive molecules |
US9084839B2 (en) | 2012-03-27 | 2015-07-21 | Berry Plastics Corporation | Adhesive for use on skin |
DE102012205493A1 (de) * | 2012-04-03 | 2013-10-10 | Acino Ag | Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem |
CN104584257B (zh) | 2012-05-02 | 2017-06-20 | 汉高知识产权控股有限责任公司 | 可固化封装剂及其用途 |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
CN104736192B (zh) | 2012-10-10 | 2018-02-13 | 3M创新有限公司 | 用于将微针装置施用至皮肤的施用装置和方法 |
EP2906284B8 (en) | 2012-10-10 | 2021-01-20 | Kindeva Drug Delivery L.P. | Force-controlled applicator for applying a microneedle device to skin |
WO2014062494A1 (en) | 2012-10-15 | 2014-04-24 | Noven Pharmaceuticals, Inc. | Compositions and methods for the transdermal delivery of methylphenidate |
EP2919849B1 (en) | 2012-11-16 | 2021-01-06 | Kindeva Drug Delivery L.P. | Force-controlled applicator for applying a microneedle device to skin |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
US20140172118A1 (en) * | 2012-12-19 | 2014-06-19 | Cook Medical Technologies Llc | Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AR094289A1 (es) | 2012-12-28 | 2015-07-22 | Noven Pharma | Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol |
CA2896055C (en) | 2012-12-28 | 2021-02-16 | Noven Pharmaceuticals, Inc. | Compositions and methods for transdermal delivery of amphetamine and clonidine |
JP6550337B2 (ja) * | 2012-12-28 | 2019-07-24 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 非ステロイド系の抗炎症薬を経皮的に送達するための組成物及び方法 |
WO2014106016A1 (en) | 2012-12-28 | 2014-07-03 | Noven Pharmaceuticals, Inc | Multi-polymer compositions for transdermal drug delivery |
US9072682B2 (en) | 2012-12-31 | 2015-07-07 | Mylan Inc. | Transdermal dosage form for low-melting point active agent |
WO2014130846A1 (en) | 2013-02-22 | 2014-08-28 | Seungpyo Hong | Transdermal drug delivery using amphiphilic dendron-coil micelles |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
EP2968652B1 (en) | 2013-03-13 | 2020-07-22 | Avery Dennison Corporation | Improving adhesive properties |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
EP2968201B1 (en) | 2013-03-13 | 2022-12-28 | Avery Dennison Corporation | Enhanced drug delivery from adhesives |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
WO2014159582A1 (en) | 2013-03-14 | 2014-10-02 | Noven Pharmaceuticals, Inc | Amphetamine transdermal compositions with acrylic block copolymer |
AR095260A1 (es) | 2013-03-15 | 2015-09-30 | Noven Pharma | Composiciones de anfetaminas transdérmicas estables y métodos de fabricación |
AR095259A1 (es) | 2013-03-15 | 2015-09-30 | Noven Pharma | Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria |
JP2016517707A (ja) | 2013-03-22 | 2016-06-20 | スリーエム イノベイティブ プロパティズ カンパニー | カウンタ組立体を備えているマイクロニードルアプリケータ |
US9682068B2 (en) * | 2013-05-20 | 2017-06-20 | Mylan Inc. | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders |
WO2014193725A1 (en) | 2013-05-31 | 2014-12-04 | 3M Innovative Properties Company | Microneedle injection and infusion apparatus and method of using same |
US9895520B2 (en) | 2013-05-31 | 2018-02-20 | 3M Innovative Properties Company | Microneedle injection apparatus comprising a dual cover |
MX353241B (es) | 2013-05-31 | 2018-01-05 | 3M Innovative Properties Co | Aparato de inyección de microagujas que comprende un accionador invertido. |
JP5415645B1 (ja) | 2013-06-28 | 2014-02-12 | 久光製薬株式会社 | 貼付剤の製造方法、貼付剤及び包装体 |
US10046151B2 (en) | 2013-07-03 | 2018-08-14 | Lts Lohmann Therapie-Systeme, Ag | Transdermal therapeutic system with electronic component |
ITTO20130663A1 (it) * | 2013-08-02 | 2015-02-03 | Abc Farmaceutici S P A | Sistema di somministrazione transdermico per l'impiego nel trattamento di patologie croniche bronco-polmonari |
WO2015023649A2 (en) | 2013-08-12 | 2015-02-19 | 3M Innovative Properties Company | Peptides for enhancing transdermal delivery |
US20160199317A1 (en) * | 2013-08-30 | 2016-07-14 | 3M Innovative Properties Company | Estradiol containing transdermal drug delivery systems and compositions |
TWI629066B (zh) | 2013-10-07 | 2018-07-11 | 帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
RU2018105761A (ru) | 2013-10-07 | 2019-02-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Устройства для трансдермальной доставки дексмедетомидина и способы их применения |
RU2648449C2 (ru) | 2013-10-07 | 2018-03-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина |
US11633367B2 (en) | 2014-05-20 | 2023-04-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
ES2954087T3 (es) * | 2014-05-20 | 2023-11-20 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que incluye un mediador de interfase |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
EP3020398A1 (en) | 2014-11-17 | 2016-05-18 | Nitto Denko Corporation | Compounds and formulations for reducing scarring |
US10028904B2 (en) | 2014-12-04 | 2018-07-24 | Wisconsin Alumni Research Foundation | Transdermal cannabinoid formulations |
US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
CN107107598B (zh) | 2014-12-18 | 2019-11-22 | 3M创新有限公司 | 处理粘合层合物贴剂的方法 |
US10406116B2 (en) | 2015-02-06 | 2019-09-10 | Noven Pharmaceuticals, Inc. | Pressure-sensitive adhesives for transdermal drug delivery |
KR102565565B1 (ko) | 2015-02-06 | 2023-08-09 | 노벤 파머수티컬즈, 인코퍼레이티드 | 경피 약물 전달용 감압 접착제 |
EP3267982A4 (en) * | 2015-03-13 | 2018-11-07 | Amneal Pharmaceuticals LLC | Fentanyl transdermal delivery system |
US20180169034A1 (en) | 2015-06-14 | 2018-06-21 | Trs Ii, Llc | Transdermal delivery formulation |
US20170000745A1 (en) | 2015-07-02 | 2017-01-05 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
JP6304457B2 (ja) * | 2015-08-27 | 2018-04-04 | 東洋インキScホールディングス株式会社 | 貼付剤 |
EP3411023A1 (en) | 2016-02-05 | 2018-12-12 | 3M Innovative Properties Company | Transdermal drug delivery systems with fluorosilicone release liners |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
CA3028436A1 (en) * | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
EP3287462A1 (en) | 2016-08-25 | 2018-02-28 | Nitto Denko Corporation | Isosorbide derivatives to treat bacterial biofilms |
PL3338768T3 (pl) * | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
KR102614709B1 (ko) | 2016-12-20 | 2023-12-18 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템 |
DE102017104026A1 (de) | 2017-02-27 | 2018-08-30 | Lts Lohmann Therapie-Systeme Ag | Nicotin enthaltendes transparentes transdermales therapeutisches System |
EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
MX2020003662A (es) | 2017-10-11 | 2020-10-01 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona. |
TWI829654B (zh) * | 2017-10-11 | 2024-01-21 | 德商洛曼治療系統股份有限公司 | 用於經皮投予胍法辛(guanfacine)的包括至少一種添加劑之經皮治療系統 |
KR20200070305A (ko) * | 2017-10-11 | 2020-06-17 | 에르테에스 로만 테라피-시스테메 아게 | 실리콘 폴리머를 포함하는 구안파신의 경피 투여용 경피흡수 치료 시스템 |
WO2019193514A1 (en) | 2018-04-05 | 2019-10-10 | 3M Innovative Properties Company | Gel adhesive comprising crosslinked blend of polydiorganosiloxane and acrylic polymer |
US20210128490A1 (en) * | 2018-04-25 | 2021-05-06 | Shinkei Therapeutics Llc | Tetrabenazine transdermal delivery device |
CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
BR112021005253A2 (pt) * | 2018-09-19 | 2021-06-15 | Isp Investments Llc | composição de polímero estável a peróxido e processo para sua preparação e aplicações da mesma |
US20210346662A1 (en) | 2018-10-23 | 2021-11-11 | Kindeva Drug Delivery L.P. | Tamper evident transdermal patch |
KR102054346B1 (ko) * | 2019-06-20 | 2019-12-10 | 한국지질자원연구원 | 알파 교감신경 차단제 화합물 및 점토광물의 복합체를 포함하는 방출성이 제어된 경구투여용 조성물 |
DE102019120403A1 (de) * | 2019-07-29 | 2021-02-04 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Herstellung von Haftklebemassen zur Verwendung in einem transdermalen therapeutischen System |
WO2021041800A1 (en) | 2019-08-30 | 2021-03-04 | Remedy Diagnostics LLC | Transdermal device comprising pain molecules |
CN110693857B (zh) * | 2019-10-17 | 2023-08-11 | 宜昌人福药业有限责任公司 | 一种舒芬太尼透皮贴剂及其制备方法 |
RU2736081C1 (ru) * | 2019-12-02 | 2020-11-11 | федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Пластырь трансдермальный с гликлазидом |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE786957A (fr) * | 1968-08-01 | 1973-01-29 | Raychem Corp | Compositions de polymeres. |
US3972995A (en) * | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
JPS5489017A (en) * | 1977-12-26 | 1979-07-14 | Lion Dentifrice Co Ltd | Ointment agent |
US4438139A (en) * | 1979-08-14 | 1984-03-20 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estrogens |
US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
JPS5843368B2 (ja) * | 1980-10-30 | 1983-09-27 | 日東電工株式会社 | 消炎鎮痛貼付剤 |
US4542013A (en) * | 1981-07-08 | 1985-09-17 | Key Pharmaceuticals, Inc. | Trinitroglycerol sustained release vehicles and preparation therefrom |
GB2105990B (en) * | 1981-08-27 | 1985-06-19 | Nitto Electric Ind Co | Adhesive skin patches |
US4750482A (en) * | 1982-02-25 | 1988-06-14 | Pfizer Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
US4699146A (en) * | 1982-02-25 | 1987-10-13 | Valleylab, Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
JPS58225010A (ja) * | 1982-06-25 | 1983-12-27 | Dai Ichi Seiyaku Co Ltd | コルチコステロイド類外用製剤 |
US4769013A (en) * | 1982-09-13 | 1988-09-06 | Hydromer, Inc. | Bio-effecting medical material and device |
US4585452A (en) * | 1983-04-12 | 1986-04-29 | Key Pharmaceuticals, Inc. | Transdermal systemic dosage forms |
US4693887A (en) * | 1983-09-15 | 1987-09-15 | The Kendall Company | Microphase separated hydrogels for controlled release of bioactive materials |
US4696821A (en) * | 1983-10-11 | 1987-09-29 | Warner-Lambert Company | Transdermal delivery system for administration of nitroglycerin |
GB8629639D0 (en) * | 1986-12-11 | 1987-01-21 | Beecham Group Plc | Composition & method |
US4845081A (en) * | 1984-10-18 | 1989-07-04 | University Of Florida | Aminomethyl derivatives of biologically active substances, and enhanced delivery thereof across topical membranes |
US4593053A (en) * | 1984-12-07 | 1986-06-03 | Medtronic, Inc. | Hydrophilic pressure sensitive biomedical adhesive composition |
DE3587616D1 (de) * | 1984-12-22 | 1993-11-11 | Sanol Arznei Schwarz Gmbh | Wirkstoffpflaster. |
US4883669A (en) * | 1985-02-25 | 1989-11-28 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration |
DE3517080A1 (de) * | 1985-05-11 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Komponente fuer therapeutische wirkstoffabgabesysteme |
GB8512358D0 (en) * | 1985-05-16 | 1985-06-19 | Euro Celtique Sa | Transdermal delivery system |
US4690683A (en) * | 1985-07-02 | 1987-09-01 | Rutgers, The State University Of New Jersey | Transdermal varapamil delivery device |
ES2025085B3 (es) * | 1986-04-29 | 1992-03-16 | Hoechst-Roussel Pharmaceuticals Incorporated | Una estructura laminar para la administracion de un producto quimico a una velocidad de liberacion controlada. |
DE3775830D1 (de) * | 1986-06-13 | 1992-02-20 | Alza Corp | Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit. |
AU607172B2 (en) * | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US4906169A (en) * | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5071656A (en) * | 1987-03-05 | 1991-12-10 | Alza Corporation | Delayed onset transdermal delivery device |
IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
US5059189A (en) * | 1987-09-08 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Method of preparing adhesive dressings containing a pharmaceutically active ingredient |
US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
US4814168A (en) * | 1988-03-04 | 1989-03-21 | Noven Pharmaceuticals, Inc. | Transdermal multipolymer drug delivery system |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
EP0343807A3 (en) * | 1988-05-27 | 1991-01-02 | SMITH & NEPHEW UNITED, INC. | Absorptive adhesive dressing with controlled hydration |
ES2062093T3 (es) * | 1988-08-02 | 1994-12-16 | Ciba Geigy Ag | Emplasto de varias capas. |
US4987893A (en) * | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
WO1990006120A1 (en) * | 1988-12-01 | 1990-06-14 | Schering Corporation | Compositions for transdermal delivery of estradiol |
DE3910543A1 (de) * | 1989-04-01 | 1990-10-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung |
DE69007886T2 (de) * | 1989-07-21 | 1994-11-17 | Izhak Blank | Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung. |
US5232703A (en) * | 1989-07-21 | 1993-08-03 | Izhak Blank | Estradiol compositions and methods for topical application |
US5262165A (en) * | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
CA2065311C (en) * | 1989-09-08 | 2000-01-11 | Chia-Ming Chiang | Solid matrix system for transdermal drug delivery |
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
DE3933460A1 (de) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
US5230896A (en) * | 1989-10-12 | 1993-07-27 | Warner-Lambert Company | Transdermal nicotine delivery system |
AU6712090A (en) * | 1989-10-13 | 1991-05-16 | Watson Laboratories, Inc. | Drug delivery systems and matrix therefor |
JP2820306B2 (ja) * | 1990-02-27 | 1998-11-05 | 積水化学工業株式会社 | 経皮吸収製剤 |
JPH07116032B2 (ja) * | 1990-04-06 | 1995-12-13 | 積水化学工業株式会社 | ニトログリセリン貼付剤 |
IT1243745B (it) * | 1990-10-17 | 1994-06-21 | Vectorpharma Int | Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione. |
US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
US5203768A (en) * | 1991-07-24 | 1993-04-20 | Alza Corporation | Transdermal delivery device |
US5676968A (en) * | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
DE4210711A1 (de) * | 1991-10-31 | 1993-05-06 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Transdermale therapeutische systeme mit kristallisationsinhibitoren |
FR2739031B1 (fr) * | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique |
-
1994
- 1994-01-07 US US08/178,558 patent/US5656286A/en not_active Expired - Lifetime
-
1995
- 1995-01-08 IL IL11226995A patent/IL112269A/xx not_active IP Right Cessation
- 1995-01-09 WO PCT/US1995/000022 patent/WO1995018603A1/en active IP Right Grant
- 1995-01-09 SG SG1996009524A patent/SG49331A1/en unknown
- 1995-01-09 ES ES95906742T patent/ES2196055T3/es not_active Expired - Lifetime
- 1995-01-09 DK DK95906742T patent/DK0737066T3/da active
- 1995-01-09 EP EP95906742A patent/EP0737066B1/en not_active Expired - Lifetime
- 1995-01-09 DE DE69530177T patent/DE69530177T2/de not_active Expired - Lifetime
- 1995-01-09 EP EP03007105A patent/EP1329225A3/en not_active Withdrawn
- 1995-01-09 CN CN95191993A patent/CN1121854C/zh not_active Expired - Lifetime
- 1995-01-09 HU HU9601856A patent/HU227814B1/hu unknown
- 1995-01-09 PT PT95906742T patent/PT737066E/pt unknown
- 1995-01-09 NZ NZ278769A patent/NZ278769A/en not_active IP Right Cessation
- 1995-01-09 AT AT95906742T patent/ATE235898T1/de active
- 1995-01-09 JP JP51854095A patent/JP4339398B2/ja not_active Expired - Lifetime
- 1995-01-09 KR KR1019960703664A patent/KR100363052B1/ko not_active IP Right Cessation
- 1995-01-09 CA CA002180530A patent/CA2180530C/en not_active Expired - Lifetime
- 1995-01-09 ZA ZA95108A patent/ZA95108B/xx unknown
- 1995-01-09 BR BRPI9506470-2B8A patent/BR9506470B8/pt not_active IP Right Cessation
- 1995-01-19 TW TW084100440A patent/TW464511B/zh not_active IP Right Cessation
-
1996
- 1996-07-05 FI FI962770A patent/FI121527B/fi not_active IP Right Cessation
- 1996-07-05 MX MX9602656A patent/MX9602656A/es unknown
- 1996-07-05 NO NO19962833A patent/NO319377B1/no not_active IP Right Cessation
-
1997
- 1997-08-11 US US08/907,906 patent/US6024976A/en not_active Expired - Lifetime
-
1999
- 1999-05-25 US US09/318,121 patent/US6221383B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW464511B (en) | Pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system and preparation method therefor | |
EP3179989B1 (en) | Silicone-containing acrylic polymers for transdermal drug delivery compositions | |
JP5856573B2 (ja) | 経皮デリバリーシステム | |
KR100893158B1 (ko) | 경피성 그라니세트론 | |
US20130319595A1 (en) | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl | |
JP2017039781A (ja) | エストロゲンの経皮デバイスおよび経皮送達 | |
US20110008413A1 (en) | Compositions and Methods of Topical Drug Delivery for the Treatment of Carpal Tunnel Syndrome | |
CA2896336C (en) | Compositions and methods for transdermal delivery of non-steroidal anti-inflammatory agents | |
US20220023425A1 (en) | Stretchable backing layers for transdermal drug delivery systems | |
KR20040030408A (ko) | 경피 약물 전달 시스템에 유용한 비반응성 접착제 | |
JPH04217919A (ja) | エペリゾンまたはトルペリゾン経皮吸収製剤 | |
AU614208B2 (en) | Transdermal therapeutic system comprising norpseudoephedrine as active component | |
JPH02270818A (ja) | ポリウレタンフィルムを支持体とする貼付剤 | |
JP4943643B2 (ja) | 経皮吸収製剤 | |
JP3224582B2 (ja) | 経皮吸収製剤 | |
JPH085806B2 (ja) | 経皮吸収製剤 | |
JPH05186371A (ja) | 経皮吸収製剤 | |
JP3176400B2 (ja) | 薬物の表皮細胞層透過促進剤および経皮吸収製剤 | |
JPH07233054A (ja) | 経皮吸収型製剤 | |
JP2019034905A (ja) | デヒドロ酢酸含有経皮吸収製剤 | |
WO2024189213A1 (en) | Medical patch comprising skin irritating active agent | |
JP2022122784A (ja) | 酸化防止剤含有経皮吸収製剤 | |
JPH05178762A (ja) | 経皮・経粘膜吸収製剤 | |
JPH06145048A (ja) | 外用貼付剤 | |
JPH0627066B2 (ja) | 外用貼付剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |